Modified polynucleotides and uses thereof

ABSTRACT

The present disclosure provides modified substrates such as modified polynucleotides, proteins, antibodies, lipids, and cells and uses thereof. Method of generating the modified substrates, which may comprise cleavage of a cleavable group linking the substrate to a labeling moiety, are also provided herein.

CROSS REFERENCE

This application claims the benefit of U.S. Provisional PatentApplication No. 62/978,072, filed Feb. 18, 2020, of which theapplication is entirely incorporated herein by reference.

BACKGROUND

The detection, quantification and sequencing of cells and biologicalmolecules may be important for molecular biology and medicalapplications, such as diagnostics. Genetic testing may be useful for anumber of diagnostic methods. For example, disorders that are caused byrare genetic alterations (e.g., sequence variants) or changes inepigenetic markers, such as cancer and partial or complete aneuploidy,may be detected or more accurately characterized with deoxyribonucleicacid (DNA) or ribonucleic acid (RNA) sequence information.

Nucleic acid sequencing is a process that can be used to providesequence information for a nucleic acid sample. Such sequenceinformation may be helpful in diagnosing and/or treating a subject witha condition. For example, the nucleic acid sequence of a subject may beused to identify, diagnose and potentially develop treatments forgenetic diseases. As another example, research into pathogens may leadto treatment of contagious diseases.

Nucleic acid sequencing may comprise the use of labeled moieties, suchas moieties may be labeled with fluorescent dyes. The sensitivity of adetection scheme can be improved by using dyes with both a highextinction coefficient and quantum yield, where the product of thesecharacteristics may be termed the dye's “brightness.” Dye brightness maybe attenuated by quenching phenomena, including quenching by biologicalmaterials, quenching by proximity to other dyes, and quenching bysolvent. Other routes to brightness loss include photobleaching,reactivity to molecular oxygen, and chemical decomposition.

Labeled moieties incorporated into polynucleotides during a sequencingapplication may impact the incorporation of additional nucleotides,including additional labeled nucleotides. Accordingly, labels may beremoved during or after such an application to facilitate additionalprocessing.

SUMMARY

The present disclosure provides compounds and compositions comprisingchemical moieties comprising an alkynyl moiety and an amido moiety, aswell as methods of preparing the same. The chemical moieties providedherein may be coupled to substrates such as nucleotides, nucleotideanalogs, cells, proteins, antibodies, and lipids. The chemical moietiesmay comprise a ring structure such as an aromatic ring system. Thechemical moieties (e.g., “scar” moieties) provided herein may begenerated upon cleavage of a cleavable group (e.g., a disulfide moiety),such as upon contacting a substrate comprising such a chemical moietywith a cleavage reagent. For example, a chemical moiety coupled to asubstrate (e.g., nucleotide or nucleotide analog) of the presentdisclosure may be generated subsequent to incorporation of the substrateinto, e.g., a polynucleotide, such as during a sequencing process. Thesubstrate may be coupled to a fluorescent labeling reagent (e.g., asdescribed herein) at the time of its incorporation into thepolynucleotide. The fluorescent labeling reagent may comprise acleavable group (e.g., as described herein) that is configured to becleaved upon contact with a cleavage reagent (e.g., as describedherein). Subsequent processing, such as subsequent incorporation ofadditional nucleotides or nucleotide analogs in a sequencing process,may be more rapid upon generation of the chemical moiety coupled to thesubstrate (e.g., “scarred substrate”) from the fluorescently labeledsubstrate than such processing would be in the absence of cleavage ofthe cleavable group to provide the polynucleotide comprising the scarredsubstrate. A “scar” moiety provided herein may be a “preferred scar” toone or more polymerase enzymes, such that a polymerase enzyme may beable to perform an incorporation process (e.g., as a step in anextension process) adjacent to or in the vicinity of such a scar as wellas or better than it could perform such a process in the absence of thescar. In other words, the inclusion of a scar moiety provided herein ina polynucleotide undergoing an extension process may or may not affectthe processivity of a polymerase enzyme performing the extensionprocess. The inclusion of a scar moiety provided herein in apolynucleotide undergoing an extension process may or may not affect thetolerance in the incorporation reaction (e.g., as described herein). Forexample, the use of polynucleotides including nucleotides comprisingsuch scar moieties may reduce context effects, which may have the effectof simplifying base determination in a sequencing process.

In an aspect, the present disclosure provides a compound of Formula (I):

or a salt thereof, wherein:

-   -   R^(A) is an optionally substituted 5-12 membered ring system,        wherein substituents on R^(A) are independently selected from        R⁴;    -   R^(B) is selected from (i) an optionally substituted monocyclic        heterocycle comprising 2 or more heteroatoms and (ii) an        optionally substituted bicyclic heterocycle, wherein        substituents on R^(B) are independently selected from R⁵;    -   R^(C) is selected from optionally substituted C₁₋₆ alkyl,        optionally substituted C₂₋₆ alkenyl, and optionally substituted        C₂₋₆ alkynyl, wherein substituents on R¹ are independently        selected from R⁶, or is absent;    -   R¹ is selected from hydrogen, halogen, —OH, —OR⁸, ═O, ═S,        optionally substituted C₁₋₆ alkyl, optionally substituted C₂₋₆        alkenyl, optionally substituted C₂₋₆ alkynyl, optionally        substituted C₃₋₆ cycloalkyl, and optionally substituted        3-6-membered heterocycloalkyl, wherein substituents on R¹ are        independently selected from R⁶;    -   R² is selected from hydrogen, optionally substituted C₁₋₆ alkyl,        optionally substituted C₂₋₆ alkenyl, optionally substituted C₂₋₆        alkynyl, optionally substituted C₃₋₆ cycloalkyl, and optionally        substituted 3-6-membered heterocycloalkyl, wherein substituents        on R² are independently selected from R⁶;    -   each R³ is independently selected from hydrogen, halogen, —CN,        —OH, —OR⁸, —C(═O)R⁸, —CO₂R⁷, —C(═O)N(R⁷)₂, —N(R⁷)₂, —NRC(═O)R⁷,        —NR⁷C(═O)N(R⁷)₂, —SR⁷, —S(═O)R⁸, —SO₂R⁸, —SO₂N(R⁷)₂, —NO₂,        optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆        alkenyl, optionally substituted C₁-C₆ alkynyl, optionally        substituted monocyclic carbocycle, and optionally substituted        monocyclic heterocycle, wherein optional substituents on C₁-C₆        alkyl, C₁-C₆ alkenyl, C₁-C₆ alkynyl, monocyclic carbocycle, and        monocyclic heterocycle are independently selected from R⁶;    -   or two R³ are taken together with the atom to which they are        attached to form an optionally substituted 3- to 6-membered        heterocycle or carbocycle, wherein optional substituents on the        3- to 6-membered heterocycle or carbocycle are independently        selected from R⁶;    -   R⁴ is selected from halogen, ═O, ═S, —CN, —OH, —OR¹⁰, —N(R⁹)₂,        —C(═O)R⁹, —C(═O)OR⁹, —OC(═O)R⁹, —C(═O)N(R⁹)₂, —NR⁹C(═O)R⁹,        —NR⁹C(═O)N(R⁹)₂, —OC(═O)N(R⁹)₂, —NR⁹C(═O)OR⁹, —OC(═O)OR⁹,        —NR⁹SO₂R⁹, —SR⁹, —S(═O)R¹⁰, —SO₂R¹⁰, or —SO₂N(R⁹)₂, —NO₂,        optionally substituted C₁-C₆ alkyl, optionally substituted C₂-C₆        alkenyl, optionally substituted C₂-C₆ alkynyl, an optionally        substituted C₃-C₁₀ carbocycle, and an optionally substituted        3-10-membered heterocycle, wherein substituents on R⁴ are        independently selected from R⁶;    -   R⁵ is selected from halogen, ═O, ═S, —CN, —OH, —OR¹⁰, —N(R⁹)₂,        —C(═O)R⁹, —C(═O)OR⁹, —OC(═O)R⁹, —C(═O)N(R⁹)₂, —NR⁹C(═O)R⁹,        —NR⁹C(═O)N(R⁹)₂, —OC(═O)N(R⁹)₂, —NR⁹C(═O)OR⁹, —OC(═O)OR⁹,        —NR⁹SO₂R⁹, —SR⁹, —S(═O)R¹⁰, —SO₂R¹⁰, or —SO₂N(R⁹)₂, —NO₂,        optionally substituted C₁-C₆ alkyl, optionally substituted C₂-C₆        alkenyl, optionally substituted C₂-C₆ alkynyl, an optionally        substituted C₃-C₁₀ carbocycle, and an optionally substituted        3-10-membered heterocycle, wherein substituents on R⁵ are        independently selected from R⁶;    -   each R⁶ is independently selected from halogen, ═O, ═S, —CN,        —OH, —OR¹⁰, —N(R⁹)₂, —C(═O)R⁹, —C(═O)OR⁹, —OC(═O)R⁹,        —C(═O)N(R⁹)₂, —NR⁹C(═O)R⁹, —NR⁹C(═O)N(R⁹)₂, —OC(═O)N(R⁹)₂,        —NR⁹C(═O)OR⁹, —OC(═O)OR⁹, —SR⁹, —S(═O)R¹⁰, —SO₂R¹⁰, —SO₂N(R⁹)₂,        —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆        haloalkyl, C₁-C₆ hydroxyalkyl, C₁-C₆ aminoalkyl, C₃-C₆        carbocycle, optionally substituted monophosphate, optionally        substituted diphosphate, optionally substituted triphosphate,        and 3- to 6-membered heterocycle;    -   each R⁷ is independently selected from hydrogen, optionally        substituted C₁-C₆ alkyl, optionally substituted C₃-C₆        carbocycle, and optionally substituted 3-6-membered heterocycle,        wherein optional substituents on the C₁-C₆ alkyl, C₃-C₆        carbocycle, and 3-6-membered heterocycle are independently        selected from R⁶;    -   or two R⁷ are taken together with the atom(s) to which they are        attached to form an optionally substituted 3- to 6-membered        heterocycle, wherein optional substituents on the 3- to        6-membered heterocycle are independently selected from R⁶;    -   each R⁸ is independently selected from optionally substituted        C₁-C₆ alkyl, optionally substituted C₃-C₆ carbocycle, and        optionally substituted 3-6-membered heterocycle, wherein        optional substituents on the C₁-C₆ alkyl, C₃-C₆ carbocycle, and        3-6-membered heterocycle are independently selected from R⁶;    -   each R⁹ is independently selected from hydrogen, C₁-C₆ alkyl,        C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₃-C₆ carbocycle,        and 3- to 6-membered heterocycle;    -   or two R⁹ on the same nitrogen atom are taken together with the        nitrogen to which they are attached to form a 3- to 6-membered        heterocycle;    -   each R¹⁰ is independently selected from C₁-C₆ alkyl, C₂-C₆        alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₃-C₆ carbocycle, and        3- to 6-membered heterocycle; and    -   n is selected from 1, 2, 3, 4, and 5.

In some embodiments, R^(B) is an optionally substituted bicyclicheterocycle. In some embodiments, the heteroatoms of R^(B) are each N.In some embodiments, R^(B) is an optionally substituted purine. In someembodiments, R^(B) is selected from

In some embodiments, R^(B) is an optionally substituted monocyclicheterocycle comprising 2 or more heteroatoms. In some embodiments, eachheteroatom of the 2 or more heteroatoms is N. In some embodiments, R^(B)is an optionally substituted pyrimidine. In some embodiments, R^(B) isselected from

In some embodiments, R^(B) is substituted with at least one R⁵ selectedfrom an optionally substituted C₃-C₁₀ carbocycle and an optionallysubstituted 3-10-membered heterocycle. In some embodiments, R^(B) issubstituted with at least one R⁵ selected from an optionally substituted5-6-membered heterocycle. In some embodiments, the optionallysubstituted 5-6-membered heterocycle is selected from optionallysubstituted ribose and deoxyribose. In some embodiments, the optionallysubstituted 5-6-membered heterocycle is substituted with one or moreoptionally substituted monophosphate, diphosphate, or triphosphatemoieties.

In some embodiments, R^(A) is an optionally substituted 5-12 memberedcarbocyclic ring system. In some embodiments, R^(A) is an optionallysubstituted 5-12 membered heterocyclic ring system. In some embodiments,R^(A) is an aromatic ring system. In some embodiments, R^(A) is anoptionally substituted 5-12 membered bicyclic ring system. In someembodiments, R^(A) is an optionally substituted 5-8 membered monocyclicring system. In some embodiments, R^(A) is an optionally substitutedphenyl moiety.

In some embodiments, each R⁴ is independently selected from halogen,—OH, —OR¹⁰, —N(R⁹)₂, —C(═O)R⁹, —C(═O)OR⁹, —OC(═O)R⁹, —C(═O)N(R⁹)₂,—NR⁹C(═O)R⁹, —NR⁹C(═O)N(R⁹)₂, —OC(═O)N(R⁹)₂, —NR⁹C(═O)OR⁹, —OC(═O)OR⁹,and optionally substituted C₁-C₆ alkyl.

In some embodiments, R² is hydrogen.

In some embodiments, each R³ is hydrogen.

In some embodiments, n is 1 and R¹ is hydrogen.

In some embodiments, R^(C) is absent.

In some embodiments, the compound is a compound of Formula (II):

or a salt thereof, wherein:

-   -   dotted lines represent bonds that may be present or absent;    -   X is selected from C and N;    -   R¹¹ is selected from hydrogen, halogen, —OH, —OR⁸, —N(R⁷)₂,        —SR⁷, =0, and optionally substituted C₁₋₆ alkyl;    -   R¹² is an optionally substituted 5-6 membered heterocycle;    -   R¹³ is selected from hydrogen and optionally substituted C₁₋₆        alkyl, or is absent;    -   R¹⁴ is selected from hydrogen, halogen, —OH, —OR⁸, —N(R⁷)₂,        —SR⁷, =0, and optionally substituted C₁₋₆ alkyl;    -   R¹⁵ is selected from hydrogen and optionally substituted C₁₋₆        alkyl, or is absent; and    -   R¹⁶ is selected from hydrogen, halogen, —OH, —OR⁸, —N(R⁷)₂,        —SR⁷, =0, and optionally substituted C₁₋₆ alkyl,    -   wherein optional substituents on R¹¹, R¹³, R¹⁴, R¹⁵, and R¹⁶ are        selected from R¹⁷; and    -   each R¹⁷ is independently selected from halogen, —OH, —OR¹⁰,        —N(R⁹)₂, —C(═O)R⁹, —C(═O)OR⁹, —OC(═O)R⁹, —C(═O)N(R⁹)₂, and        —NR⁹C(═O)R⁹.

In some embodiments, X is C.

In some embodiments, R¹² is selected from optionally substituted riboseand deoxyribose. In some embodiments, R¹² is optionally substituted withan optionally substituted monophosphate, diphosphate, or triphosphatemoiety.

In some embodiments, R² is hydrogen.

In some embodiments, each R³ is hydrogen.

In some embodiments, R^(A) is an optionally substituted 5-8 memberedmonocyclic ring system. In some embodiments, R^(A) is an optionallysubstituted phenyl moiety.

In some embodiments, n is 1 and R¹ is hydrogen.

In some embodiments, the compound is a compound of Formula (III):

or a salt thereof, wherein:

-   -   dotted lines represent bonds that may be present or absent;    -   R¹⁸ is selected from hydrogen, halogen, —OH, —OR⁸, —N(R⁷)₂,        —SR⁷, =0, and optionally substituted C₁₋₆ alkyl;    -   R¹⁹ is an optionally substituted 5-6 membered heterocycle;    -   R²⁰ is selected from hydrogen, halogen, —OH, —OR⁸, —N(R⁷)₂,        —SR⁷, =0, and optionally substituted C₁₋₆ alkyl;    -   R²¹ is selected from hydrogen and optionally substituted C₁₋₆        alkyl, or is absent; and    -   R²² is selected from hydrogen, halogen, —OH, —OR⁸, —N(R⁷)₂,        —SR⁷, =0, and optionally substituted C₁₋₆ alkyl,    -   wherein optional substituents on R¹⁸, R²⁰, R²¹, and R²² are        selected from R²³; and    -   each R²³ is independently selected from halogen, —OH, —OR¹⁰,        —N(R⁹)₂, —C(═O)R⁹, —C(═O)OR⁹, —OC(═O)R⁹, —C(═O)N(R⁹)₂, and        —NR⁹C(═O)R⁹.

In some embodiments, R¹⁹ is selected from optionally substituted riboseand deoxyribose. In some embodiments, R¹⁹ is optionally substituted withan optionally substituted monophosphate, diphosphate, or triphosphatemoiety.

In some embodiments, R² is hydrogen.

In some embodiments, each R³ is hydrogen.

In some embodiments, R^(A) is an optionally substituted 5-8 memberedmonocyclic ring system. In some embodiments, R^(A) is an optionallysubstituted phenyl moiety.

In some embodiments, n is 1 and R¹ is hydrogen.

In another aspect, the present disclosure provides a compositioncomprising a chemical moiety of Formula (IV):

or a salt thereof, wherein:

-   -   R^(A) is an optionally substituted 5-12 membered ring system,        wherein substituents on R^(A) are independently selected from        R⁴;    -   R^(C) is selected from optionally substituted C₁₋₆ alkyl,        optionally substituted C₂₋₆ alkenyl, and optionally substituted        C₂₋₆ alkynyl, wherein substituents on R¹ are independently        selected from R⁶, or is absent;    -   R¹ is selected from hydrogen, halogen, —OH, —OR⁸, ═O, ═S,        optionally substituted C₁₋₆ alkyl, optionally substituted C₂₋₆        alkenyl, optionally substituted C₂₋₆ alkynyl, optionally        substituted C₃₋₆ cycloalkyl, and optionally substituted        3-6-membered heterocycloalkyl, wherein substituents on R¹ are        independently selected from R⁶;    -   R² is selected from hydrogen, optionally substituted C₁₋₆ alkyl,        optionally substituted C₂₋₆ alkenyl, optionally substituted C₂₋₆        alkynyl, optionally substituted C₃₋₆ cycloalkyl, and optionally        substituted 3-6-membered heterocycloalkyl, wherein substituents        on R² are independently selected from R⁶;    -   each R³ is independently selected from hydrogen, halogen, —CN,        —OH, —OR⁸, —C(═O)R⁸, —CO₂R⁷, —C(═O)N(R⁷)₂, —N(R⁷)₂, —NRC(═O)R⁷,        —NR⁷C(═O)N(R⁷)₂, —SR⁷, —S(═O)R⁸, —SO₂R⁸, —SO₂N(R⁷)₂, —NO₂,        optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆        alkenyl, optionally substituted C₁-C₆ alkynyl, optionally        substituted monocyclic carbocycle, and optionally substituted        monocyclic heterocycle, wherein optional substituents on C₁-C₆        alkyl, C₁-C₆ alkenyl, C₁-C₆ alkynyl, monocyclic carbocycle, and        monocyclic heterocycle are independently selected from R⁶;    -   or two R³ are taken together with the atom to which they are        attached to form an optionally substituted 3- to 6-membered        heterocycle or carbocycle, wherein optional substituents on the        3- to 6-membered heterocycle or carbocycle are independently        selected from R⁶;    -   R⁴ is selected from halogen, ═O, ═S, —CN, —OH, —OR¹⁰, —N(R⁹)₂,        —C(═O)R⁹, —C(═O)OR⁹, —OC(═O)R⁹, —C(═O)N(R⁹)₂, —NR⁹C(═O)R⁹,        —NR⁹C(═O)N(R⁹)₂, —OC(═O)N(R⁹)₂, —NR⁹C(═O)OR⁹, —OC(═O)OR⁹,        —NR⁹SO₂R⁹, —SR⁹, —S(═O)R¹⁰, —SO₂R¹⁰, or —SO₂N(R⁹)₂, —NO₂,        optionally substituted C₁-C₆ alkyl, optionally substituted C₂-C₆        alkenyl, optionally substituted C₂-C₆ alkynyl, an optionally        substituted C₃-C₁₀ carbocycle, and an optionally substituted        3-10-membered heterocycle, wherein substituents on R⁴ are        independently selected from R⁶;    -   each R⁶ is independently selected from halogen, ═O, ═S, —CN,        —OH, —OR¹⁰, —N(R⁹)₂, —C(═O)R⁹, —C(═O)OR⁹, —OC(═O)R⁹,        —C(═O)N(R⁹)₂, —NR⁹C(═O)R⁹, —NR⁹C(═O)N(R⁹)₂, —OC(═O)N(R⁹)₂,        —NR⁹C(═O)OR⁹, —OC(═O)OR⁹, —SR⁹, —S(═O)R¹⁰, —SO₂R¹⁰, —SO₂N(R⁹)₂,        —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆        haloalkyl, C₁-C₆ hydroxyalkyl, C₁-C₆ aminoalkyl, C₃-C₆        carbocycle, optionally substituted monophosphate, optionally        substituted diphosphate, optionally substituted triphosphate,        and 3- to 6-membered heterocycle;    -   each R⁷ is independently selected from hydrogen, optionally        substituted C₁-C₆ alkyl, optionally substituted C₃-C₆        carbocycle, and optionally substituted 3-6-membered heterocycle,        wherein optional substituents on the C₁-C₆ alkyl, C₃-C₆        carbocycle, and 3-6-membered heterocycle are independently        selected from R⁶;    -   or two R⁷ are taken together with the atom(s) to which they are        attached to form an optionally substituted 3- to 6-membered        heterocycle, wherein optional substituents on the 3- to        6-membered heterocycle are independently selected from R⁶;    -   each R⁸ is independently selected from optionally substituted        C₁-C₆ alkyl, optionally substituted C₃-C₆ carbocycle, and        optionally substituted 3-6-membered heterocycle, wherein        optional substituents on the C₁-C₆ alkyl, C₃-C₆ carbocycle, and        3-6-membered heterocycle are independently selected from R⁶;    -   each R⁹ is independently selected from hydrogen, C₁-C₆ alkyl,        C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₃-C₆ carbocycle,        and 3- to 6-membered heterocycle;    -   or two R⁹ on the same nitrogen atom are taken together with the        nitrogen to which they are attached to form a 3- to 6-membered        heterocycle;    -   each R¹⁰ is independently selected from C₁-C₆ alkyl, C₂-C₆        alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₃-C₆ carbocycle, and        3- to 6-membered heterocycle;    -   n is selected from 1, 2, 3, 4, and 5; and    -   Z is a substrate selected from a nucleotide or nucleotide        analog, cell, protein, lipid, and antibody.

In some embodiments, Z is a cell, protein, lipid, or antibody. In someembodiments, Z is a nucleotide or nucleotide analog. In someembodiments, the nucleotide or nucleotide analog is incorporated into apolynucleotide.

In some embodiments, R^(A) is an optionally substituted 5-12 memberedcarbocyclic ring system. In some embodiments, R^(A) is an optionallysubstituted 5-12 membered heterocyclic ring system. In some embodiments,R^(A) is an aromatic ring system. In some embodiments, R^(A) is anoptionally substituted 5-12 membered bicyclic ring system. In someembodiments, R^(A) is an optionally substituted 5-8 membered monocyclicring system. In some embodiments, R^(A) is an optionally substitutedphenyl moiety.

In some embodiments, R^(C) is absent.

In some embodiments, each R⁴ is independently selected from halogen,—OH, —OR¹⁰, —N(R⁹)₂, —C(═O)R⁹, —C(═O)OR⁹, —OC(═O)R⁹, —C(═O)N(R⁹)₂,—NR⁹C(═O)R⁹, —NR⁹C(═O)N(R⁹)₂, —OC(═O)N(R⁹)₂, —NR⁹C(═O)OR⁹, —OC(═O)OR⁹,and optionally substituted C₁-C₆ alkyl.

In some embodiments, R² is hydrogen.

In some embodiments, each R³ is hydrogen.

In some embodiments, n is 1 and R¹ is hydrogen.

In a further aspect, the present disclosure provides a modifiedpolynucleotide comprising a compound described herein.

In some embodiments, the modified polynucleotide comprises two or morecompounds described herein. In some embodiments, the two or morecompounds have the same or different structures. In some embodiments,the two or more compounds are separated by at least one nucleotide. Insome embodiments, the two or more compounds are included in a samestrand of the modified polynucleotide.

In some embodiments, the modified polynucleotide comprises ribonucleicacid. In some embodiments, the modified polynucleotide comprisesdeoxyribonucleic acid.

In another aspect, the present disclosure provides a method ofgenerating a compound described herein, comprising: (a) providing alabeled substrate comprising a substrate, a labeling moiety, and alinker coupling the labeling moiety to the substrate, wherein the linkercomprises a cleavable group that is configured to be cleaved to separatethe labeling moiety from the substrate; and (b) contacting the labeledsubstrate a cleavage reagent configured to cleave the cleavable group ofthe linker, thereby separating the labeling moiety and the substrate toprovide the compound.

In some embodiments, the labeling moiety comprises a fluorescent label.

In some embodiments, the cleavable group comprises a disulfide bond.

In some embodiments, the cleavage reagent is selected from the groupconsisting of tris(2-carboxyethyl)phosphine (TCEP), dithiothreitol(DTT), tetrahydropyranyl (THP), ultraviolet (UV) light, and acombination thereof.

In some embodiments, the substrate is a nucleotide or nucleotide analog.In some embodiments, the labeled substrate is incorporated into apolynucleotide.

In a further aspect, the present disclosure provides a method ofgenerating a composition described herein, comprising: (a) providing alabeled substrate comprising a substrate, a labeling moiety, and alinker coupling the labeling moiety to the substrate, wherein the linkercomprises a cleavable group that is configured to be cleaved to separatethe labeling moiety from the substrate; and (b) contacting the labeledsubstrate a cleavage reagent configured to cleave the cleavable group ofthe linker, thereby separating the labeling moiety and the substrate toprovide the compound.

In some embodiments, the labeling moiety comprises a fluorescent label.

In some embodiments, the cleavable group comprises a disulfide bond.

In some embodiments, the cleavage reagent is selected from the groupconsisting of tris(2-carboxyethyl)phosphine (TCEP), dithiothreitol(DTT), tetrahydropyranyl (THP), ultraviolet (UV) light, and acombination thereof.

In some embodiments, the substrate is a nucleotide or nucleotide analog.In some embodiments, the labeled substrate is incorporated into apolynucleotide. In some embodiments, the substrate is a protein, lipid,cell, or antibody.

In another aspect, the present disclosure provides a method ofgenerating a modified polynucleotide described herein, comprising: (a)providing a precursor of the compound and a template nucleic acidmolecule coupled to a nucleic acid strand; (b) subjecting the templatenucleic acid molecule and the precursor of the compound to conditionssufficient to incorporate the precursor of the compound into the nucleicacid strand coupled to the template nucleic acid molecule; and (c)subjecting the precursor of the compound to conditions sufficient togenerate the compound from the precursor.

In some embodiments, (b) comprises using a polymerase enzyme toincorporate the compound into the nucleic acid strand. In someembodiments, the polymerase enzyme is a strand displacement polymeraseenzyme.

In some embodiments, the template nucleic acid molecule comprisesdeoxyribonucleic acid. In some embodiments, the template nucleic acidmolecule comprises ribonucleic acid.

In some embodiments, the template nucleic acid molecule is immobilizedto a support.

In some embodiments, the precursor of the compound comprises a labelingmoiety. In some embodiments, the labeling moiety comprises a fluorescentdye. In some embodiments, the precursor comprises the labeling moietycoupled to a substrate via linker.

In some embodiments, the substrate is a nucleotide or nucleotide analog.In some embodiments, the linker comprises a cleavable group configuredto be cleaved to separate the labeling moiety from the substrate. Insome embodiments, the cleavable group comprises a disulfide bond. Insome embodiments, (c) comprises contacting the precursor of the compoundwith a cleavage reagent configured to cleave the cleavable group of thelinker, thereby generating the compound.

Another aspect of the present disclosure provides a non-transitorycomputer readable medium comprising machine executable code that, uponexecution by one or more computer processors, implements any of themethods above or elsewhere herein.

Another aspect of the present disclosure provides a system comprisingone or more computer processors and computer memory coupled thereto. Thecomputer memory comprises machine executable code that, upon executionby the one or more computer processors, implements any of the methodsabove or elsewhere herein.

Additional aspects and advantages of the present disclosure will becomereadily apparent to those skilled in this art from the followingdetailed description, wherein only illustrative embodiments of thepresent disclosure are shown and described. As will be realized, thepresent disclosure is capable of other and different embodiments, andits several details are capable of modifications in various obviousrespects, all without departing from the disclosure. Accordingly, thedrawings and description are to be regarded as illustrative in nature,and not as restrictive.

INCORPORATION BY REFERENCE

All publications, patents, and patent applications mentioned in thisspecification are herein incorporated by reference to the same extent asif each individual publication, patent, or patent application wasspecifically and individually indicated to be incorporated by reference.To the extent publications and patents or patent applicationsincorporated by reference contradict the disclosure contained in thespecification, the specification is intended to supersede and/or takeprecedence over any such contradictory material.

BRIEF DESCRIPTION OF THE DRAWINGS

The novel features of the invention are set forth with particularity inthe appended claims. A better understanding of the features andadvantages of the present invention will be obtained by reference to thefollowing detailed description that sets forth illustrative embodiments,in which the principles of the invention are utilized, and theaccompanying drawings (also “Figure” and “FIG.” herein), of which:

FIG. 1A shows examples of linkers of the present disclosure;

FIG. 1B shows an example of a linker of the present disclosure;

FIG. 1C shows an example of a linker of the present disclosure, where Ris a water solubilizing group;

FIG. 2A shows an example of a method for synthesizing a linker of thepresent disclosure having an effective length of about 2 nanometers;

FIG. 2B shows an example of reagents that can be used in the method ofFIG. 2A for synthesizing a linker of the present disclosure as well assome trifunctional reagents;

FIG. 2C shows an example of a method for synthesizing a linker of thepresent disclosure that is polymeric with defined molecular weight andlinking groups; and

FIG. 3 shows a computer system that is programmed or otherwiseconfigured to implement methods provided herein;

FIG. 4 shows an example of a method for constructing a labelednucleotide comprising a propargyl-derivatized nucleotide, a linker, anda dye.

FIGS. 5A and 5B show an example method for preparing a labelednucleotide comprising a dGTP analog.

FIG. 6 shows an example method for the preparing a labeled nucleotidecomprising dCTP.

FIG. 7 shows components used to construct dye-labeled nucleotides forexcitation at about 530 nm.

FIG. 8 shows an example method for preparing a labeled nucleotidecomprising a guanine analog.

FIG. 9 shows a schematic of a bead-based assay for evaluating labelednucleotides.

FIG. 10 shows results of a bead-based assay for different labeled dUTPs.

FIG. 11 shows results of a bead-based assay for different labeled dATPs.

FIG. 12 shows results of a bead-based assay for different labeled dGTPs.

FIGS. 13A-13C show an example method for preparing a labeled nucleotidecomprising a guanine analog.

FIGS. 14A and 14B show an example method for preparing a labelednucleotide comprising repeating units of an amino acid.

FIG. 15 shows a schematic of an assay for evaluating quenching.

FIG. 16 shows quenching results for red dye linkers.

FIG. 17 shows quenching results for green dye linkers.

FIG. 18 shows an example sequencing procedure.

FIG. 19 shows tolerances of different labeled nucleotides.

FIGS. 20A and 20B show examples of constructs including homopolymericregions.

FIG. 20C shows signals detected from sequencing a template having ahomopolymeric region using labeled nucleotides.

FIG. 21A shows example results of a sequencing analysis utilizingpopulations of nucleotides comprising 20% fluorophore labeled dNTPs.

FIG. 21B shows fluorescence signal intensity as a function ofhomopolymer length.

FIG. 22 shows example results of a sequencing analysis utilizingpopulations of nucleotides comprising 100% fluorophore labeled dNTPs.

DETAILED DESCRIPTION

While various embodiments of the invention have been shown and describedherein, it will be obvious to those skilled in the art that suchembodiments are provided by way of example only. Numerous variations,changes, and substitutions may occur to those skilled in the art withoutdeparting from the invention. It should be understood that variousalternatives to the embodiments of the invention described herein may beemployed.

Where values are described as ranges, it will be understood that suchdisclosure includes the disclosure of all possible sub-ranges withinsuch ranges, as well as specific numerical values that fall within suchranges irrespective of whether a specific numerical value or specificsub-range is expressly stated.

The terms “about” and “approximately” shall generally mean an acceptabledegree of error or variation for a given value or range of values, suchas, for example, a degree of error or variation that is within 20percent (%), within 15%, within 10%, or within 5% of a given value orrange of values.

The term “subject,” as used herein, generally refers to an individual orentity from which a biological sample (e.g., a biological sample that isundergoing or will undergo processing or analysis) may be derived. Asubject may be an animal (e.g., mammal or non-mammal) or plant. Thesubject may be a human, dog, cat, horse, pig, bird, non-human primate,simian, farm animal, companion animal, sport animal, or rodent. Asubject may be a patient. The subject may have or be suspected of havinga disease or disorder, such as cancer (e.g., breast cancer, colorectalcancer, brain cancer, leukemia, lung cancer, skin cancer, liver cancer,pancreatic cancer, lymphoma, esophageal cancer or cervical cancer) or aninfectious disease. Alternatively or in addition to, a subject may beknown to have previously had a disease or disorder. The subject may haveor be suspected of having a genetic disorder such as achondroplasia,alpha-1 antitrypsin deficiency, antiphospholipid syndrome, autism,autosomal dominant polycystic kidney disease, Charcot-Marie-tooth, cridu chat, Crohn's disease, cystic fibrosis, Dercum disease, downsyndrome, Duane syndrome, Duchenne muscular dystrophy, factor V Leidenthrombophilia, familial hypercholesterolemia, familial Mediterraneanfever, fragile x syndrome, Gaucher disease, hemochromatosis, hemophilia,holoprosencephaly, Huntington's disease, Klinefelter syndrome, Marfansyndrome, myotonic dystrophy, neurofibromatosis, Noonan syndrome,osteogenesis imperfecta, Parkinson's disease, phenylketonuria, Polandanomaly, porphyria, progeria, retinitis pigmentosa, severe combinedimmunodeficiency, sickle cell disease, spinal muscular atrophy,Tay-Sachs, thalassemia, trimethylaminuria, Turner syndrome,velocardiofacial syndrome, WAGR syndrome, or Wilson disease. A subjectmay be undergoing treatment for a disease or disorder. A subject may besymptomatic or asymptomatic of a given disease or disorder. A subjectmay be healthy (e.g., not suspected of having disease or disorder). Asubject may have one or more risk factors for a given disease. A subjectmay have a given weight, height, body mass index, or other physicalcharacteristic. A subject may have a given ethnic or racial heritage,place of birth or residence, nationality, disease or remission state,family medical history, or other characteristic.

As used herein, the term “biological sample” generally refers to asample obtained from a subject. The biological sample may be obtaineddirectly or indirectly from the subject. A sample may be obtained from asubject via any suitable method, including, but not limited to,spitting, swabbing, blood draw, biopsy, obtaining excretions (e.g.,urine, stool, sputum, vomit, or saliva), excision, scraping, andpuncture. A sample may be obtained from a subject by, for example,intravenously or intraarterially accessing the circulatory system,collecting a secreted biological sample (e.g., stool, urine, saliva,sputum, etc.), breathing, or surgically extracting a tissue (e.g.,biopsy). The sample may be obtained by non-invasive methods includingbut not limited to: scraping of the skin or cervix, swabbing of thecheek, or collection of saliva, urine, feces, menses, tears, or semen.Alternatively, the sample may be obtained by an invasive procedure suchas biopsy, needle aspiration, or phlebotomy. A sample may comprise abodily fluid such as, but not limited to, blood (e.g., whole blood, redblood cells, leukocytes or white blood cells, platelets), plasma, serum,sweat, tears, saliva, sputum, urine, semen, mucus, synovial fluid,breast milk, colostrum, amniotic fluid, bile, bone marrow, interstitialor extracellular fluid, or cerebrospinal fluid. For example, a samplemay be obtained by a puncture method to obtain a bodily fluid comprisingblood and/or plasma. Such a sample may comprise both cells and cell-freenucleic acid material. Alternatively, the sample may be obtained fromany other source including but not limited to blood, sweat, hairfollicle, buccal tissue, tears, menses, feces, or saliva. The biologicalsample may be a tissue sample, such as a tumor biopsy. The sample may beobtained from any of the tissues provided herein including, but notlimited to, skin, heart, lung, kidney, breast, pancreas, liver,intestine, brain, prostate, esophagus, muscle, smooth muscle, bladder,gall bladder, colon, or thyroid. The methods of obtaining providedherein include methods of biopsy including fine needle aspiration, coreneedle biopsy, vacuum assisted biopsy, large core biopsy, incisionalbiopsy, excisional biopsy, punch biopsy, shave biopsy or skin biopsy.The biological sample may comprise one or more cells. A biologicalsample may comprise one or more nucleic acid molecules such as one ormore deoxyribonucleic acid (DNA) and/or ribonucleic acid (RNA) molecules(e.g., included within cells or not included within cells). Nucleic acidmolecules may be included within cells. Alternatively or in addition to,nucleic acid molecules may not be included within cells (e.g., cell-freenucleic acid molecules). The biological sample may be a cell-freesample.

The term “cell-free sample,” as used herein, generally refers to asample that is substantially free of cells (e.g., less than 10% cells ona volume basis). A cell-free sample may be derived from any source(e.g., as described herein). For example, a cell-free sample may bederived from blood, sweat, urine, or saliva. For example, a cell-freesample may be derived from a tissue or bodily fluid. A cell-free samplemay be derived from a plurality of tissues or bodily fluids. Forexample, a sample from a first tissue or fluid may be combined with asample from a second tissue or fluid (e.g., while the samples areobtained or after the samples are obtained). In an example, a firstfluid and a second fluid may be collected from a subject (e.g., at thesame or different times) and the first and second fluids may be combinedto provide a sample. A cell-free sample may comprise one or more nucleicacid molecules such as one or more DNA or RNA molecules.

A sample that is not a cell-free sample (e.g., a sample comprising oneor more cells) may be processed to provide a cell-free sample. Forexample, a sample that includes one or more cells as well as one or morenucleic acid molecules (e.g., DNA and/or RNA molecules) not includedwithin cells (e.g., cell-free nucleic acid molecules) may be obtainedfrom a subject. The sample may be subjected to processing (e.g., asdescribed herein) to separate cells and other materials from the nucleicacid molecules not included within cells, thereby providing a cell-freesample (e.g., comprising nucleic acid molecules not included withincells). The cell-free sample may then be subjected to further analysisand processing (e.g., as provided herein). Nucleic acid molecules notincluded within cells (e.g., cell-free nucleic acid molecules) may bederived from cells and tissues. For example, cell-free nucleic acidmolecules may derive from a tumor tissue or a degraded cell (e.g., of atissue of a body). Cell-free nucleic acid molecules may comprise anytype of nucleic acid molecules (e.g., as described herein). Cell-freenucleic acid molecules may be double-stranded, single-stranded, or acombination thereof. Cell-free nucleic acid molecules may be releasedinto a bodily fluid through secretion or cell death processes, e.g.,cellular necrosis, apoptosis, or the like. Cell-free nucleic acidmolecules may be released into bodily fluids from cancer cells (e.g.,circulating tumor DNA (ctDNA)). Cell free nucleic acid molecules mayalso be fetal DNA circulating freely in a maternal blood stream (e.g.,cell-free fetal nucleic acid molecules such as cffDNA). Alternatively orin addition to, cell-free nucleic acid molecules may be released intobodily fluids from healthy cells.

A biological sample may be obtained directly from a subject and analyzedwithout any intervening processing, such as, for example, samplepurification or extraction. For example, a blood sample may be obtaineddirectly from a subject by accessing the subject's circulatory system,removing the blood from the subject (e.g., via a needle), andtransferring the removed blood into a receptacle. The receptacle maycomprise reagents (e.g., anti-coagulants) such that the blood sample isuseful for further analysis. Such reagents may be used to process thesample or analytes derived from the sample in the receptacle or anotherreceptacle prior to analysis. In another example, a swab may be used toaccess epithelial cells on an oropharyngeal surface of the subject.Following obtaining the biological sample from the subject, the swabcontaining the biological sample may be contacted with a fluid (e.g., abuffer) to collect the biological fluid from the swab.

Any suitable biological sample that comprises one or more nucleic acidmolecules may be obtained from a subject. A sample (e.g., a biologicalsample or cell-free biological sample) suitable for use according to themethods provided herein may be any material comprising tissues, cells,degraded cells, nucleic acids, genes, gene fragments, expressionproducts, gene expression products, and/or gene expression productfragments of an individual to be tested. A biological sample may besolid matter (e.g., biological tissue) or may be a fluid (e.g., abiological fluid). In general, a biological fluid may include any fluidassociated with living organisms. Non-limiting examples of a biologicalsample include blood (or components of blood—e.g., white blood cells,red blood cells, platelets) obtained from any anatomical location (e.g.,tissue, circulatory system, bone marrow) of a subject, cells obtainedfrom any anatomical location of a subject, skin, heart, lung, kidney,breath, bone marrow, stool, semen, vaginal fluid, interstitial fluidsderived from tumorous tissue, breast, pancreas, cerebral spinal fluid,tissue, throat swab, biopsy, placental fluid, amniotic fluid, liver,muscle, smooth muscle, bladder, gall bladder, colon, intestine, brain,cavity fluids, sputum, pus, microbiota, meconium, breast milk, prostate,esophagus, thyroid, serum, saliva, urine, gastric and digestive fluid,tears, ocular fluids, sweat, mucus, earwax, oil, glandular secretions,spinal fluid, hair, fingernails, skin cells, plasma, nasal swab ornasopharyngeal wash, spinal fluid, cord blood, emphatic fluids, and/orother excretions or body tissues. Methods for determining samplesuitability and/or adequacy are provided. A sample may include, but isnot limited to, blood, plasma, tissue, cells, degraded cells, cell-freenucleic acid molecules, and/or biological material from cells or derivedfrom cells of an individual such as cell-free nucleic acid molecules.The sample may be a heterogeneous or homogeneous population of cells,tissues, or cell-free biological material. The biological sample may beobtained using any method that can provide a sample suitable for theanalytical methods described herein.

A sample (e.g., a biological sample or cell-free biological sample) mayundergo one or more processes in preparation for analysis, including,but not limited to, filtration, centrifugation, selective precipitation,permeabilization, isolation, agitation, heating, purification, and/orother processes. For example, a sample may be filtered to removecontaminants or other materials. In an example, a sample comprisingcells may be processed to separate the cells from other material in thesample. Such a process may be used to prepare a sample comprising onlycell-free nucleic acid molecules. Such a process may consist of amulti-step centrifugation process. Multiple samples, such as multiplesamples from the same subject (e.g., obtained in the same or differentmanners from the same or different bodily locations, and/or obtained atthe same or different times (e.g., seconds, minutes, hours, days, weeks,months, or years apart)) or multiple samples from different subjects maybe obtained for analysis as described herein. In an example, the firstsample is obtained from a subject before the subject undergoes atreatment regimen or procedure and the second sample is obtained fromthe subject after the subject undergoes the treatment regimen orprocedure. Alternatively or in addition to, multiple samples may beobtained from the same subject at the same or approximately the sametime. Different samples obtained from the same subject may be obtainedin the same or different manner. For example, a first sample may beobtained via a biopsy and a second sample may be obtained via a blooddraw. Samples obtained in different manners may be obtained by differentmedical professionals, using different techniques, at different times,and/or at different locations. Different samples obtained from the samesubject may be obtained from different areas of a body. For example, afirst sample may be obtained from a first area of a body (e.g., a firsttissue) and a second sample may be obtained from a second area of thebody (e.g., a second tissue).

A biological sample as used herein (e.g., a biological sample comprisingone or more nucleic acid molecules) may not be purified when provided ina reaction vessel. Furthermore, for a biological sample comprising oneor more nucleic acid molecules, the one or more nucleic acid moleculesmay not be extracted when the biological sample is provided to areaction vessel. For example, ribonucleic acid (RNA) and/ordeoxyribonucleic acid (DNA) molecules of a biological sample may not beextracted from the biological sample when providing the biologicalsample to a reaction vessel. Moreover, a target nucleic acid (e.g., atarget RNA or target DNA molecules) present in a biological sample maynot be concentrated when providing the biological sample to a reactionvessel. Alternatively, a biological sample may be purified and/ornucleic acid molecules may be isolated from other materials in thebiological sample.

A biological sample as described herein may contain a target nucleicacid. As used herein, the terms “template nucleic acid”, “target nucleicacid”, “nucleic acid molecule,” “nucleic acid sequence,” “nucleic acidfragment,” “oligonucleotide,” “polynucleotide,” and “nucleic acid”generally refer to polymeric forms of nucleotides of any length, such asdeoxyribonucleotides (dNTPs) or ribonucleotides (rNTPs), or analogsthereof, and may be used interchangeably. Nucleic acids may have anythree-dimensional structure, and may perform any function, known orunknown. A nucleic acid molecule may have a length of at least about 10nucleic acid bases (“bases”), 20 bases, 30 bases, 40 bases, 50 bases,100 bases, 200 bases, 300 bases, 400 bases, 500 bases, 1 kilobase (kb),2 kb, 3, kb, 4 kb, 5 kb, 10 kb, 50 kb, or more. An oligonucleotide istypically composed of a specific sequence of four nucleotide bases:adenine (A); cytosine (C); guanine (G); and thymine (T) (uracil (U) forthymine (T) when the polynucleotide is RNA). Oligonucleotides mayinclude one or more nonstandard nucleotide(s), nucleotide analog(s)and/or modified nucleotides. Non-limiting examples of nucleic acidsinclude DNA, RNA, genomic DNA (e.g., gDNA such as sheared gDNA),cell-free DNA (e.g., cfDNA), synthetic DNA/RNA, coding or non-codingregions of a gene or gene fragment, loci (locus) defined from linkageanalysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomalRNA, short interfering RNA (siRNA), short-hairpin RNA (shRNA), micro-RNA(miRNA), ribozymes, complementary DNA (cDNA), recombinant nucleic acids,branched nucleic acids, plasmids, vectors, isolated DNA of any sequence,isolated RNA of any sequence, nucleic acid probes, and primers. Anucleic acid may comprise one or more modified nucleotides, such asmethylated nucleotides and nucleotide analogs. If present, modificationsto the nucleotide structure may be made before or following assembly ofthe nucleic acid. The sequence of nucleotides of a nucleic acid may beinterrupted by non-nucleotide components. A nucleic acid may be furthermodified following polymerization, such as by conjugation or bindingwith a reporter agent.

A target nucleic acid or sample nucleic acid as described herein may beamplified to generate an amplified product. A target nucleic acid may bea target RNA or a target DNA. When the target nucleic acid is a targetRNA, the target RNA may be any type of RNA, including types of RNAdescribed elsewhere herein. The target RNA may be viral RNA and/or tumorRNA. A viral RNA may be pathogenic to a subject. Non-limiting examplesof pathogenic viral RNA include human immunodeficiency virus I (HIV I),human immunodeficiency virus n (HIV 11), orthomyxoviruses, Ebola virus.Dengue virus, influenza viruses (e.g., H1N1, H3N2, H7N9, or H5N1),hepesvirus, hepatitis A virus, hepatitis B virus, hepatitis C (e.g.,armored RNA-HCV virus) virus, hepatitis D virus, hepatitis E virus,hepatitis G virus, Epstein-Barr virus, mononucleosis virus,cytomegalovirus, SARS virus, West Nile Fever virus, polio virus, andmeasles virus.

A biological sample may comprise a plurality of target nucleic acidmolecules. For example, a biological sample may comprise a plurality oftarget nucleic acid molecules from a single subject. In another example,a biological sample may comprise a first target nucleic acid moleculefrom a first subject and a second target nucleic acid molecule from asecond subject.

The term “nucleotide,” as used herein, generally refers to a substanceincluding a base (e.g., a nucleobase), sugar moiety, and phosphatemoiety. A nucleotide may comprise a free base with attached phosphategroups. A substance including a base with three attached phosphategroups may be referred to as a nucleoside triphosphate. When anucleotide is being added to a growing nucleic acid molecule strand, theformation of a phosphodiester bond between the proximal phosphate of thenucleotide to the growing chain may be accompanied by hydrolysis of ahigh-energy phosphate bond with release of the two distal phosphates asa pyrophosphate. The nucleotide may be naturally occurring ornon-naturally occurring (e.g., a modified or engineered nucleotide).

The term “nucleotide analog,” as used herein, may include, but is notlimited to, a nucleotide that may or may not be a naturally occurringnucleotide. For example, a nucleotide analog may be derived from and/orinclude structural similarities to a canonical nucleotide such asadenine-(A), thymine-(T), cytosine-(C), uracil-(U), or guanine-(G)including nucleotide. A nucleotide analog may comprise one or moredifferences or modifications relative to a natural nucleotide. Examplesof nucleotide analogs include inosine, diaminopurine, 5-fluorouracil,5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine,deazaxanthine, deazaguanine, isocytosine, isoguanine, 4-acetylcytosine,5-(carboxyhydroxylmethyl)uracil,5-carboxymethylaminomethyl-2-thiouridine,5-carboxymethylaminomethyluracil, dihydrouracil,beta-D-galactosylqueosine, N6-isopentenyladenine, 1-methylguanine,1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine,3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine,5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil,beta-D-mannosylqueosine, 5′-methoxycarboxymethyluracil, 5-methoxyuracil,2-methylthio-D46-isopentenyladenine, uracil-5-oxyacetic acid (v),wybutoxosine, pseudouracil, queosine, 2-thiocytosine,5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil,uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v),5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w,2,6-diaminopurine, ethynyl nucleotide bases, 1-propynyl nucleotidebases, azido nucleotide bases, phosphoroselenoate nucleic acids, andmodified versions thereof (e.g., by oxidation, reduction, and/oraddition of a substituent such as an alkyl, hydroxyalkyl, hydroxyl, orhalogen moiety). Nucleic acid molecules (e.g., polynucleotides,double-stranded nucleic acid molecules, single-stranded nucleic acidmolecules, primers, adapters, etc.) may be modified at the base moiety(e.g., at one or more atoms that typically are available to form ahydrogen bond with a complementary nucleotide and/or at one or moreatoms that are not typically capable of forming a hydrogen bond with acomplementary nucleotide), sugar moiety, or phosphate backbone. In somecases, a nucleotide may include a modification in its phosphate moiety,including a modification to a triphosphate moiety. Additional,non-limiting examples of modifications include phosphate chains ofgreater length (e.g., a phosphate chain having, 4, 5, 6, 7, 8, 9, 10 ormore phosphate moieties), modifications with thiol moieties (e.g.,alpha-thio triphosphate and beta-thiotriphosphates), and modificationswith selenium moieties (e.g., phosphoroselenoate nucleic acids). Anucleotide or nucleotide analog may comprise a sugar selected from thegroup consisting of ribose, deoxyribose, and modified versions thereof(e.g., by oxidation, reduction, and/or addition of a substituent such asan alkyl, hydroxyalkyl, hydroxyl, or halogen moiety). A nucleotideanalog may also comprise a modified linker moiety (e.g., in lieu of aphosphate moiety). Nucleotide analogs may also contain amine-modifiedgroups, such as aminoallyl-dUTP (aa-dUTP) and aminohexylacrylamide-dCTP(aha-dCTP) to allow covalent attachment of amine reactive moieties, suchas N-hydroxysuccinimide esters (NHS). Alternatives to standard DNA basepairs or RNA base pairs in the oligonucleotides of the presentdisclosure may provide, for example, higher density in bits per cubicmm, higher safety (resistant to accidental or purposeful synthesis ofnatural toxins), easier discrimination in photo-programmed polymerases,and/or lower secondary structure. Nucleotide analogs may be capable ofreacting or bonding with detectable moieties for nucleotide detection.

The term “homopolymer,” as used herein, generally refers to a polymer ora portion of a polymer comprising identical monomer units. A homopolymermay have a homopolymer sequence. A nucleic acid homopolymer may refer toa polynucleotide or an oligonucleotide comprising consecutiverepetitions of a same nucleotide or any nucleotide variants thereof. Forexample, a homopolymer can be poly(dA), poly(dT), poly(dG), poly(dC),poly(rA), poly(U), poly(rG), or poly(rC). A homopolymer can be of anylength. For example, the homopolymer can have a length of at least 2, 3,4, 5, 10, 20, 30, 40, 50, 100, 200, 300, 400, 500, or more nucleic acidbases. The homopolymer can have from 10 to 500, or 15 to 200, or 20 to150 nucleic acid bases. The homopolymer can have a length of at most500, 400, 300, 200, 100, 50, 40, 30, 20, 10, 5, 4, 3, or 2 nucleic acidbases. A molecule, such as a nucleic acid molecule, can include one ormore homopolymer portions and one or more non-homopolymer portions. Themolecule may be entirely formed of a homopolymer, multiple homopolymers,or a combination of homopolymers and non-homopolymers. In nucleic acidsequencing, multiple nucleotides can be incorporated into ahomopolymeric region of a nucleic acid strand. Such nucleotides may benon-terminated to permit incorporation of consecutive nucleotides (e.g.,during a single nucleotide flow).

The terms “amplifying,” “amplification,” and “nucleic acidamplification” are used interchangeably and generally refer togenerating one or more copies of a nucleic acid or a template. Forexample, “amplification” of DNA generally refers to generating one ormore copies of a DNA molecule. An amplicon may be a single-stranded ordouble-stranded nucleic acid molecule that is generated by anamplification procedure from a starting template nucleic acid molecule.Such an amplification procedure may include one or more cycles of anextension or ligation procedure. The amplicon may comprise a nucleicacid strand, of which at least a portion may be substantially identicalor substantially complementary to at least a portion of the startingtemplate. Where the starting template is a double-stranded nucleic acidmolecule, an amplicon may comprise a nucleic acid strand that issubstantially identical to at least a portion of one strand and issubstantially complementary to at least a portion of either strand. Theamplicon can be single-stranded or double-stranded irrespective ofwhether the initial template is single-stranded or double-stranded.Amplification of a nucleic acid may linear, exponential, or acombination thereof. Amplification may be emulsion based or may benon-emulsion based. Non-limiting examples of nucleic acid amplificationmethods include reverse transcription, primer extension, polymerasechain reaction (PCR), ligase chain reaction (LCR), helicase-dependentamplification, asymmetric amplification, rolling circle amplification,and multiple displacement amplification (MDA). Where PCR is used, anyform of PCR may be used, with non-limiting examples that includereal-time PCR, allele-specific PCR, assembly PCR, asymmetric PCR,digital PCR, emulsion PCR, dial-out PCR, helicase-dependent PCR, nestedPCR, hot start PCR, inverse PCR, methylation-specific PCR, miniprimerPCR, multiplex PCR, nested PCR, overlap-extension PCR, thermalasymmetric interlaced PCR and touchdown PCR. Moreover, amplification canbe conducted in a reaction mixture comprising various components (e.g.,a primer(s), template, nucleotides, a polymerase, buffer components,co-factors, etc.) that participate or facilitate amplification. In somecases, the reaction mixture comprises a buffer that permits contextindependent incorporation of nucleotides. Non-limiting examples includemagnesium-ion, manganese-ion and isocitrate buffers. Additional examplesof such buffers are described in Tabor, S. et al. C.C. PNAS, 1989, 86,4076-4080 and U.S. Pat. Nos. 5,409,811 and 5,674,716, each of which isherein incorporated by reference in its entirety.

Amplification may be clonal amplification. The term “clonal,” as usedherein, generally refers to a population of nucleic acids for which asubstantial portion (e.g., greater than about 50%, 60%, 70%, 80%, 90%,95%, or 99%) of its members have sequences that are at least about 50%,60%, 70%, 80%, 90%, 95%, or 99% identical to one another. Members of aclonal population of nucleic acid molecules may have sequence homologyto one another. Such members may have sequence homology to a templatenucleic acid molecule. The members of the clonal population may bedouble stranded or single stranded. Members of a population may not be100% identical or complementary, e.g., “errors” may occur during thecourse of synthesis such that a minority of a given population may nothave sequence homology with a majority of the population. For example,at least 50% of the members of a population may be substantiallyidentical to each other or to a reference nucleic acid molecule (i.e., amolecule of defined sequence used as a basis for a sequence comparison).At least 60%, at least 70%, at least 80%, at least 90%, at least 95%, atleast 99%, or more of the members of a population may be substantiallyidentical to the reference nucleic acid molecule. Two molecules may beconsidered substantially identical (or homologous) if the percentidentity between the two molecules is at least 60%, 70%, 75%, 80%, 85%,90%, 95%, 98%, 99%, 99.9% or greater. Two molecules may be consideredsubstantially complementary if the percent complementarity between thetwo molecules is at least 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%,99.9% or greater. A low or insubstantial level of mixing ofnon-homologous nucleic acids may occur, and thus a clonal population maycontain a minority of diverse nucleic acids (e.g., less than 30%, e.g.,less than 10%).

Useful methods for clonal amplification from single molecules includerolling circle amplification (RCA) (Lizardi et al., Nat. Genet.19:225-232 (1998), which is incorporated herein by reference), bridgePCR (Adams and Kron, Method for Performing Amplification of Nucleic Acidwith Two Primers Bound to a Single Solid Support, Mosaic Technologies,Inc. (Winter Hill, Mass.); Whitehead Institute for Biomedical Research,Cambridge, Mass., (1997); Adessi et al., Nucl. Acids Res. 28:E87 (2000);Pemov et al., Nucl. Acids Res. 33:e11(2005); or U.S. Pat. No. 5,641,658,each of which is incorporated herein by reference), polony generation(Mitra et al., Proc. Natl. Acad. Sci. USA 100:5926-5931 (2003); Mitra etal., Anal. Biochem. 320:55-65(2003), each of which is incorporatedherein by reference), and clonal amplification on beads using emulsions(Dressman et al., Proc. Natl. Acad. Sci. USA 100:8817-8822 (2003), whichis incorporated herein by reference) or ligation to bead-based adapterlibraries (Brenner et al., Nat. Biotechnol. 18:630-634 (2000); Brenneret al., Proc. Natl. Acad. Sci. USA 97:1665-1670 (2000)); Reinartz, etal., Brief Funct. Genomic Proteomic 1:95-104 (2002), each of which isincorporated herein by reference). The enhanced signal-to-noise ratioprovided by clonal amplification more than outweighs the disadvantagesof the cyclic sequencing requirement.

The term “polymerizing enzyme” or “polymerase,” as used herein,generally refers to any enzyme capable of catalyzing a polymerizationreaction. A polymerizing enzyme may be used to extend a nucleic acidprimer paired with a template strand by incorporation of nucleotides ornucleotide analogs. A polymerizing enzyme may add a new strand of DNA byextending the 3′ end of an existing nucleotide chain, adding newnucleotides matched to the template strand one at a time via thecreation of phosphodiester bonds. The polymerase used herein can havestrand displacement activity or non-strand displacement activity.Examples of polymerases include, without limitation, a nucleic acidpolymerase. An example polymerase is a Φ29 DNA polymerase or aderivative thereof. A polymerase can be a polymerization enzyme. In somecases, a transcriptase or a ligase is used (i.e., enzymes which catalyzethe formation of a bond). Examples of polymerases include a DNApolymerase, an RNA polymerase, a thermostable polymerase, a wild-typepolymerase, a modified polymerase, E. coli DNA polymerase I, T7 DNApolymerase, bacteriophage T4 DNA polymerase Φ29 (phi29) DNA polymerase,Taq polymerase, Tth polymerase, Tli polymerase, Pfu polymerase, Pwopolymerase, VENT polymerase, DEEPVENT polymerase, EX-Taq polymerase,LA-Taq polymerase, Sso polymerase, Poc polymerase, Pab polymerase, Mthpolymerase, ES4 polymerase, Tru polymerase, Tac polymerase, Tnepolymerase, Tma polymerase, Tea polymerase, Tih polymerase, Tfipolymerase, Platinum Taq polymerases, Tbr polymerase, Tfl polymerase,Pfu-turbo polymerase, Pyrobest polymerase, Pwo polymerase, KODpolymerase, Bst polymerase, Sac polymerase, Klenow fragment, polymerasewith 3′ to 5′ exonuclease activity, and variants, modified products andderivatives thereof. In some cases, the polymerase is a single subunitpolymerase. The polymerase can have high processivity, namely thecapability of the polymerase to consecutively incorporate nucleotidesinto a nucleic acid template without releasing the nucleic acidtemplate. In some cases, a polymerase is a polymerase modified to acceptdideoxynucleotide triphosphates, such as for example, Taq polymerasehaving a 667Y mutation (see e.g., Tabor et al, PNAS, 1995, 92,6339-6343, which is herein incorporated by reference in its entirety forall purposes). In some cases, a polymerase is a polymerase having amodified nucleotide binding, which may be useful for nucleic acidsequencing, with non-limiting examples that include ThermoSequenaspolymerase (GE Life Sciences), AmpliTaq FS (ThermoFisher) polymerase andSequencing Pol polymerase (Jena Bioscience). In some cases, thepolymerase is genetically engineered to have discrimination againstdideoxynucleotides, such as for example, Sequenase DNA polymerase(ThermoFisher).

A polymerase may be Family A polymerase or a Family B DNA polymerase.Family A polymerases include, for example, Taq, Klenow, and Bstpolymerases. Family B polymerases include, for example, Vent(exo-) andTherminator polymerases. Family B polymerases are known to accept morevaried nucleotide substrates than Family A polymerases. Family Apolymerases are used widely in sequencing by synthesis methods, likelydue to their high processivity and fidelity.

The term “complementary sequence,” as used herein, generally refers to asequence that hybridizes to another sequence. Hybridization between twosingle-stranded nucleic acid molecules may involve the formation of adouble-stranded structure that is stable under certain conditions. Twosingle-stranded polynucleotides may be considered to be hybridized ifthey are bonded to each other by two or more sequentially adjacent basepairings. A substantial proportion of nucleotides in one strand of adouble-stranded structure may undergo Watson-Crick base-pairing with anucleoside on the other strand. Hybridization may also include thepairing of nucleoside analogs, such as deoxyinosine, nucleosides with2-aminopurine bases, and the like, that may be employed to reduce thedegeneracy of probes, whether or not such pairing involves formation ofhydrogen bonds.

The term “denaturation,” as used herein, generally refers to separationof a double-stranded molecule (e.g., DNA) into single-strandedmolecules. Denaturation may be complete or partial denaturation. Inpartial denaturation, a single-stranded region may form in adouble-stranded molecule by denaturation of the two deoxyribonucleicacid (DNA) strands flanked by double-stranded regions in DNA.

The term “melting temperature” or “melting point,” as used herein,generally refers to the temperature at which at least a portion of astrand of a nucleic acid molecule in a sample has separated from atleast a portion of a complementary strand. The melting temperature maybe the temperature at which a double-stranded nucleic acid molecule haspartially or completely denatured. The melting temperature may refer toa temperature of a sequence among a plurality of sequences of a givennucleic acid molecule, or a temperature of the plurality of sequences.Different regions of a double-stranded nucleic acid molecule may havedifferent melting temperatures. For example, a double-stranded nucleicacid molecule may include a first region having a first melting pointand a second region having a second melting point that is higher thanthe first melting point. Accordingly, different regions of adouble-stranded nucleic acid molecule may melt (e.g., partiallydenature) at different temperatures. The melting point of a nucleic acidmolecule or a region thereof (e.g., a nucleic acid sequence) may bedetermined experimentally (e.g., via a melt analysis or other procedure)or may be estimated based upon the sequence and length of the nucleicacid molecule. For example, a software program such as MELTING may beused to estimate a melting temperature for a nucleic acid sequence(Dumousseau M, Rodriguez N, Juty N, Le Novere N, MELTING, a flexibleplatform to predict the melting temperatures of nucleic acids. BMCBioinformatics. 2012 May 16; 13:101. doi: 10.1186/1471-2105-13-101).Accordingly, a melting point as described herein may be an estimatedmelting point. A true melting point of a nucleic acid sequence may varybased upon the sequences or lack thereof adjacent to the nucleic acidsequence of interest as well as other factors.

The term “sequencing,” as used herein, generally refers to a process forgenerating or identifying a sequence of a biological molecule, such as anucleic acid molecule or a polypeptide. Such sequence may be a nucleicacid sequence, which may include a sequence of nucleic acid bases (e.g.,nucleobases). Sequencing may be, for example, single moleculesequencing, sequencing by synthesis, sequencing by hybridization, orsequencing by ligation. Sequencing may be performed using templatenucleic acid molecules immobilized on a support, such as a flow cell orone or more beads. A sequencing assay may yield one or more sequencingreads corresponding to one or more template nucleic acid molecules.

The term “read,” as used herein, generally refers to a nucleic acidsequence, such as a sequencing read. A sequencing read may be aninferred sequence of nucleic acid bases (e.g., nucleotides) or basepairs obtained via a nucleic acid sequencing assay. A sequencing readmay be generated by a nucleic acid sequencer, such as a massivelyparallel array sequencer (e.g., Illumina or Pacific Biosciences ofCalifornia). A sequencing read may correspond to a portion, or in somecases all, of a genome of a subject. A sequencing read may be part of acollection of sequencing reads, which may be combined through, forexample, alignment (e.g., to a reference genome), to yield a sequence ofa genome of a subject.

The term “detector,” as used herein, generally refers to a device thatis capable of detecting or measuring a signal, such as a signalindicative of the presence or absence of an incorporated nucleotide ornucleotide analog. A detector may include optical and/or electroniccomponents that may detect and/or measure signals. Non-limiting examplesof detection methods involving a detector include optical detection,spectroscopic detection, electrostatic detection, and electrochemicaldetection. Optical detection methods include, but are not limited to,fluorimetry and UV-vis light absorbance. Spectroscopic detection methodsinclude, but are not limited to, mass spectrometry, nuclear magneticresonance (NMR) spectroscopy, and infrared spectroscopy. Electrostaticdetection methods include, but are not limited to, gel based techniques,such as, for example, gel electrophoresis. Electrochemical detectionmethods include, but are not limited to, electrochemical detection ofamplified product after high-performance liquid chromatographyseparation of the amplified products.

The term “support”, as used herein, generally refers to any solid orsemi-solid article on which reagents such as nucleic acid molecules maybe immobilized. Nucleic acid molecules may be synthesized, attached,ligated, or otherwise immobilized. Nucleic acid molecules may beimmobilized on a support by any method including, but not limited to,physical adsorption, by ionic or covalent bond formation, orcombinations thereof. A support may be 2-dimensional (e.g., a planar 2Dsupport) or 3-dimensional. In some cases, a support may be a componentof a flow cell and/or may be included within or adapted to be receivedby a sequencing instrument. A support may include a polymer, a glass, ora metallic material. Examples of supports include a membrane, a planarsupport, a microtiter plate, a bead (e.g., a magnetic bead), a filter, atest strip, a slide, a cover slip, and a test tube. A support maycomprise organic polymers such as polystyrene, polyethylene,polypropylene, polyfluoroethylene, polyethyleneoxy, and polyacrylamide(e.g., polyacrylamide gel), as well as co-polymers and grafts thereof. Asupport may comprise latex or dextran. A support may also be inorganic,such as glass, silica, gold, controlled-pore-glass (CPG), orreverse-phase silica. The configuration of a support may be, forexample, in the form of beads, spheres, particles, granules, a gel, aporous matrix, or a support. In some cases, a support may be a singlesolid or semi-solid article (e.g., a single particle), while in othercases a support may comprise a plurality of solid or semi-solid articles(e.g., a collection of particles). Supports may be planar, substantiallyplanar, or non-planar. Supports may be porous or non-porous, and mayhave swelling or non-swelling characteristics. A support may be shapedto comprise one or more wells, depressions, or other containers,vessels, features, or locations. A plurality of supports may beconfigured in an array at various locations. A support may beaddressable (e.g., for robotic delivery of reagents), or by detectionapproaches, such as scanning by laser illumination and confocal ordeflective light gathering. For example, a support may be in opticaland/or physical communication with a detector. Alternatively, a supportmay be physically separated from a detector by a distance. Anamplification support (e.g., a bead) can be placed within or on anothersupport (e.g., within a well of a second support).

The term “label,” as used herein, generally refers to a moiety that iscapable of coupling with a species, such as, for example a nucleotideanalog. A label may include an affinity moiety. In some cases, a labelmay be a detectable label that emits a signal (or reduces an alreadyemitted signal) that can be detected. In some cases, such a signal maybe indicative of incorporation of one or more nucleotides or nucleotideanalogs. In some cases, a label may be coupled to a nucleotide ornucleotide analog, which nucleotide or nucleotide analog may be used ina primer extension reaction. In some cases, the label may be coupled toa nucleotide analog after a primer extension reaction. The label, insome cases, may be reactive specifically with a nucleotide or nucleotideanalog. Coupling may be covalent or non-covalent (e.g., via ionicinteractions, Van der Waals forces, etc.). In some cases, coupling maybe via a linker, which may be cleavable, such as photo-cleavable (e.g.,cleavable under ultra-violet light), chemically-cleavable (e.g., via areducing agent, such as dithiothreitol (DTT),tris(2-carboxyethyl)phosphine (TCEP), tris(hydroxypropyl)phosphine (THP)or enzymatically cleavable (e.g., via an esterase, lipase, peptidase orprotease). In some cases, the label may be luminescent; that is,fluorescent or phosphorescent. For example, the label may be or comprisea fluorescent moiety (e.g., a dye). Dyes and labels may be incorporatedinto nucleic acid sequences. Dyes and labels may also be incorporatedinto or attached to linkers, such as linkers for linking one or morebeads to one another. For example, labels such as fluorescent moietiesmay be linked to nucleotides or nucleotide analogs via a linker (e.g.,as described herein). Non-limiting examples of dyes include SYBR green,SYBR blue, DAPI, propidium iodine, Hoechst, SYBR gold, ethidium bromide,acridine, proflavine, acridine orange, acriflavine, fluorcoumanin,ellipticine, daunomycin, chloroquine, distamycin D, chromomycin,homidium, mithramycin, ruthenium polypyridyls, anthramycin,phenanthridines and acridines, propidium iodide, hexidium iodide,dihydroethidium, ethidium homodimer-1 and -2, ethidium monoazide, ACMA,Hoechst 33258, Hoechst 33342, Hoechst 34580, DAPI, acridine orange,7-AAD, actinomycin D, LDS751, hydroxystilbamidine, SYTOX Blue, SYTOXGreen, SYTOX Orange, POPO-1, POPO-3, YOYO-1, YOYO-3, TOTO-1, TOTO-3,JOJO-1, LOLO-1, OBO-1, BOBO-3, PO-PRO-1, PO-PRO-3, BO-PRO-1, BO-PRO-3,TO-PRO-1, TO-PRO-3, TO-PRO-5, JO-PRO-1, LO-PRO-1, YO-PRO-1, YO-PRO-3,PicoGreen, OliGreen, RiboGreen, SYBR Gold, SYBR Green I, SYBR Green II,SYBR DX, SYTO labels (e.g., SYTO-40, -41, -42, -43, -44, and -45 (blue);SYTO-13, -16, -24, -21, -23, -12, -11, -20, -22, -15, -14, and -25(green); SYTO-81, -80, -82, -83, -84, and -85 (orange); and SYTO-64,-17, -59, -61, -62, -60, and -63 (red)), fluorescein, fluoresceinisothiocyanate (FITC), tetramethyl rhodamine isothiocyanate (TRITC),rhodamine, tetramethyl rhodamine, R-phycoerythrin, Cy-2, Cy-3, Cy-3.5,Cy-5, Cy5.5, Cy-7, Texas Red, Phar-Red, allophycocyanin (APC), SybrGreen I, Sybr Green II, Sybr Gold, CellTracker Green, 7-AAD, ethidiumhomodimer I, ethidium homodimer II, ethidium homodimer III, ethidiumbromide, umbelliferone, eosin, green fluorescent protein, erythrosin,coumarin, methyl coumarin, pyrene, malachite green, stilbene, luciferyellow, cascade blue, dichlorotriazinylamine fluorescein, dansylchloride, fluorescent lanthanide complexes such as those includingeuropium and terbium, carboxy tetrachloro fluorescein, 5 and/or6-carboxy fluorescein (FAM), VIC, 5- (or 6-) iodoacetamidofluorescein,5-{[2(and 3)-5-(Acetylmercapto)-succinyl]amino} fluorescein(SAMSA-fluorescein), lissamine rhodamine B sulfonyl chloride, 5 and/or 6carboxy rhodamine (ROX), 7-amino-methyl-coumarin,7-Amino-4-methylcoumarin-3-acetic acid (AMCA), BODIPY fluorophores,8-methoxypyrene-1,3,6-trisulfonic acid trisodium salt,3,6-Disulfonate-4-amino-naphthalimide, phycobiliproteins, AlexaFluorlabels (e.g., AlexaFluor 350, 405, 430, 488, 532, 546, 555, 568, 594,610, 633, 635, 647, 660, 680, 700, 750, and 790 dyes), DyLight labels(e.g., DyLight 350, 405, 488, 550, 594, 633, 650, 680, 755, and 800dyes), Black Hole Quencher Dyes (Biosearch Technologies) (e.g., BH1-0,BHQ-1, BHQ-3, and BHQ-10), QSY Dye fluorescent quenchers (MolecularProbes/Invitrogen) (e.g., QSY7, QSY9, QSY21, and QSY35), Dabcyl, Dabsyl,Cy5Q, Cy7Q, Dark Cyanine dyes (GE Healthcare), Dy-Quenchers (Dyomics)(e.g., DYQ-660 and DYQ-661), ATTO fluorescent quenchers (ATTO-TEC GmbH)(e.g., ATTO 540Q, ATTO 580Q, ATTO 612Q, Atto532 [e.g., Atto 532succinimidyl ester], and Atto633), and other fluorophores and/orquenchers. Additional examples are included in structures providedherein. Dyes included in structures provided herein are contemplated foruse in combination with any linker and substrate described herein. Afluorescent dye may be excited by application of energy corresponding tothe visible region of the electromagnetic spectrum (e.g., between about430-770 nanometers (nm)). Excitation may be done using any usefulapparatus, such as a laser and/or light emitting diode. Optical elementsincluding, but not limited to, mirrors, waveplates, filters,monochromaters, gratings, beam splitters, and lenses may be used todirect light to or from a fluorescent dye. A fluorescent dye may emitlight (e.g., fluoresce) in the visible region of the electromagneticspectrum ((e.g., between about 430-770 nm). A fluorescent dye may beexcited over a single wavelength or a range of wavelengths. Afluorescent dye may be excitable by light in the red region of thevisible portion of the electromagnetic spectrum (about 625-740 nm)(e.g., have an excitation maximum in the red region of the visibleportion of the electromagnetic spectrum). Alternatively or in additionto, fluorescent dye may be excitable by light in the green region of thevisible portion of the electromagnetic spectrum (about 500-565 nm)(e.g., have an excitation maximum in the green region of the visibleportion of the electromagnetic spectrum). A fluorescent dye may emitsignal in the red region of the visible portion of the electromagneticspectrum (about 625-740 nm) (e.g., have an emission maximum in the redregion of the visible portion of the electromagnetic spectrum).Alternatively or in addition to, fluorescent dye may emit signal in thegreen region of the visible portion of the electromagnetic spectrum(about 500-565 nm) (e.g., have an emission maximum in the green regionof the visible portion of the electromagnetic spectrum).

Labels may be quencher molecules. The term “quencher,” as used herein,generally refers to molecules that may be energy acceptors. A quenchermay be a molecule that can reduce an emitted signal. For example, atemplate nucleic acid molecule may be designed to emit a detectablesignal. Incorporation of a nucleotide or nucleotide analog comprising aquencher can reduce or eliminate the signal, which reduction orelimination is then detected. Luminescence from labels (e.g.,fluorescent moieties, such as fluorescent moieties linked to nucleotidesor nucleotide analogs) may also be quenched (e.g., by incorporation ofother nucleotides that may or may not comprise labels). In some cases,as described elsewhere herein, labelling with a quencher can occur afternucleotide or nucleotide analog incorporation (e.g., after incorporationof a nucleotide or nucleotide analog comprising a fluorescent moiety).In some cases, the label may be a type that does not self-quench orexhibit proximity quenching. Non-limiting examples of a label type thatdoes not self-quench or exhibit proximity quenching include Bimanederivatives such as Monobromobimane. The term “proximity quenching,” asused herein, generally refers to a phenomenon where one or more dyesnear each other may exhibit lower fluorescence as compared to thefluorescence they exhibit individually. In some cases, the dye may besubject to proximity quenching wherein the donor dye and acceptor dyeare within 1 nm to 50 nm of each other. Examples of quenchers include,but are not limited to, Black Hole Quencher Dyes (BiosearchTechnologies) (e.g., BH1-0, BHQ-1, BHQ-3, and BHQ-10), QSY Dyefluorescent quenchers (Molecular Probes/Invitrogen) (e.g., QSY7, QSY9,QSY21, and QSY35), Dabcyl, Dabsyl, Cy5Q, Cy7Q, Dark Cyanine dyes (GEHealthcare), Dy-Quenchers (Dyomics) (e.g., DYQ-660 and DYQ-661), andATTO fluorescent quenchers (ATTO-TEC GmbH) (e.g., ATTO 540Q, ATTO 580Q,and ATTO 612Q). Fluorophore donor molecules may be used in conjunctionwith a quencher. Examples of fluorophore donor molecules that can beused in conjunction with quenchers include, but are not limited to,fluorophores such as Cy3B, Cy3, or Cy5; Dy-Quenchers (Dyomics) (e.g.,DYQ-660 and DYQ-661); and ATTO fluorescent quenchers (ATTO-TEC GmbH)(e.g., ATTO 540Q, 580Q, and 612Q).

The term “labeling fraction,” as used herein, generally refers to theratio of dye-labeled nucleotide or nucleotide analog tonatural/unlabeled nucleotide or nucleotide analog of a single canonicaltype in a flow solution. The labeling fraction can be expressed as theconcentration of the labeled nucleotide or nucleotide analog divided bythe sum of the concentrations of labeled and unlabeled nucleotide ornucleotide analog. The labeling fraction may be expressed as a % oflabeled nucleotides included in a solution (e.g., a nucleotide flow).The labeling fraction may be at least about 0.5%, 1%, 2%, 3%, 4%, 5, 10,15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or higher. For example, thelabeling fraction may be at least about 20%. The labeling fraction maybe about 100%. The labeling fraction may also be expressed as a ratio oflabeled nucleotides to unlabeled nucleotides included in a solution. Forexample, the ratio of labeled nucleotides to unlabeled nucleotides maybe at least about 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, 5:1, orhigher. For example, the ratio of labeled nucleotides to unlabelednucleotides may be at least about 1:4. For example, the ratio of labelednucleotides to unlabeled nucleotides may be at least about 1:1. Forexample, the ratio of labeled nucleotides to unlabeled nucleotides maybe at least about 5:1.

The term “labeled fraction,” as used herein, generally refers to theactual fraction of labeled nucleic acid (e.g., DNA) resulting aftertreatment of a primer-template with a mixture of the dye-labeled andnatural nucleotide or nucleotide analog. The labeled fraction may beabout the same as the labeling fraction. For example, if 20% ofnucleotides in a nucleotide flow are labeled, about 20% of nucleotidesincorporated into a growing nucleic acid strand (e.g., during nucleicacid sequencing) may be labeled. Alternatively, the labeled fraction maybe greater than the labeled fraction. For example, if 20% of nucleotidesin a nucleotide flow are labeled, greater than 20% of nucleotidesincorporated into a growing nucleic acid strand (e.g., during nucleicacid sequencing) may be labeled. Alternatively, the labeled fraction maybe less than the labeled fraction. For example, if 20% of nucleotides ina nucleotide flow are labeled, less than 20% of nucleotides incorporatedinto a growing nucleic acid strand (e.g., during nucleic acidsequencing) may be labeled.

When a solution including less than 100% labeled nucleotides ornucleotide analogs is used in an incorporation process such as asequencing process (e.g., as described herein), both labeled (“bright”)and unlabeled (“dark”) nucleotides or nucleotide analogs may beincorporated into a growing nucleic acid strand. The term “tolerance,”as used herein, generally refers to the ratio of the labeled fraction(e.g., “bright” incorporated fraction) to the labeling fraction (e.g.,“bright” fraction in solution). For example, if a labeling fraction of0.2 is used resulting in a labeled fraction of 0.4 the tolerance is 2.Similarly, if an incorporation process such as a sequencing process isperformed using 2.5% labeled fraction in solution (b_(f), brightsolution fraction) and 5% is labeled (b_(i), bright incorporatedfraction), the tolerance may be 2 (e.g., tolerance). This model may belinear for low labeling fractions (e.g., 10% or lower labelingfraction). For higher labeling fractions, tolerance may take intoaccount competing dark incorporation. Tolerance may refer to acomparison of the ratio of bright incorporated fraction to darkincorporated fraction (b_(i)/d_(i)) to the ratio of bright solutionfraction to dark solution fraction (b_(f)/d_(f)):Tolerance=b _(i) /d _(i) /b _(f) /d _(f) where d _(i)=1−b _(i) (e.g.,dark incorporated fraction and bright incorporated fraction sum to 1assuming 100% bright fraction is normalized to 1)

Though d_(i) cannot easily be measured, b_(i), the bright incorporatedfraction, can be measured (e.g., as described herein) and used todetermine tolerance by fitting a curve of bright solution fraction(b_(f)) vs. bright incorporated fraction (b_(i)):

$b_{i} = \frac{{tol}\left( {b_{f}/d_{f}} \right)}{1 + {{tol}\left( {b_{f}/d_{f}} \right)}}$

A “positive” tolerance number (>1) indicates that at 50% labelingfraction, more than 50% is labeled. A “negative” tolerance number (<1)indicates that at 50% labeling fraction, less than 50% is labeled.

The term “context,” as used herein, generally refers to the sequence ofthe neighboring nucleotides, or context, has been observed to affect thetolerance in an incorporation reaction. The nature of the enzyme, the pHand other factors may also affect the tolerance. Reducing contexteffects to a minimum greatly simplifies base determination.

The term “scar,” as used herein, generally refers to a residue left on apreviously labeled nucleotide or nucleotide analog after cleavage of anoptical (e.g., fluorescent) dye and, optionally, all or a portion of alinker attaching the optical dye to the nucleotide or nucleotide analog.Examples of scars include, but are not limited to, hydroxyl moieties(e.g., resulting from cleavage of an azidomethyl group,hydrocarbyldithiomethyl linkage, or 2-nitrobenzyloxy linkage), thiolmoieties (e.g., resulting from cleavage of a disulfide linkage), andbenzyl moieties. For example, a scar may comprise an aromatic group suchas a phenyl or benzyl group. The size and nature of a scar may affectsubsequent incorporations.

The term “misincorporation,” as used herein, generally refers tooccurrences when the DNA polymerase incorporates a nucleotide, eitherlabeled or unlabeled, that is not the correct Watson-Crick partner forthe template base. Misincorporation can occur more frequently in methodsthat lack competition of all four bases in an incorporation event, andleads to strand loss, and thus limits the read length of a sequencingmethod.

The term “mispair extension”, as used herein, generally refers tooccurrences when the DNA polymerase incorporates a nucleotide, eitherlabeled or unlabeled, that is not the correct Watson-Crick partner forthe template base, then subsequently incorporates the correctWatson-Crick partner for the following base. Mispair extension generallyresults in lead phasing and limits the read length of a sequencingmethod.

Regarding quenching, dye-dye quenching between two dye moieties linkedto different nucleotides (e.g., adjacent nucleotides in a growingnucleic acid strand, or nucleotides in a nucleic acid strand that areseparated by one or more other nucleotides) may be strongly dependent onthe distance between the two dye moieties. The distance between two dyemoieties may be at least partially dependent on the properties oflinkers connecting the two dye moieties to respective nucleotides ornucleotide analogs, including the linker compositions and functionallengths. Features of the linkers, including composition and functionallength, may be affected by temperature, solvent, pH and saltconcentration (e.g., within a solution). Quenching may also vary basedon the nature of the dyes used. Quenching may also take place betweendye moieties and nucleobase moieties (e.g., between a fluorescent dyeand a nucleobase of a nucleotide with which it is associated).Controlling quenching phenomena may be a key feature of the methodsdescribed herein.

Regarding flows, a nucleotide flow can consist of a mixture of labeledand unlabeled nucleotides or nucleotide analogs (e.g., nucleotides ornucleotide analogs of a single canonical type). For example, a solutioncomprising a plurality of optically (e.g., fluorescently) labelednucleotides and a plurality of unlabeled nucleotides may be contactedwith, e.g., a sequencing template (as described herein). The pluralityof optically labeled nucleotides and a plurality of unlabelednucleotides may each comprise the same canonical nucleotide ornucleotide analog. A flow may include only labeled nucleotides ornucleotide analogs. Alternatively, a flow may include only unlabelednucleotides or nucleotide analogs. A flow may include a mixture ofnucleotide or nucleotide analogs of different types (e.g., A and G).

A wash flow (e.g., a solution comprising a buffer) may be used to removeany nucleotides that are not incorporated into a nucleic acid complex(e.g., a sequencing template, as described herein). A cleavage flow(e.g., a solution comprising a cleavage reagent) may be used to removedye moieties (e.g., fluorescent dye moieties) from optically (e.g.,fluorescently) labeled nucleotides or nucleotide analogs. In some cases,different dyes (e.g., fluorescent dyes) may be removable using differentcleavage reagents. In other cases, different dyes (e.g., fluorescentdyes) may be removable using the same cleavage reagents. Cleavage of dyemoieties from optically labeled nucleotides or nucleotide analogs maycomprise cleavage of all or a portion of a linker connecting anucleotide or nucleotide analog to a dye moiety.

The term “cycle,” as used herein, generally refers to a process in whicha nucleotide flow, a wash flow, and a cleavage flow corresponding toeach canonical nucleotide (e.g., dATP, dCTP, dGTP, and dTTP or dUTP, ormodified versions thereof) are used (e.g., provided to a sequencingtemplate, as described herein). Multiple cycles may be used to sequenceand/or amplify a nucleic acid molecule. The order of nucleotide flowscan be varied.

Phasing can be lead or lag phasing. Lead phasing generally refers to thephenomenon in which a population of strands show incorporation of anucleotide a flow ahead of the expected cycle (e.g., due tocontamination in the system). Lag phasing refers to the phenomenon inwhich a population of strands shows incorporation of a nucleotide a flowbehind the expected cycle (e.g., due to incompletion of extension in anearlier cycle).

Compounds and chemical moieties described herein, including linkers, maycontain one or more asymmetric centers and thus give rise toenantiomers, diastereomers, and other stereoisomeric forms that aredefined, in terms of absolute stereochemistry, as (R)- or (S)-, and, interms of relative stereochemistry, as (D)- or (L)-. The D/L systemrelates molecules to the chiral molecule glyceraldehyde and is commonlyused to describe biological molecules including amino acids. Unlessstated otherwise, it is intended that all stereoisomeric forms of thecompounds disclosed herein are contemplated by this disclosure. When thecompounds described herein contain alkene double bonds, and unlessspecified otherwise, it is intended that this disclosure includes both Eand Z geometric isomers (e.g., cis or trans.) Likewise, all possibleisomers, as well as their racemic and optically pure forms, and alltautomeric forms are also intended to be included. The term “geometricisomer” refers to E or Z geometric isomers (e.g., cis or trans) of analkene double bond. The term “positional isomer” refers to structuralisomers around a central ring, such as ortho-, meta-, and para-isomersaround a phenyl ring. Separation of stereoisomers may be performed bychromatography or by forming diastereomers and separating byrecrystallization, or chromatography, or any combination thereof. (JeanJacques, Andre Collet, Samuel H. Wilen, “Enantiomers, Racemates andResolutions”, John Wiley and Sons, Inc., 1981, herein incorporated byreference for this disclosure). Stereoisomers may also be obtained bystereoselective synthesis.

Compounds and chemical moieties described herein, including linkers, mayexist as tautomers. A “tautomer” refers to a molecule wherein a protonshift from one atom of a molecule to another atom of the same moleculeis possible. In circumstances where tautomerization is possible, achemical equilibrium of the tautomers will exist. Unless otherwisestated, chemical structures depicted herein are intended to includestructures which are different tautomers of the structures depicted. Forexample, the chemical structure depicted with an enol moiety alsoincludes the keto tautomer form of the enol moiety. The exact ratio ofthe tautomers depends on several factors, including physical state,temperature, solvent, and pH. Some examples of tautomeric equilibriuminclude:

Compounds and chemical moieties described herein, including linkers anddyes, may be provided in different enriched isotopic forms. For example,compounds may be enriched in the content of ²H, ³H, ¹¹C, ¹³C and/or ¹⁴C.For example, a linker, substrate (e.g., nucleotide or nucleotideanalog), or dye may be deuterated in at least one position. In someexamples, a linker, substrate (e.g., nucleotide or nucleotide analog),or dye may be fully deuterated. Such deuterated forms can be made by theprocedure described in U.S. Pat. Nos. 5,846,514 and 6,334,997, each ofwhich are herein incorporated by reference in their entireties. Asdescribed in U.S. Pat. Nos. 5,846,514 and 6,334,997, deuteration canimprove the metabolic stability and or efficacy, thus increasing theduration of action of drugs.

Unless otherwise stated, structures depicted and described herein areintended to include compounds which differ only in the presence of oneor more isotopically enriched atoms. For example, compounds and chemicalmoieties having the present structures except for the replacement of ahydrogen by a deuterium or tritium, or the replacement of a carbon by¹³C- or ¹⁴C-enriched carbon are within the scope of the presentdisclosure.

The compounds and chemical moieties of the present disclosure maycontain unnatural proportions of atomic isotopes at one or more atomsthat constitute such compounds. For example, a compound or chemicalmoiety such as a linker, substrate (e.g., nucleotide or nucleotideanalog), or dye, or a combination thereof, may be labeled with one ormore isotopes, such as deuterium (²H), tritium (³H), iodine-125 (¹²⁵I)or carbon-14 (¹⁴C). Isotopic substitution with ²H, ¹¹C, ¹³C, ¹⁴C, ¹⁵C,¹²N ¹³N, ¹⁵N, ¹⁶N, ¹⁶O, ¹⁷O, ¹⁴F, ¹⁵F, ¹⁶F, ¹⁷F, ¹⁸F, ³³S, ³⁴S, ³³S,³⁶S, ³⁵C₁, ³⁷C₁, ⁷⁹Br, ⁸¹Br, and ¹²⁵I are all contemplated. All isotopicvariations of the compounds and chemical moieties described herein,whether radioactive or not, are encompassed within the scope of thepresent disclosure.

Linkers for Optical Detection

The present disclosure provides an optical (e.g., fluorescent) labelingreagent comprising a dye (e.g., fluorescent dye) and a linker that isconnected to the dye and capable of associating with a substrate to beoptically (e.g., fluorescently) labeled. The substrate can be anysuitable molecule, analyte, cell, tissue or surface that is to beoptically labeled. Examples include cells, including eukaryotic cells,prokaryotic cells, healthy cells, and diseased cells; cellularreceptors; antibodies; proteins; lipids; metabolites; probes; reagents;nucleotides and nucleotide analogs; and nucleic acid molecules. Theassociation between the linker and the substrate can be any suitableassociation including a covalent or non-covalent bond, such as anassociation between a purine-containing nucleotide and apyrimidine-containing nucleotide in a nucleic acid molecule. In somecases, such an association may be a biotin-avidin interaction. In othercases, the association between the linker and the substrate may be via apropargylamino moiety. In some cases, the association between the linkerand the substrate may be via an amide bond (e.g., a peptide bond).

A linker can be semi-rigid. The semi-rigid nature of the linker can bemost readily achieved by use of structure that comprises a series ofring systems (e.g., aliphatic and aromatic rings). As used herein, aring (e.g., ring structure) is a cyclic moiety comprising any number ofatoms connected in a closed, essentially circular fashion, as used inthe field of organic chemistry. A ring may be defined by any number ofatoms. For example, a ring may include between 3-12 atoms, such asbetween 3-12 carbon atoms. In certain examples, a ring may be afive-membered ring (i.e., a pentagon) or a six-membered ring (i.e., ahexagon). A ring can be aromatic or non-aromatic. A ring may bealiphatic. A ring may comprise one or more double bonds.

A ring (e.g., ring structure) may be a component of a ring system thatmay comprise one or more ring structures (e.g., a multi-cycle system).For example, a ring system may comprise a monocycle. In another example,a ring system may be a bicycle or bridged system. A ring structure maybe a carbocycle or component thereof formed of carbon atoms. Acarbocycle may be a saturated, unsaturated, or aromatic ring in whicheach atom of the ring is carbon. A carbocycle includes 3- to 10-memberedmonocyclic rings, 4- to 12-membered bicyclic rings (e.g., 6- to12-membered bicyclic rings), and 5- to 12-membered bridged rings. Eachring of a bicyclic carbocycle may be selected from saturated,unsaturated, and aromatic rings. For example, a bicyclic carbocycle mayinclude an aromatic ring (e.g., phenyl) fused to a saturated orunsaturated ring (e.g., cyclohexane, cyclopentane, or cyclohexene). Abicyclic carbocycle may include any combination of saturated,unsaturated, and aromatic bicyclic rings, as valence permits. A bicycliccarbocycle may include any combination of ring sizes such as 4-5 fusedring systems, 5-5 fused ring systems, 5-6 fused ring systems, and 6-6fused ring systems. A carbocycle may be, for example, cyclopropyl,cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, adamantyl, phenyl,indanyl, or naphthyl. A saturated carbocycle includes no multiple bonds(e.g., double or triple bonds). A saturated carbocycle may be, forexample, cyclopropane, cyclobutane, cyclopentane, or cyclohexane. Anunsaturated carbocycle includes at least one multiple bond (e.g., doubleor triple bond) but is not an aromatic carbocycle. An unsaturatedcarbocycle may be, for example, cyclohexadiene, cyclohexene, orcyclopentene. Other examples of carbocycles include, but are not limitedto, cyclopropane, cyclobutane, cyclopentane, cyclopentadiene,cyclohexane, cycloheptane, cycloheptene, naphthalene, and adamantine. Anaromatic carbocycle (e.g., aryl moiety) may be, for example, phenyl,naphthyl, or dihydronaphthyl.

In some cases, a ring may include one or more heteroatoms, such as oneor more oxygen, nitrogen, silicon, phosphorous, boron, or sulfur atoms.A ring may be a heterocycle or component thereof including one or moreheteroatoms. A heterocycle may be a saturated, unsaturated, or aromaticring in which at least one atom is a heteroatom. A heteroatom includes3- to 10-membered monocyclic rings, 6- to 12-membered bicyclic rings,and 6- to 12-membered bridged rings. A bicyclic heterocycle may includeany combination of saturated, unsaturated and aromatic bicyclic rings,as valence permits. For example, a heteroaromatic ring (e.g., pyridyl)may be fused to a saturated or unsaturated ring (e.g., cyclohexane,cyclopentane, morpholine, piperidine or cyclohexene). A bicyclicheterocycle may include any combination of ring sizes such as 4-5 fusedring systems, 5-5 fused ring systems, 5-6 fused ring systems, and 6-6fused ring systems. An unsaturated heterocycle includes at least onemultiple bond (e.g., double or triple bond) but is not an aromaticheterocycle. An unsaturated heterocycle may be, for example,dihydropyrrole, dihydrofuran, oxazoline, pyrazoline, or dihydropyridine.Additional examples of heterocycles include, but are not limited to,indole, benzothiophene, benzthiazole, benzoxazole, benzimidazole,oxazolopyridine, imidazopyridine, thiazolopyridine, furan, oxazole,pyrrole, pyrazole, imidazole, thiophene, thiazole, isothiazole, andisoxazole. A heteroaryl moiety may be an aromatic single ring structure,such as a 5- to 7-membered ring, including at least one heteroatom, suchas one to four heteroatoms. Alternatively, a heteroaryl moiety may be apolycyclic ring system having two or more cyclic rings in which two ormore atoms are common to two adjoining rings wherein at least one of therings is heteroaromatic. Heteroaryl groups include, for example,pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole,pyridine, pyrazine, pyridazine, and pyrimidine, and the like.

A ring can be substituted or un-substituted. A substituent replaces ahydrogen atom on one or more atoms of a ring or a substitutableheteroatom of a ring (e.g., NH or NH₂). Substitution is in accordancewith permitted valence of the various components of the ring system andprovides a stable compound (e.g., a compound that does not undergospontaneous transformation by, for example, rearrangement, elimination,or cyclization). A substituent may replace a single hydrogen atom ormultiple hydrogen atoms (e.g., on the same ring atom or different ringatoms). A substituent on a ring may be, for example, halogen, hydroxy,oxo, thioxo, thiol, amido, amino, carboxy, nitrilo, cyano, nitro, imino,oximo, hydrazino, alkoxy, alkenyl, alkynyl, aryl, aralkyl, aralkenyl,aralkynyl, cycloalkyl, cycloalkylalkyl, alkylcycloalkyl,heterocycloalkyl, heterocycyl, alkylheterocycyl, or any other usefulsubstituent. A substituent may be water-soluble. Examples ofwater-soluble substituents include, but are not limited to, apyridinium, an imidazolium, a quaternary ammonium group, a sulfonate, aphosphate, an alcohol, an amine, an imine, a nitrile, an amide, a thiol,a carboxylic acid, a polyether, an aldehyde, a boronic acid, and aboronic ester.

A linker can have any number of rings, including at least 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more rings.The rings can share an edge in some cases (e.g., be components of abicyclic ring system). In general, the ring portion of the linker canprovide a degree of physical rigidity to the linker and/or can serve tophysically separate the dye (e.g., fluorescent dye) on one end of thelinker from the substrate to be labeled and/or from a second dye (e.g.,fluorescent dye) associated with the substrate and/or associated withthe linker. A ring can be a component of an amino acid (e.g., anon-proteinogenic amino acid, as described herein).

In some cases, a linker may be “fully rigid” (e.g., substantiallyinflexible). For example, ring systems of the linker may not beseparated by any sp² or sp³ carbon atoms. In general, sp² and sp³ carbonatoms (e.g., between ring systems) provide the linker with a degree ofphysical flexibility. sp³ carbon atoms in particular can confersignificant flexibility. Without limitation, flexibility can allow apolymerase to accept a substrate (e.g., a nucleotide or nucleotideanalog) modified with the linker and the dye (e.g., fluorescent dye), orotherwise improve the performance of a labeled system. However, in amultiple dye system (e.g., a system comprising multiple fluorescentlabeling reagents, such as a polynucleotide including two or morenucleotides coupled to two or more fluorescent labeling reagents), anoverly flexible linker may defeat the feature of rigidity and allow twodyes (e.g., fluorescent dyes) to come into close association and bequenched. Accordingly, ring systems of a linker may be connected to eachother by a limited number of sp³ bonds, such as by no more than two sp³bonds (e.g., 0, 1, or 2 sp³ bonds). For example, at least two ringsystems of a linker may be connected to each other by no more than twosp³ bonds (e.g., by 0, 1, or 2 sp³ bonds). For example, at least tworing systems of a linker may be connected to each other by a no morethan two sp² bonds, such as by no more than 1 sp² bond. Ring systems ofa linker may be connected to each other by a limited number of atoms,such as by no more than 2 atoms. For example, at least two ring systemsof a linker may be connected to each other by no more than 2 atoms, suchas by only 1 atom or by no atoms (e.g., directly connected).

The series of ring systems of a linker may comprise aromatic and/oraliphatic rings. At least two ring systems of a linker may be connectedto each other directly without an intervening carbon atom. A linker maycomprise at least one amino acid that may comprise a ring system. Forexample, a linker may comprise at least one non-proteinogenic amino acid(e.g., as described herein), such as a hydroxyproline.

Many applications of optical (e.g., fluorescent) labeling reagents(e.g., nucleic acid sequencing reactions) can be performed in aqueoussolutions. In some cases, a linker that has too high of a proportion ofcarbon and hydrogen atoms and/or a lack of charged chemical groups canbe insufficiently water-soluble to be useful in an aqueous solution.Therefore, the linkers described herein can have a water-soluble groupor groups.

A linker may include a water-soluble group at any useful position. Forexample, a linker may comprise a water-soluble group at or near a pointof attachment to a label (e.g., dye, as described herein). Alternativelyor in addition to, a linker may comprise a water-soluble group at ornear a point of attachment to a substrate (e.g., a protein or anucleotide or nucleotide analog). Alternatively or in addition to, alinker may comprise a water-soluble group between points of attachmentto a label (e.g., dye, as described herein) and a substrate (e.g., aprotein or a nucleotide or nucleotide analog). One or more rings of alinker may comprise a water-soluble group. For example, each of therings may comprise a water-soluble group, two or more rings may comprisea water-soluble group, only one of the rings may comprise awater-soluble group, or anywhere there between. A given ring maycomprise one or more water-soluble moieties. For example, a ring of alinker may comprise two water-soluble moieties. The water-solublegroup(s) can be a constituent part of the backbone of a ring of a linkeror can be appended to a ring of a linker (e.g., as a substituent). Eachwater-soluble moiety of a linker may be different. Alternatively, one ormore water-soluble moieties of a linker may be the same. For example,each water-soluble moiety of a linker may be the same. In some cases,the water-soluble group is positively charged. Examples of suitablewater-soluble groups include, but are not limited to, a pyridinium, animidazolium, a quaternary ammonium group, a sulfonate, a phosphate, analcohol, an amine, an imine, a nitrile, an amide, a thiol, a carboxylicacid, a polyether, an aldehyde, and a boronic acid or boronic ester.

A water-soluble group can be any functional group that decreases(including making more negative) the log P of the optical (e.g.,fluorescent) labeling reagent. Log P is the partition coefficient for amolecule between water and n-octanol. A greasy molecule is more likelyto partition into octanol, giving a positive and large log P value. Aformula for Log P can be represented as log P_(octanol/water)=log([solute]_(octanol)/[solute]_(water)), where [solute]_(octanol) is theconcentration of the solute (i.e., the labeling reagent) in octanol and[solute]_(water) is the concentration of the solute in water. Therefore,the more a compound partitions into water compared to octanol, the morenegative the log P. Log P can be measured experimentally or predictedusing software algorithms. The water-soluble group can have any suitableLog P value. In some cases, the Log P is less than about 2, less thanabout 1.5, less than about 1, less than about 0.5, less than about 0,less than about −0.5, less than about −1, less than about −1.5, lessthan about −2, or lower. In some cases, the Log P is between about 2.0and about −2.0.

A linker may include one or more asymmetric (e.g., chiral) centers(e.g., as described herein). All stereochemical isomers of linkers arecontemplated, including racemates and enantiomerically pure linkers.

A linker, and/or a substrate (e.g., protein or nucleotide or nucleotideanalog) or dye to which it may be attached, may include one or moreisotopic (e.g., radio) labels (e.g., as described herein). All isotopicvariations of linkers are contemplated.

The structural features of a linker, including the number of rings, therigidity of the linker, and the like, can combine to establish afunctional distance between a dye (e.g., fluorescent) dye and asubstrate (e.g., protein or nucleotide or nucleotide analog) that arelinked by the linker. In some cases, the distance corresponds to thelength (and/or the functional length) of the linker. In some cases, thefunctional length varies based on the temperature, solvent, pH, and/orsalt concentration of the solution in which the length is measured orestimated. The functional length can be measured in a solution in whichan optical (e.g., fluorescent) signal from the substrate is measured.The functional length may an average or ensemble value of a distributionof functional lengths (e.g., over rotational, vibrational, andtranslational motions) and may differ based on, e.g., temperature,solvent, pH, and/or salt concentrations. The functional length may beestimated (e.g., based on bond lengths and steric considerations, suchas by use of a chemical drawing or modeling program) and/or measured(e.g., using molecular imaging and/or crystallographic techniques).

A linker can establish any suitable functional length between a dye(e.g., fluorescent dye) and a substrate (e.g., protein or nucleotide ornucleotide analog). In some cases, the functional length is at mostabout 500 nanometers (nm), about 200 nm, about 100 nm, about 75 nm,about 50 nm, about 40 nm, about 30 nm, about 20 nm, about 10 nm, about 5nm, about 2 nm, about 1.0 nm, about 0.5 nm, about 0.3 nm, about 0.2 nm,or less. In some instances, the functional length is at least about 0.2nanometers (nm), at least about 0.3 nm, at least about 0.5 nm, at leastabout 1.0 nm, at least about 2 nm, at least about 5 nm, at least about10 nm, at least about 20 nm, at least about 30 nm, at least about 40 nm,at least about 50 nm, at least about 75 nm, at least about 100 nm, atleast about 200 nm, at least about 500 nm, or more. In some instances,the functional length is between about 0.5 nm and about 50 nm.

In some cases, the linker forms a straight and/or contiguous chain. Insome instances, the linker is branched. The linker can be capable offorming a bond with a plurality of dyes (e.g., fluorescent dyes) and/orsubstrates (e.g., nucleotides and/or nucleotide analogs).

A linker may be a polymer having a regularly repeating unit.Alternatively, a linker may be a co-polymer without a regularlyrepeating unit. In some cases, the linker is not the result of apolymerization process. In general, a polymerization process cangenerate products having a variety of degrees of polymerization andmolecular weights. In contrast, in some cases, the linkers describedherein have a defined (i.e., known) molecular weight.

A linker may be constructed from one or more amino acids. For example, alinker may be constructed from two or more amino acids. An amino acidmay be a natural amino acid or a non-natural amino acid. An amino acidmay be a proteinogenic amino acid or a non-proteinogenic amino acid. A“proteinogenic amino acid,” as used herein, generally refers to agenetically encoded amino acid that may be incorporated into a proteinduring translation. Proteinogenic amino acids include arginine,histidine, lysine, aspartic acid, glutamic acid, serine, threonine,asparagine, glutamine, cysteine, selenocysteine, glycine, proline,alanine, isoleucine, leucine, methionine, phenylalanine, tryptophan,tyrosine, valine, selenocysteine, and pyrrolysine. A “non-proteinogenicamino acid,” as used herein, is an amino acid that is not aproteinogenic amino acid. A non-proteinogenic amino acid may be anaturally occurring amino acid or a non-naturally occurring amino acid.Non-proteinogenic amino acids include amino acids that are not found inproteins and/or are not naturally encoded or found in the genetic codeof an organism. Examples of non-proteinogenic amino acids include, butare not limited to, hydroxyproline, selenomethionine, hypusine,2-aminoisobutyric acid, ay-aminobutyric acid, ornithine, citrulline,β-alanine (3-aminopropanoic acid), δ-aminolevulinic acid, 4-aminobenzoicacid, dehydroalanine, carboxyglutamic acid, pyroglutamic acid,norvaline, norleucine, alloisoleucine, t-leucine, pipecolic acid,allothreonine, homocysteine, homoserine, α-amino-n-heptanoic acid,α,β-diaminopropionic acid, α,γ-diaminobutyric acid, β-amino-n-butyricacid, β-aminoisobutyric acid, isovaline, sarcosine, N-ethyl glycine,N-propyl glycine, N-isopropyl glycine, N-methyl alanine, N-ethylalanine, N-methyl β-alanine, N-ethyl β-alanine, isoserine, andα-hydroxy- γ-aminobutyric acid. Additional examples of non-proteinogenicamino acids include the non-natural amino acids described herein. Anon-proteinogenic amino acid may comprise a ring structure. For example,a non-proteinogenic amino acid may be trans-4-aminomethylcyclohexanecarboxylic acid or 4-hydrazinobenzoic acid. Such compounds may beFMOC-protected with FMOC (fluorenylmethyloxycarbohyl chloride) andutilized in solid-phase peptide synthesis. The structures of thesecompounds are shown below:

Where a linker comprises multiple amino acids, such as multiplenon-proteinogenic amino acids, an amine moiety adjacent to a ring moiety(e.g., the amine moiety in the hydrazine moiety) can function as awater-solubilizing group. To synthesize a water-soluble peptide, ahybrid linker can be made that comprises alternating non-water-solubleamino acids and water-soluble amino acids (e.g., hydroxyproline). Othermoieties can be used to increase water-solubility. For example, linkingamino acids with oxamate moieties can provide water-solubility throughthe additional hydrogen bonding without adding any sp³ linkages. Thestructure of the oxamate precursor 2-amino-2-oxoacetic acid is shownbelow:

In some cases, a component (e.g., a monomer unit) of a linker may havean amino group, a carboxy group, and a water-solubilizing moiety. Insome cases, a monomer may be deconstructed as two “half-monomers.” Thatis, by using two different units, one that contains two amino groups andanother that contains two carboxy groups, an amino acid moiety can beconstructed, which amino acid moiety may be a unit (e.g., a repeatedunit) of a linker. One or both units may include one or more watersolubilizing moieties. For example, at least one unit may include awater-soluble group (e.g., as described herein). For example,2,5-diaminohydroquinone can be one half-monomer (A), and2,5-dihydroxyterephthalic acid may be the other half-monomer (B). Such ascheme is shown below:

As shown above, A is a diamine and B is a diacid. Accordingly,non-proteinogenic (e.g., non-natural) amino acids may be constructedfrom diamines and diacids. An additional example of such a constructionis shown below:

A polymer based on two half-monomers (e.g., as shown above) can beconstructed via solid phase synthesis. Because the half-monomers can behomobifunctional in the linking moiety, in some cases no FMOC protectionis required. For example, the dicarboxylic acid can be appended to thesolid support, then an excess of the diamine added with appropriatecoupling reagent (HBTU/HOBT/collidine). After washing away excessreagent, an excess of the dicarboxylic acid can be added with thecoupling reagent. Side-products consisting of one molecule of the fluidphase reagent reacting with two solid-phase attached reagent can resultin truncation of the synthesis. These side products can be separatedfrom a product after cleavage from the support and purification by HPLC.

An advantage of the half-monomers approach can be increased flexibilityin creating polymers. The diamine (A) can be replaced in a subsequentstep by a different diamine (A′) to change the properties of thepolymer, in a repeating or non-repeating manner. Such a scheme mayfacilitate construction of a polymer such as ABA′BABA′B.

Additional examples of half-monomers for use according to the schemesdescribed above include 2,5-diaminopyridine and 2,5-dicarboxypyridine,both of which are shown below, as well as the other moieties shownbelow:

As described above, an amino acid (e.g., a non-proteinogenic amino acidthat may be a non-natural amino acid) may be constructed from a diamineand a dicarboxylic acid. An amino acid (e.g., a non-proteinogenic aminoacid that may be a non-natural amino acid) may also be constructed froman amino thiol and a thiol carboxylic acid. Examples of amino thiols andthiol carboxylic acids are shown below:

Examples of amino acids (e.g., non-natural amino acids) constructed froman amino thiol and a thiol carboxylic acid are shown below:

As shown above, amino acids constructed using an amino thiol and a thiolcarboxylic acid may include a disulfide bond. As described elsewhereherein, a disulfide bond may be cleavable using a cleavage reagent(e.g., as described herein). Accordingly, an amino acid constructed froman amino thiol and a thiol carboxylic acid may serve as a cleavableportion of a linker. An amino acid constructed from an amino thiol and acarboxylic acid may be a component of a linker (e.g., as describedherein) that may couple labeling moiety (e.g., a fluorescent dye) to asubstrate (e.g., a nucleotide or nucleotide analog). The variousstructures allow different hydrophobicities for incorporation and mayprovide different “scar” moieties subsequent to interaction with acleavage reagent (e.g., as described herein). Two or more amino acids,such as two or more amino acids constructed from an amino thiol and athiol carboxylic acid, may be included in a linker. For example, two ormore amino acids may be included in a linker and separated by no morethan 2 sp³ carbon atoms, such as by no more than 2 sp² carbon atoms orby no more than 2 atoms. Where two or more amino acids formed of aminothiols and thiol carboxylic acids are connected to one another within alinker, cleavage may be more rapid as there will be multiple possiblesites for cleavage. An example of a portion of a linker including such acomponent is shown below:

As described above, two half-monomers may combine to provide an aminoacid (e.g., a non-proteinogenic amino acid, such as a non-natural aminoacid). Accordingly, a non-natural amino acid may include any knownnon-natural amino acid, as well as any non-natural amino acid that maybe constructed as described herein.

Half-monomers such as those described herein can be constructed intopolypeptide polymers. An example of a nucleotide constructed with tworepeating units of an amino acid is shown below:

In some cases, before or after peptide coupling, the nitrogen in anitrogen-containing ring can be quaternized to provide pyridiniummoieties, thereby improving water-solubility of the final product. Anexample linker sequence generated in this manner is shown below:

Water-solubilizing linkages that can work with the half-monomer methodinclude, for example, those that have symmetrical functional groups,such as secondary amides, bishydrazides, and ureas. Examples of suchmoieties are shown below:

Amino acid linker subunits may be assembled into polymers by peptidesynthesis methods. For example, a solid support method known as SPPS(Solid Phase Peptide Synthesis) or by liquid-phase synthesis may be usedto assemble amino acids into a linker. SPPS methods can use a solidphase bead where the initial step is attachment of the C-terminal aminoacid via its carboxylic acid moiety, leaving its free amine ready forcoupling. Peptide synthesis can be initiated by flowing FMOCamine-protected monomers with peptide coupling reagents such as HBTU andan organic base. Excess reagent can be washed away and the next monomeris introduced. After one or more amino acids have been appended thefinal peptide can be cleaved from the beads and purified by HPLC. Liquidphase synthesis can use the same reagents (except the beads) butpurification occurs after each step. The advantage of either stepwisepolymerization process is that the resultant linkers can have a definedmolecular weight that may be confirmed by mass spectrometry.

A linker may include one or more components. For example, a linker mayinclude a first component that includes a polymeric region (e.g., thatincludes a repeating unit) and a second unit that does not include apolymeric region. The second component may include a cleavable component(e.g., as described herein). Examples of cleavable linkers include, butare not limited to, the structures E and B shown below:

In the structures shown above, the disulfide moieties may be cleaved(e.g., as described herein) to provide thiol scars. The cleavablelinkers may be attached to substrates upon reaction between a carboxylmoiety of the linker moiety and an amine moiety attached to a substrate(e.g., protein or nucleotide or nucleotide analog) to provide thesubstrate attached to the cleavable linker via an amide moiety. Forexample, the substrate may be a nucleotide or nucleotide analogincluding a propargylamino moiety, and a fluorescent labeling reagentcomprising a dye and a linker described herein may be configured toassociate with the substrate via the propargylamino moiety. Examples ofsuch substrates are shown below:

The first component of a linker including first and second componentsmay include a repeating unit. For example, the linker may include afirst component including one or more hydroxyproline moieties. Anexample of such a linker component is shown below:

The linker shown above includes 10 hydroxyproline moieties and a glycinemoiety and is referred to herein as “H” or “hyp10”. An alternate versionof the linker above includes 20 hydroxyproline moieties and a glycinemoiety and is referred to herein as “hyp20”. As described herein, allstereoisomers of hyp10 and hyp20, as well as combinations thereof, arecontemplated. A linker component such as hyp10 can be linked to acleavable linker via reaction between a free carboxyl moiety of thelinker component and an amino moiety of a cleavable linker. A linkercomponent such as hyp10 can be linked to a dye via the free amino moietyof the linker component. Examples of optical labeling reagent includinga first linker component including a repeating unit (e.g., hyp10) and asecond linker component including a cleavable linker are providedelsewhere herein.

Linkers may provide linkages between fluorescent moieties (e.g., dyes,as described herein) and substrates (e.g., proteins or nucleotides ornucleotide analogs). For example, an optical (e.g., fluorescent)labeling reagent may comprise an optical dye (e.g., fluorescent dye)attached to a linker (e.g., as described herein). Non-limiting examplesof dyes (e.g., fluorescent dyes) include SYBR green, SYBR blue, DAPI,propidium iodine, Hoechst, SYBR gold, ethidium bromide, acridine,proflavine, acridine orange, acriflavine, fluorcoumanin, ellipticine,daunomycin, chloroquine, distamycin D, chromomycin, homidium,mithramycin, ruthenium polypyridyls, anthramycin, phenanthridines andacridines, propidium iodide, hexidium iodide, dihydroethidium, ethidiumhomodimer-1 and -2, ethidium monoazide, ACMA, Hoechst 33258, Hoechst33342, Hoechst 34580, DAPI, acridine orange, 7-AAD, actinomycin D,LDS751, hydroxystilbamidine, SYTOX Blue, SYTOX Green, SYTOX Orange,POPO-1, POPO-3, YOYO-1, YOYO-3, TOTO-1, TOTO-3, JOJO-1, LOLO-1, BOBO-1,BOBO-3, PO-PRO-1, PO-PRO-3, BO-PRO-1, BO-PRO-3, TO-PRO-1, TO-PRO-3,TO-PRO-5, JO-PRO-1, LO-PRO-1, YO-PRO-1, YO-PRO-3, PicoGreen, OliGreen,RiboGreen, SYBR Gold, SYBR Green I, SYBR Green II, SYBR DX, SYTO dyes(e.g., SYTO-40, -41, -42, -43, -44, and -45 (blue); SYTO-13, -16, -24,-21, -23, -12, -11, -20, -22, -15, -14, and -25 (green); SYTO-81, -80,-82, -83, -84, and -85 (orange); SYTO-64, -17, -59, -61, -62, -60, and-63 (red)), fluorescein, fluorescein isothiocyanate (FITC), tetramethylrhodamine isothiocyanate (TRITC), rhodamine, tetramethyl rhodamine,R-phycoerythrin, Cy-2, Cy-3, Cy-3.5, Cy-5, Cy5.5, Cy-7, Texas Red,Phar-Red, allophycocyanin (APC), Sybr Green I, Sybr Green II, Sybr Gold,CellTracker Green, 7-AAD, ethidium homodimer I, ethidium homodimer II,ethidium homodimer III, ethidium bromide, umbelliferone, eosin, greenfluorescent protein, erythrosin, coumarin, methyl coumarin, pyrene,malachite green, stilbene, lucifer yellow, cascade blue,dichlorotriazinylamine fluorescein, dansyl chloride, fluorescentlanthanide complexes such as those including europium and terbium,carboxy tetrachloro fluorescein, 5 and/or 6-carboxy fluorescein (FAM),VIC, 5- (or 6-) iodoacetamidofluorescein, 5-{[2(and3)-5-(Acetylmercapto)-succinyl]amino} fluorescein (SAMSA-fluorescein),lissamine rhodamine B sulfonyl chloride, 5 and/or 6 carboxy rhodamine(ROX), 7-amino-methyl-coumarin, 7-Amino-4-methylcoumarin-3-acetic acid(AMCA), BODIPY fluorophores, 8-methoxypyrene-1,3,6-trisulfonic acidtrisodium salt, 3,6-Disulfonate-4-amino-naphthalimide,phycobiliproteins, AlexaFluor dyes (e.g., AlexaFluor 350, 405, 430, 488,532, 546, 555, 568, 594, 610, 633, 635, 647, 660, 680, 700, 750, and 790dyes), DyLight dyes (e.g., DyLight 350, 405, 488, 550, 594, 633, 650,680, 755, and 800 dyes), Black Hole Quencher Dyes (BiosearchTechnologies) (e.g., BH1-0, BHQ-1, BHQ-3, and BHQ-10), QSY Dyefluorescent quenchers (from Molecular Probes/Invitrogen)(e.g., QSY7,QSY9, QSY21, and QSY35), Dabcyl, Dabsyl. Cy5Q, Cy7Q, Dark Cyanine dyes(GE Healthcare), Dy-Quenchers (Dyomics) (e.g., DYQ-660 and DYQ-661),ATTO fluorescent quenchers (ATTO-TEC GmbH) (e.g., ATTO 540Q, 580Q, 612Q,532, and 633), and other fluorophores and quenchers (e.g., as describedherein). In some cases, the label may be a type that does notself-quench or exhibit proximity quenching. Non-limiting examples of alabel type that does not self-quench or exhibit proximity quenchinginclude Bimane derivatives such as Monobromobimane. Additional dyesincluded in structures provided herein may also be utilized incombination with any of the linkers provided herein, and with anysubstrate described herein, regardless of the context of theirdisclosure.

An optical (e.g., fluorescent) labeling reagent comprising an opticaldye (e.g., fluorescent dye) and a linker can further comprise acleavable group that is capable of being cleaved to separate the opticaldye from a substrate with which the optical labeling reagent isassociated. All or a portion of the linker may be part of the cleavablegroup. In some cases, cleaving a cleavable group may leave a scar groupassociated with substrate. The cleavable group can be, for example, anazidomethyl group capable of being cleaved bytris(2-carboxyethyl)phosphine (TCEP), dithiothreitol (DTT), ortetrahydropyranyl (THP) to leave a hydroxyl scar group. The cleavablegroup can be, for example, a disulfide bond capable of being cleaved byTCEP, DTT or THP to leave a thiol scar group. The cleavable group canbe, for example, a hydrocarbyldithiomethyl group capable of beingcleaved by TCEP, DTT or THP to leave a hydroxyl scar group. Thecleavable group can be, for example, a 2-nitrobenzyloxy group capable ofbeing cleaved by ultraviolet (UV) light to leave a hydroxyl scar group.A scar may also be, for example, an aromatic group such as a phenyl orbenzyl moiety.

An optical (e.g., fluorescent) labeling reagent may be configured toassociate with a substrate such as a nucleotide or nucleotide analog(e.g., as described herein). Alternatively or in addition to, an optical(e.g., fluorescent) labeling reagent may be configured to associate witha substrate such as a protein, cell, lipid, or antibody. For example,the optical labeling reagent may be configured to associate with aprotein. A protein substrate may be any protein, and may include anyuseful modification, mutation, or label, including any isotopic label.For example, a protein may be an antibody such as a monoclonal antibody.A protein associated with one or more optical (e.g., fluorescent)labeling reagents (e.g., as described herein) may be, for example, anantibody (e.g., a monoclonal antibody) useful for labeling a cell, whichlabeled cell may be analyzed and sorted using flow cytometry.

An optical (e.g., fluorescent) labeling reagent (e.g., as describedherein) can decrease quenching (e.g., between dyes coupled tonucleotides or nucleotide analogs incorporated into a growing nucleicacid strand, such as during nucleic acid sequencing). For example, anoptical (e.g., fluorescent) signal emitted by a substrate (e.g., anucleotide or nucleotide analog that may be incorporated into a growingnucleic acid strand) can be proportional to the number of optical (e.g.,fluorescent) labels associated with the substrate (e.g., to the numberof optical labels incorporated adjacent or in proximity to thesubstrate). For example, multiple optical labeling reagents includingsubstrates of the same or different types (e.g., nucleotides ornucleotide analogs of a same or different type) may be incorporated inproximity to one another in a growing nucleic acid strand (e.g., duringnucleic acid sequencing). In such a system, signal emitted by thecollective substrates may be approximately proportional (e.g., linearlyproportional) to the number of dye-labeled substrates incorporated. Inother words, quenching may not significantly impact the signal emitted.This may be observable in a system in which 100% labeling fractions areused. Where less than 100% of substrates are labeled (e.g., less than100% of nucleotides in a nucleotide flow are labeled), an optical (e.g.,fluorescent) signal emitted by substrates (e.g., nucleotides ornucleotide analogs) incorporated into a plurality of growing nucleicacid strands (e.g., a plurality of growing nucleic acid strands coupledto sequencing templates coupled to a support, as described herein) maybe proportional to the length of a homopolymer region of the growingnucleic acid strands. Similarly, where less than 100% of substrates arelabeled (e.g., less than 100% of nucleotides in each of successivenucleotide flows are labeled), an optical (e.g., fluorescent) signalemitted by substrates (e.g., nucleotides or nucleotide analogs)incorporated into a plurality of growing nucleic acid strands (e.g., aplurality of growing nucleic acid strands coupled to sequencingtemplates coupled to a support, as described herein) may be proportionalto the length of a heteropolymeric and/or homopolymer region of thegrowing nucleic acid strands. In some such cases, the intensity of ameasured optical (e.g., fluorescent) signal may be linearly proportionalto the length of a heteropolymeric and/or homopolymeric region intowhich substrates have incorporated. For example, a measured optical(e.g., fluorescent) signal may be linearly proportional with a slope ofapproximately 1.0 when optical (e.g., fluorescent) signal is plottedagainst the length in substrates of a heteropolymeric and/orhomopolymeric region into which substrates have incorporated.

An optical (e.g., fluorescent) labeling reagent (e.g., as describedherein) can decrease quenching in a protein system. When labelingproteins, quenching may start to happen at a fluorophore to proteinratio (F/P) of around 3. Using optical labeling reagents providedherein, higher F/P ratios, and thus brighter reagents, may be obtained.This may be useful for analyzing proteins (e.g., using imaging) and/orfor analyzing cells labeled with proteins (e.g., antibodies) associatedwith one or more optical (e.g., fluorescent) labeling reagents.

Examples of the linkers described herein are found, e.g., in FIGS.1A-1C, 2A, 4, 5A, 5B, 6, 7, 8, 13A-13C, 14A, 14B, 16, and 17 . In somecases, the R group included in these linkers (e.g., as in FIG. 1C)confers sufficient water solubility on the labeling reagent. Additionalexamples are included elsewhere herein, including in the Examples below.

In as aspect, the present disclosure provides an oligonucleotidemolecule comprising a fluorescent labeling reagent or derivative thereof(e.g., as described herein). The oligonucleotide molecule may compriseone or more additional fluorescent labeling reagents of a same type(e.g., comprising linkers having the same chemical structure, dyescomprising the same chemical structure, and/or associated withsubstrates (e.g., nucleotides) of a same type). The fluorescent labelingreagent and one or more additional fluorescent labeling reagents of theoligonucleotide molecule may be associated with nucleotides. Forexample, the fluorescent labeling reagents may be connected tonucleobases of nucleotides of the oligonucleotide molecule. Afluorescent labeling reagent and one or more additional fluorescentlabeling reagent may be connected to adjacent nucleotides of theoligonucleotide molecule. Alternatively or in addition to, thefluorescent labeling reagent and the one or more additional fluorescentlabeling reagents may be connected to nucleotides of the oligonucleotidemolecule that are separated by one or more nucleotides that are notconnected to fluorescent labeling reagents. The oligonucleotide moleculemay be a single-stranded molecule. Alternatively, the oligonucleotidemolecule may be a double-stranded or partially double-stranded molecule.A double-stranded or partially double-stranded molecule may comprisefluorescent labeling reagents associated with a single strand or bothstrands. The oligonucleotide molecule may be a deoxyribonucleic acidmolecule. The oligonucleotide molecule may a ribonucleic acid molecule.The oligonucleotide molecule may be generated and/or modified via anucleic acid sequencing process (e.g., as described herein).

The linker of the fluorescent labeling reagent may comprise a cleavablegroup that is configured to be cleaved to separate the fluorescent dyeof the fluorescent labeling reagent from a substrate (e.g., nucleotide)with which it is associated. For example, the linker may comprise acleavable group comprising an azidomethyl group, a disulfide bond, ahydrocarbyldithiomethyl group, or a 2-nitrobenzyloxy group. Thecleavable group may be configured to be cleaved by application of one ormore members of the group consisting of tris(2-carboxyethyl)phosphine(TCEP), dithiothreitol (DTT), tetrahydropyranyl (THP), ultraviolet (UV)light, and a combination thereof. The oligonucleotide moleculecomprising a fluorescent labeling reagent may be configured to emit afluorescent signal (e.g., upon excitation at an appropriate range ofenergy, as described herein).

In another aspect, the present disclosure provides a kit comprising aplurality of linkers (e.g., as described herein). A linker of theplurality of linkers may comprise (i) one or more water soluble groupsand (ii) two or more ring systems. At least two of the two or more ringsystems may be connected to each other by no more than two sp³ carbonatoms. For example, at least two of the two or more ring systems may beconnected to each other by an sp² carbon atom. At least two of the twoor more ring systems may be connected to each other by no more than twoatoms. The linker may comprise a non-proteinogenic amino acid (e.g., asdescribed herein) comprising a ring system of the two or more ringsystems. For example, the linker may comprise a hydroxyproline or anamino acid constructed from, e.g., a diamine and a dicarboxylic acid oran amino thiol and a thiol carboxylic acid. The linker may be connectedto a fluorescent dye (e.g., as described herein) and/or associated witha substrate. For example, the linker may be connected to a fluorescentdye and coupled to a substrate selected from a nucleotide, a protein, alipid, a cell, and an antibody. For example, the linker may be connectedto a fluorescent dye and a nucleotide.

The linker may comprise a plurality of amino acids, such as a pluralityof non-proteinogenic (e.g., non-natural) amino acids. For example, thelinker may comprise a plurality of hydroxyprolines (e.g., a hyp10moiety). At least one water-soluble group of the one or morewater-soluble groups may be appended to a ring structure of the two ormore ring systems. The one or more water soluble groups may be selectedfrom the group consisting of a pyridinium, an imidazolium, a quaternaryammonium group, a sulfonate, a phosphate, an alcohol, an amine, animine, a nitrile, an amide, a thiol, a carboxylic acid, a polyether, analdehyde, a boronic acid, and a boronic ester. The linker may comprise acleavable group that is configured to be cleaved to separate a firstportion of the linker from a second portion of the linker. The cleavablegroup may be selected from the group consisting of an azidomethyl group,a disulfide bond, a hydrocarbyldithiomethyl group, and a2-nitrobenzyloxy group. The cleavable group may be cleavable byapplication of one or more members of the group consisting oftris(2-carboxyethyl)phosphine (TCEP), dithiothreitol (DTT),tetrahydropyranyl (THP), ultraviolet (UV) light, and a combinationthereof. The linker may comprise a moiety selected from the groupconsisting of

These moieties both comprise disulfide groups and so may be consideredcleavable groups.

The plurality of linkers of the kit may comprise a first linkerassociated with a first substrate (e.g., a first nucleotide) and asecond linker associated with a second substrate (e.g., a secondnucleotide). The first substrate and the second substrate may be ofdifferent types (e.g., different canonical nucleotides). The firstsubstrate and the second substrate may be nucleotides comprisingnucleobases of different types (e.g., A, C, G, U, and T). The firstlinker and the second linker may comprise the same chemical structure.Similarly, the first linker may be connected to a first fluorescent dyeand the second linker may be connected to a second fluorescent dye. Thefirst fluorescent dye and the second fluorescent dye may be of differenttypes. For example, the first and second fluorescent dyes may fluoresceat different wavelengths and/or have different maximum excitationwavelengths. The first and second fluorescent dyes may fluoresce atsimilar wavelengths and/or have similar maximum excitation wavelengthsregardless of whether they share the same chemical structure.

The plurality of linkers of the kit may further comprise a third linkerassociated with a third substrate and a fourth linker associated with afourth substrate. The first substrate, the second substrate, the thirdsubstrate, and the fourth substrate may be of different types. Forexample, the first substrate, the second substrate, the third substrate,and the fourth substrate may be nucleotides comprising nucleobases ofdifferent types (e.g., A, C, G, and U/T). The first linker and the thirdlinker may comprise different chemical structures. The first and thirdlinker may comprise a same chemical group, such as a same cleavablegroup (e.g., as described herein). For example, the first linker and thethird linker may each comprise a moiety comprising a disulfide bond.Similarly, the first linker and the fourth linker may comprise differentchemical structures. The first and fourth linker may comprise a samechemical group, such as a same cleavable group (e.g., as describedherein). For example, the first linker and the fourth linker may eachcomprise a moiety comprising a disulfide bond.

In an example, the first linker comprises a hyp10 moiety and a firstcleavable moiety, the second linker comprises a hyp10 moiety and asecond cleavable moiety, the third linker comprises a third cleavablemoiety and does not comprise a hyp10 moiety, and the fourth linkercomprises a fourth cleavable moiety and does not comprise a hyp10moiety. The second cleavable moiety may have a chemical structure thatis different than the first cleavable moiety. Alternatively, the secondcleavable moiety and the first cleavable moiety may have the samechemical structures. The third cleavable moiety and the fourth cleavablemoiety may have the same chemical structure. Alternatively, the thirdcleavable moiety and the fourth cleavable moiety may have differentchemical structures. In an example, the first linker and the secondlinker each have a first chemical structure and the third linker and thefourth linker each have a second chemical structure, which secondstructure is different than the first chemical structure. In anotherexample, the first linker, the second linker, the third linker, and thefourth linker all have the same chemical structure. In another example,the first linker, the second linker, the third linker, and the fourthlinker all have different chemical structures.

Methods for Using the Optical Labeling Reagents

There are several different types of quenching that can be reduced anddifferent types of applications that can be performed using the optical(e.g., fluorescent) labeling reagents described herein.

The methods described herein can be used to reduce quenching, includingG-quenching. Attachment of dyes (e.g., fluorescent dyes) to nucleotides(e.g., via a linker provided herein) can result in dye-quenching formany dyes, particularly when the dye is attached to a guanosinenucleotide. Dye quenching may take place between a dye and a nucleotidewith which it is associated, as well as between dye moieties, such asbetween dye moieties coupled to different nucleotides (e.g., adjacentnucleotides or nucleotides separated by one or more other nucleotides).Use of the linkers provided herein can alleviate the quenching allowingmore sensitive detection of sequences containing G. In addition, adye-labeled nucleotide in proximity to a G-homopolymer region may showreduced fluorescence. Any nucleic acid sequencing method that requiresattachment of a dye to dGTP may benefit from these linkers, includingsingle molecule detection, sequencing using 3′-blocked nucleotides, andsequencing by hybridization.

The methods described herein can be used to reduce dye-dye quenching onadjacent or neighboring nucleotides (e.g., nucleotides separated by one,two, or more other nucleotides) on the same DNA strand. Methods thatrequire dyes on adjacent or neighboring nucleotides can result inproximity quenching; that is, two dyes next to each other are lessbright than twice the brightness of one dye, or often, less bright thaneven a single dye. Use of the linkers provided herein may alleviate thequenching, allowing quantitative detection of multiple dyes. Forexample, in sequencing methods such as mostly natural nucleotide flowsequencing, the fraction of labeled dye is typically less than 5%, sincehomopolymers are not linear in signal to homopolymer length at higherfractions due to the quenching problem. The reagents described hereincan allow more (e.g., more than 5%, in some cases up to 100%) of thenucleotides to be labeled while facilitating sensitive and accuratedetection of incorporated nucleotides.

The use of a dye-linker-nucleotide provided herein may result in moreefficient incorporation into a growing nucleic acid strand (e.g.,increased tolerance) by a polymerase (e.g., as described herein),compared to a dye-nucleotide lacking the linker (e.g., during nucleicacid sequencing). The result may be that a lower amount of thedye-labeled nucleotide is used to achieve the same signal.

The use of a dye-linker-nucleotide provided herein may result in lessmisincorporation by a polymerase (e.g., as described herein) (e.g.,during nucleic acid sequencing). The result may be less loss of templatestrands, and thus longer sequencing reads.

The use of a dye-linker-nucleotide provided herein may result in lessmispair extension (e.g., during nucleic acid sequencing), and thusreduced lead phasing.

The methods described herein can be used to reduce dye-dye quenching inmulti-dye applications. Hybridization assays can also benefit fromlinkers that prevent quenching. Quenching effects may result innon-linearity of target to signal.

The methods described herein can be used in combination with oligomersand dendrimers for signal amplification. Non-quenching linkers may allowthe synthesis of very bright polymers for antibody labeling. Thesebright antibodies may be used for cell-surface labeling in flowcytometry or for antigen detection methods such as lateral flow testsand fluorescent immunoassays.

The optical (e.g., fluorescent) labeling reagent of the presentdisclosure may be used as a molecular ruler. The substrate can be afluorescence quencher, a fluorescence donor, or a fluorescence acceptor.In some cases, the substrate is a nucleotide. The linker can be attachedto the nucleotide on the nucleobase as shown below, where the dye isAtto633:

The structure shown above is an optical (e.g., fluorescent) labelingreagent comprising a cleavable (via the disulfide bond) moiety and afluorescent dye attached via a pyridinium linker to a dGTP analog(dGTP-SS-py-Atto633). Additional examples of optical labeling reagentsare provided throughout the disclosure.

The dye-labeled nucleotides described herein can be used in a sequencingby synthesis method using a mixture of dye-labeled and naturalnucleotides in a flow-based scheme. Such methods often use a lowpercentage of labeled nucleotides compared to natural nucleotides.However, using a low percentage of labeled nucleotides compared tonatural nucleotides in flow mixtures (e.g., less than 20%) can havemultiple drawbacks: (a) since a small fraction of the template providessequence information, the method requires a high template copy number;(b) variability in DNA polymerase extension rates between labeled andunlabeled nucleotides can result in context-dependent labelingfractions, thus increasing the difficulty of distinguishing a singlebase incorporation from multiple base incorporations; and (c) the lowfraction of labeling moieties can result in high binomial noise in thepopulations of labeled product. Methods for flow-based sequencing usingmostly natural nucleotides are further described in U.S. Pat. No.8,772,473, which is incorporated herein by reference in its entirety forall purposes.

The semi-rigid linkers provided herein may allow a labeled fraction ofdye-labeled nucleotide to natural nucleotide in each flow to besufficiently high (e.g., 20-100% labeling) to avoid or reduce the effectof the aforementioned disadvantages of such schemes. This higherpercentage labeling can result in greater optical (e.g., fluorescent)signal and thus a lower template requirement. If 100% labeling is used,the binomial noise and context variation may be essentially eliminated.The key technical barrier overcome by the solution described herein isthat the dye-labeled nucleotides on adjacent or nearby nucleotides mustshow minimal quenching. The overall result of the combined advantagesmay be more accurate DNA sequencing.

The present disclosure provides a method for sequencing a nucleic acidmolecule. The method can comprise contacting the nucleic acid moleculewith a primer under conditions sufficient to hybridize the primer to thenucleic acid molecule, thereby generating a sequencing template. Thesequencing template may then be contacted with a polymerase (e.g., asdescribed herein) and a solution (e.g., a nucleotide flow) comprising aplurality of optically (e.g., fluorescently) labeled nucleotides (e.g.,as described herein). Each optically (e.g., fluorescently) labelednucleotide of the plurality of optically (e.g., fluorescently) labelednucleotides may comprise the same chemical structure (e.g., each labelednucleotide may comprise a dye of a same type, a linker of a same type,and a nucleotide or nucleotide analog of a same type). An opticallylabeled nucleotide of the plurality of optically labeled nucleotides maybe complementary to the nucleic acid molecule at a plurality ofpositions adjacent to the primer hybridized to the nucleic acidmolecule. Accordingly, one or more optically labeled nucleotides of theplurality of optically labeled nucleotides may be incorporated into thesequencing template. Where the nucleic acid molecule includes ahomopolymeric region, multiple nucleotides (e.g., labeled and unlabelednucleotides) may be incorporated. Incorporation of multiple nucleotidesadjacent to one another may be facilitated by the use of non-terminatednucleotides. The solution comprising the plurality of optically labelednucleotides may then be washed away from the sequencing template (e.g.,using a wash flow, as described herein). An optical (e.g., fluorescent)signal from the sequencing template may be measured. Where two or morelabeled nucleotides are incorporated into a homopolymeric region, theintensity of the measured optical (e.g., fluorescent) signal may begreater than an optical (e.g., fluorescent) signal that may be measuredif a single optically (e.g., fluorescently) labeled nucleotide of theplurality of optically (e.g., fluorescently) labeled nucleotides hadbeen incorporated into the sequencing template. Such a method may beparticularly useful for sequencing of homopolymers or portions ofnucleic acids that are homopolymeric (i.e., have a plurality of the samebase in a row). An optically labeled nucleotide of the plurality ofoptically labeled nucleotides may comprise a dye (e.g., fluorescent dye)and a linker connected to the dye and a nucleotide (e.g., as describedherein). The linker may comprise (i) one or more water soluble groupsand (ii) two or more ring systems, wherein at least two of the two ormore ring systems are connected to each other by no more than two sp³carbon atoms, such as by no more than two atoms. The linker may comprisea non-proteinogenic amino acid comprising a ring system of the two ormore ring systems. For example, the linker may comprise a hydroxyprolineor an amino acid constructed from, e.g., a diamine and a dicarboxylicacid or an amino thiol and a thiol carboxylic acid. The linker may beconfigured to establish a functional length between the dye and thenucleotide of at least about 0.5 nanometers.

The intensity of the measured optical (e.g., fluorescent) signal may beproportional to the number of optically (e.g., fluorescently) labelednucleotides incorporated into the sequencing template (e.g., where 100%labeling fraction is used). In other words, quenching may notsignificantly impact the signal emitted. For example, the intensity maybe linearly proportional to the number of optically (e.g.,fluorescently) labeled nucleotides incorporated into the sequencingtemplate. The intensity of the measured optical (e.g., fluorescent)signal may be linearly proportional with a slope of approximately 1.0when plotted against the number of optically (e.g., fluorescently)labeled nucleotides incorporated into the sequencing template. Whereless than 100% of substrates are labeled (e.g., less than 100% ofnucleotides in a nucleotide flow are labeled), an optical (e.g.,fluorescent) signal emitted by substrates (e.g., nucleotides ornucleotide analogs) incorporated into a plurality of growing nucleicacid strands (e.g., a plurality of growing nucleic acid strands coupledto sequencing templates coupled to a support, as described herein) maybe proportional to the length of a homopolymer region of the growingnucleic acid strands. Similarly, where less than 100% of substrates arelabeled (e.g., less than 100% of nucleotides in each of successivenucleotide flows are labeled), an optical (e.g., fluorescent) signalemitted by substrates (e.g., nucleotides or nucleotide analogs)incorporated into a plurality of growing nucleic acid strands (e.g., aplurality of growing nucleic acid strands coupled to sequencingtemplates coupled to a support, as described herein) may be proportionalto the length of a heteropolymeric and/or homopolymer region of thegrowing nucleic acid strands. In some such cases, the intensity of ameasured optical (e.g., fluorescent) signal may be linearly proportionalto the length of a heteropolymeric and/or homopolymeric region intowhich substrates have incorporated. For example, a measured optical(e.g., fluorescent) signal may be linearly proportional with a slope ofapproximately 1.0 when optical (e.g., fluorescent) signal is plottedagainst the length in substrates of a heteropolymeric and/orhomopolymeric region into which substrates have incorporated

The solution comprising the plurality of optically (e.g., fluorescently)labeled nucleotides may also contain un-labeled nucleotides (e.g., thelabeling fraction may be less than 100%). For example, at least about20% of nucleotides in the solution may be optically labeled, and atleast about 80% of nucleotides in the solution may not be opticallylabeled. In some cases, the majority of the nucleotides in the solutionmay be optically labeled (e.g., between about 50-100%).

In some cases, two or more optically (e.g., fluorescently) labelednucleotides of the plurality of optically (e.g., fluorescently) labelednucleotides are incorporated into the sequencing template (e.g., into ahomopolymeric region). In some cases, three or more optically (e.g.,fluorescently) labeled nucleotides of the plurality of optically (e.g.,fluorescently) labeled nucleotides are incorporated into the sequencingtemplate. The number of optically labeled nucleotides incorporated intothe sequencing template during a given nucleotide flow may depend on thehomopolymeric nature of the nucleic acid molecule. In some cases, afirst optically (e.g., fluorescently) labeled nucleotide of theplurality of optically (e.g., fluorescently) labeled nucleotides isincorporated within four positions of a second optically (e.g.,fluorescently) labeled nucleotide of the plurality of optically (e.g.,fluorescently) labeled nucleotides.

An optically (e.g., fluorescently) labeled nucleotide may comprise acleavable group to facilitate cleavage of the optical (e.g.,fluorescent) label (e.g., as described herein). In some cases, a methodmay further comprise, subsequent to incorporation of the one or moreoptically (e.g., fluorescently) labeled nucleotides and washing away ofresidual solution, cleaving optical (e.g., fluorescent) labels of theone or more optically (e.g., fluorescently) labeled nucleotidesincorporated into the sequencing template (e.g., as described herein).The cleavage flow may be followed by an additional wash flow.

In some cases, a nucleotide flow and wash flow may be followed by a“chase” flow comprising unlabeled nucleotides and no labelednucleotides. The chase flow may be used to complete the sequencingreaction for a given nucleotide position or positions of the sequencingtemplate (e.g., across a plurality of such templates immobilized to asupport). The chase flow may precede detection of an optical signal froma template. Alternatively, the chase flow may follow detection of anoptical signal from a template. The chase flow may precede a cleavageflow. Alternatively, the chase flow may follow a cleavage flow. Thechase flow may be followed by a wash flow.

The methods provided herein can also be used to sequence heteropolymersand/or heteropolymeric regions of a nucleic acid molecule (i.e.,portions that are not homopolymeric). Accordingly, the methods describedherein can be used to sequence a nucleic acid molecule having any degreeof heteropolymeric or homopolymeric nature.

Regarding homopolymers, a nucleotide flow at a homopolymer region mayincorporate several nucleotides in a row. Contacting a sequencingtemplate comprising a nucleic acid molecule (e.g., a nucleic acidmolecule hybridized to an unextended primer) comprising a homopolymerregion with a solution comprising a plurality of nucleotides (e.g.,labeled and unlabeled nucleotides), where each nucleotide of theplurality of nucleotides is of a same type, may result in multiplenucleotides of the plurality of nucleotides being incorporated into thesequencing template. In some cases, at least 2, at least 3, at least 4,at least 5, at least 6, at least 7, at least 8, at least 9, or at least10 nucleotides are incorporated (i.e., in a homopolymeric region of anucleic acid molecule). The plurality of nucleotides incorporated intothe sequencing template may comprise a plurality of labeled nucleotides(e.g., optically labeled, such as fluorescently labeled), as describedherein. In such an instance, one or more of said nucleotidesincorporated into a homopolymer region may be labeled, and may eitheroccupy adjacent or non-adjacent positions to other labeled nucleotidesincorporated into the homopolymeric region. The intensity of a signalobtained from a nucleic acid molecule may be proportional to the numberof incorporated labeled nucleotides (e.g., where a labeling fraction of100% is used). For example, the intensity of an optical signal (e.g.,fluorescent signal) obtained from a nucleic acid molecule containing twolabeled nucleotides may be of greater intensity than the optical signalobtained from a nucleic acid molecule containing one labeled nucleotide.Furthermore, the intensity of a signal obtained from a nucleic acidmolecule may depend on the relative positioning of labeled nucleotideswithin a nucleic acid molecule. For example, a nucleic acid moleculecontaining two labeled nucleotides in non-adjacent positions may providea different signal intensity than a nucleic acid molecule containing twolabeled nucleotides in adjacent positions. Quenching in such systems maybe optimized by careful selection of linkers and dyes (e.g., fluorescentdyes). In some cases, a plot of optical signal (e.g., fluorescence) vs.homopolymer length can be linear. For example, measured optical signalfor an ensemble of growing nucleic acid strands including homopolymericregions into which labeled nucleotides are incorporated may beapproximately linearly proportional to the nucleotide length of thehomopolymeric region.

In another aspect, the present disclosure provides a method forsequencing a nucleic acid molecule. The method can comprise contactingthe nucleic acid molecule with a primer under conditions sufficient tohybridize the primer to the nucleic acid molecule, thereby generating asequencing template. The may then be contacted with a polymerase and afirst solution comprising a plurality of first optically (e.g.,fluorescently) labeled nucleotides (and, optionally, a plurality offirst unlabeled nucleotides). Each first optically (e.g., fluorescently)labeled nucleotide of the plurality of first optically (e.g.,fluorescently) labeled nucleotides is of a same type. A first optically(e.g., fluorescently) labeled nucleotide of the plurality of firstoptically (e.g., fluorescently) labeled nucleotides may be complementaryto the nucleic acid molecule to be sequenced at a position adjacent tothe primer. A first optically (e.g., fluorescently) labeled nucleotideof the plurality of first optically (e.g., fluorescently) labelednucleotides may thus be incorporated into the sequencing template togenerate an extended primer. The first solution comprising the pluralityof first optically (e.g., fluorescently) labeled nucleotides may then bewashed away from the sequencing template (e.g., using a wash solution).A first optical (e.g., fluorescent) signal emitted by the sequencingtemplate may then be measured (e.g., as described herein). Thesequencing template may then be contacted with a polymerase and a secondsolution comprising a plurality of second optically (e.g.,fluorescently) labeled nucleotides (and, optionally, a plurality ofsecond unlabeled nucleotides). Each second optically (e.g.,fluorescently) labeled nucleotide of the plurality of second optically(e.g., fluorescently) labeled nucleotides may be of a same type. Asecond optically (e.g., fluorescently) labeled nucleotide of theplurality of second optically (e.g., fluorescently) labeled nucleotidesmay be complementary to the nucleic acid molecule to be sequenced at aposition adjacent to the extended primer. A second optically (e.g.,fluorescently) labeled nucleotide of the plurality of second optically(e.g., fluorescently) labeled nucleotides may thus be incorporated intothe sequencing template. The second solution comprising the plurality ofsecond optically (e.g., fluorescently) labeled nucleotides may then bewashed away from the sequencing template. A second optical (e.g.,fluorescent) signal emitted by the sequencing template may then bemeasured. In some cases, the intensity of the second optical (e.g.,fluorescent) signal may be greater than the intensity of the firstoptical (e.g., fluorescent) signal.

A first optically labeled nucleotide of the plurality of first opticallylabeled nucleotides may comprise a first dye (e.g., fluorescent dye) anda first linker connected to the first dye and a first nucleotide (e.g.,as described herein). Similarly, a second optically labeled nucleotideof the plurality of second optically labeled nucleotides may comprise asecond dye (e.g., fluorescent dye) and a second linker connected to thesecond dye and a second nucleotide (e.g., as described herein). Thefirst linker may comprise (i) one or more water soluble groups and (ii)two or more ring systems, wherein at least two of the two or more ringsystems are connected to each other by no more than two sp³ carbonatoms, such as by no more than two atoms. For example, at least two ofthe two or more ring systems may be connected to each other by an sp²carbon atom. The linker may comprise a non-proteinogenic amino acidcomprising a ring system of the two or more ring systems. For example,the first linker may comprise one or more hydroxyproline moieties (e.g.,as described herein). The first linker may be configured to establish afunctional length between the first dye and the first nucleotide of atleast about 0.5 nanometers. Similarly, the second linker may comprise(i) one or more water soluble groups and (ii) two or more ring systems,wherein at least two of the two or more ring systems are connected toeach other by no more than two sp³ carbon atoms, such as by no more thantwo atoms. For example, at least two of the two or more ring systems maybe connected to each other by an sp² carbon atom. The linker maycomprise a non-proteinogenic amino acid comprising a ring system of thetwo or more ring systems. For example, the second linker may compriseone or more hydroxyproline moieties (e.g., as described herein). Thesecond linker may be configured to establish a functional length betweenthe second dye and the second nucleotide of at least about 0.5nanometers. The first linker and the second linker may have the samestructure. Alternatively, the first linker and the second linker mayhave different structures. The first linker and the second linker maycomprise a shared structural motif, such as a shared cleavable component(e.g., as described herein). The first linker and/or the second linkermay comprise a cleavable group configured to be cleaved with a cleavagereagent (e.g., as described herein).

The first solution comprising the plurality of first optically (e.g.,fluorescently) labeled nucleotides may also contain first un-labelednucleotides. For example, about 20% of the nucleotides of the firstsolution may be un-labeled. In some cases, at least 20% of thenucleotides of the first solution may be optically labeled, such as atleast 50% or at least 80%. The un-labeled nucleotides may comprise thesame nucleotide moiety (e.g., canonical nucleotide moiety) as theoptically labeled nucleotides. Similarly, the second solution comprisingthe plurality of first optically labeled nucleotides may also containsecond un-labeled nucleotides. For example, about 20% of the nucleotidesof the second solution may be un-labeled. In some cases, at least 20% ofthe nucleotides of the second solution may be optically labeled, such asat least 50% or at least 80%. The un-labeled nucleotides may comprisethe same nucleotide moiety (e.g., canonical nucleotide moiety) as theoptically labeled nucleotides.

The plurality of first optically (e.g., fluorescently) labelednucleotides may be different than the plurality of second optically(e.g., fluorescently) labeled nucleotides. For example, the plurality offirst optically (e.g., fluorescently) labeled and the plurality ofsecond optically (e.g., fluorescently) labeled nucleotides may comprisethe same optical (e.g., fluorescent) label (e.g., the same dye) anddifferent nucleotides. Alternatively, the plurality of first optically(e.g., fluorescently) labeled and the plurality of second optically(e.g., fluorescently) labeled nucleotides may comprise different optical(e.g., fluorescent) labels (e.g., different dyes) and the samenucleotides. In some cases, the plurality of first optically (e.g.,fluorescently) labeled and the plurality of second optically (e.g.,fluorescently) labeled nucleotides may comprise different optical (e.g.,fluorescent) labels (e.g., different dyes) and different nucleotides.The first dye of the first plurality of optically labeled nucleotidesand the second dye of the second plurality of optically labelednucleotides may emit signal at approximately the same wavelength orrange of wavelengths (e.g., whether the first and second dyes have thesame or different chemical structures). For example, the first dye andthe second dye may both emit signal in the green region of the visibleportion of the electromagnetic spectrum.

In some cases, two or more first optically (e.g., fluorescently) labelednucleotides may be incorporated into the sequencing template (e.g., in ahomopolymeric region of the nucleic acid molecule). In some cases, twoor more second optically (e.g., fluorescently) labeled nucleotides maybe incorporated into the sequencing template.

Additional optically (e.g., fluorescently) labeled nucleotides may alsobe provided and incorporated into the sequencing template (e.g., insuccessive nucleotide flows, as described herein). For example, themethod may further comprise contacting the sequencing template with apolymerase and a third solution comprising a plurality of thirdoptically (e.g., fluorescently) labeled nucleotides, wherein each thirdoptically (e.g., fluorescently) labeled nucleotide of the plurality ofthird optically (e.g., fluorescently) labeled nucleotides is of a sametype, and wherein a third optically (e.g., fluorescently) labelednucleotide of the plurality of third optically (e.g., fluorescently)labeled nucleotides is complementary to the nucleic acid molecule at aposition adjacent to the further extended primer hybridized to thenucleic acid molecule, thereby incorporating a third optically (e.g.,fluorescently) labeled nucleotide of the plurality of third optically(e.g., fluorescently) labeled nucleotides into the sequencing template;washing the third solution comprising the plurality of third optically(e.g., fluorescently) labeled nucleotides away from the sequencingtemplate; and measuring a third optical (e.g., fluorescent) signalemitted by the sequencing template. In some cases, the intensity of thethird optical signal may be greater than the intensity of the firstoptical (e.g., fluorescent) signal and the intensity of the secondoptical (e.g., fluorescent) signal. This process may be repeated with afourth solution, etc. The third and fourth solutions may compriseoptically (e.g., fluorescently) labeled nucleotides having differentnucleotides than the first and second solutions, such that eachcanonical nucleotide (A, C, G, and U/T) may be provided in sequence tothe sequencing template. A cycle in which each canonical nucleotide isprovided to the sequencing template may be repeated one or more times tosequence and/or amplify the nucleic acid molecule.

A third optically labeled nucleotide of the plurality of third opticallylabeled nucleotides may comprise a third dye (e.g., fluorescent dye) anda third linker connected to the third dye and a third nucleotide (e.g.,as described herein). The third linker may comprise (i) one or morewater soluble groups and (ii) two or more ring systems, wherein at leasttwo of the two or more ring systems are connected to each other by nomore than two sp³ carbon atoms, such as by no more than two atoms. Forexample, at least two of the two or more ring systems may be connectedto each other by an sp² carbon atom. The linker may comprise anon-proteinogenic amino acid comprising a ring system of the two or morering systems. For example, the third linker may comprise one or morehydroxyproline moieties (e.g., as described herein). The third linkermay be configured to establish a functional length between the third dyeand the third nucleotide of at least about 0.5 nanometers. The thirdlinker and the first linker may have the same or different structures.Similarly, the third linker and the second linker may have the same ordifferent structures. The third dye may have the same or a differentstructure as the first dye. Similarly, the third dye may have the sameor a different structure as the second dye. The third dye and the firstand/or second dye may emit at approximately the same wavelength or rangeof wavelengths (e.g., whether these dyes have the same or differentchemical structures). Further, the third nucleotide may be of a same ordifferent type as the first nucleotide, or the third nucleotide may beof a same or different type as the second nucleotide.

The method may further comprise, subsequent to washing a given solution(e.g., nucleotide flow) away (e.g., using a wash solution), cleaving theoptical (e.g., fluorescent) label of its respective nucleotides. Forexample, after the first solution is washed away, the optical (e.g.,fluorescent) label of the first optically (e.g., fluorescently) labelednucleotide incorporated into the sequencing template may be cleaved(e.g., using a cleavage reagent to cleave a cleavable group of a linkerof the first optically labeled nucleotide, as described herein). Forexample, the fluorescent dye(s) of the first optically labelednucleotide(s) incorporated into the sequencing template may be cleavedprior to contacting the sequencing template with second opticallylabeled nucleotides (e.g., in a second nucleotide flow, as describedherein). Accordingly, signal may be detected from one or more firstoptically labeled nucleotides prior to incorporation of one or moresecond optically labeled nucleotides into the sequencing template.Separation of the fluorescent dye (s) of the first optically labelednucleotide(s) incorporated into the sequencing template may provide ascarred nucleotide(s) comprising a portion of the linker of the firstoptically labeled nucleotide, or a derivative thereof. Similarly, afterthe second solution (e.g., second nucleotide flow) is washed away, theoptical (e.g., fluorescent) label of the second optically (e.g.,fluorescently) labeled nucleotide incorporated into the sequencingtemplate may be cleaved. All of a portion of the first and secondlinkers may be cleaved during the respective cleaving processes.

In another aspect, provided herein is a method for sequencing a nucleicacid molecule. The method can comprise providing a solution comprising aplurality of optically (e.g., fluorescently) labeled nucleotides,wherein each optically (e.g., fluorescently) labeled nucleotide of theplurality of optically (e.g., fluorescently) labeled nucleotides is of asame type. A given optically (e.g., fluorescently) labeled nucleotide ofthe plurality of fluorescently labeled nucleotides may comprise anoptical (e.g., fluorescent) dye that is connected to a nucleotide via asemi-rigid water-soluble linker having a defined molecular weight. Thelinker connecting the dye and nucleotide may provide a functional lengthof at least about 0.5 nanometers (nm) between the dye and nucleotide.The nucleic acid molecule may then be contacted with a primer underconditions sufficient to hybridize the primer to a nucleic acid moleculeto be sequenced to generate a sequencing template. The sequencingtemplate may then be contacted with a polymerase and the solutioncontaining the plurality of optically (e.g., fluorescently) labelednucleotides, wherein an optically (e.g., fluorescently) labelednucleotide of the plurality of optically (e.g., fluorescently) labelednucleotides is complementary to the nucleic acid molecule to besequenced at a position adjacent to the primer. One or more optically(e.g., fluorescently) labeled nucleotides of the plurality of optically(e.g., fluorescently) labeled nucleotides may thus be incorporated intothe sequencing template. The solution comprising the plurality ofoptically (e.g., fluorescently) labeled nucleotides may be washed awayfrom the sequencing template (e.g., using a wash solution). An optical(e.g., fluorescent) signal emitted by the sequencing template may thenbe measured.

The linker may comprise (i) one or more water soluble groups and (ii)two or more ring systems, wherein at least two of the two or more ringsystems are connected to each other by no more than two sp³ carbonatoms, such as by no more than two atoms (e.g., as described herein).For example, at least two of the two or more ring systems may beconnected to each other by an sp² carbon atom. The linker may comprise anon-proteinogenic amino acid comprising a ring system of the two or morering systems. For example, the linker may comprise one or morehydroxyproline moieties (e.g., as described herein). The linker mayestablish a functional length between the fluorescent dye and thenucleotide of at least about 0.5 nanometers (e.g., as described herein).

The measured optical (e.g., fluorescent) signal may be proportional tothe number of optically (e.g., fluorescently) labeled nucleotides thatwere incorporated into the sequencing template. For example, where 100%labeling fraction is used (e.g., all nucleotides in the solution arelabeled), quenching may not diminish the emitted signal. In such asystem, the measured optical (e.g., fluorescent) signal can be linearlyproportional to the number of optically (e.g., fluorescently) labelednucleotides that were incorporated into the sequencing template. Themeasured optical (e.g., fluorescent) signal may be linearly proportionalwith a slope of approximately 1.0 when plotted against the number ofoptically (e.g., fluorescently) labeled nucleotides that wereincorporated into the sequencing template. Where less than 100% ofnucleotides are labeled (e.g., less than 100% of nucleotides in thesolution are labeled), an optical (e.g., fluorescent) signal emitted bynucleotides incorporated into a plurality of growing nucleic acidstrands (e.g., a plurality of growing nucleic acid strands coupled tosequencing templates coupled to a support, as described herein) may beproportional to the length of a homopolymer region of the growingnucleic acid strands. Similarly, where less than 100% of nucleotides arelabeled, an optical (e.g., fluorescent) signal emitted by nucleotidesincorporated into a plurality of growing nucleic acid strands (e.g., aplurality of growing nucleic acid strands coupled to sequencingtemplates coupled to a support, as described herein) may be proportionalto the length of a heteropolymeric and/or homopolymer region of thegrowing nucleic acid strands. In some such cases, the intensity of ameasured optical (e.g., fluorescent) signal may be linearly proportionalto the length of a heteropolymeric and/or homopolymeric region intowhich nucleotides have incorporated. For example, a measured optical(e.g., fluorescent) signal may be linearly proportional with a slope ofapproximately 1.0 when optical (e.g., fluorescent) signal is plottedagainst the length in nucleotides of a heteropolymeric and/orhomopolymeric region into which nucleotides have incorporated

In some cases, the solution containing an optically (e.g.,fluorescently) labeled nucleotide also contains un-labeled nucleotides.The un-labeled nucleotides may comprise the same nucleotide moiety(e.g., the same canonical nucleotide). In some embodiments, about 5%,about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about70%, about 80%, about 90%, or about 100% of nucleotides in the solutionare fluorescently labeled. In some cases, at least about 5%, at leastabout 10%, at least about 20%, at least about 30%, at least about 40%,at least about 50%, at least about 60%, at least about 70%, at leastabout 80%, at least about 90%, or more of nucleotides in the solutionare fluorescently labeled. In some cases, at least about 5%, at leastabout 10%, at least about 20%, at least about 30%, at least about 40%,at least about 50%, at least about 60%, at least about 70%, at leastabout 80%, at least about 90%, or more of nucleotides in the solutionare not fluorescently labeled.

A plurality of labeled nucleotides can be incorporated at locationsalong a nucleic acid molecule in proximity to each other. In some cases,a first optically (e.g., fluorescently) labeled nucleotide isincorporated within 4 positions, within 3 positions, within 2 positions,or next to a second optically (e.g., fluorescently) labeled nucleotide(e.g., a second optically labeled nucleotide of a same or differentnucleotide type). In some cases, the method further comprises cleavingthe optical (e.g., fluorescent) labels from the nucleotides aftermeasuring the optical (e.g., fluorescent) signal (e.g., as describedherein). Cleaving an optical (e.g., fluorescent) label may leave behinda scar (e.g., as described herein). A nucleic acid sequencing assay maybe used to evaluate dye-labeled nucleotides. The assay may use a nucleicacid template having a known sequence, which sequence may include one ormore homopolymeric regions. The template may be immobilized to a support(e.g., as described herein) via an adapter. A primer having a sequenceat least partly complementary to the adapter or a portion thereof mayhybridize to the adapter or portion thereof and provide a starting pointfor generation of a nucleic acid strand having a sequence complementaryto that of the template via incorporation of labeled and unlabelednucleotides (e.g., as described herein). The sequencing assay may usefour distinct four nucleotide flows including different canonicalnucleobases that may be repeated in cyclical fashion (e.g., cycle 1: A,G, C, U; cycle 2 A, G, C, U; etc.). Each nucleotide flow may includenucleotides including nucleobases of a single canonical type (or analogsthereof), some of which may be include optical labeling reagentsprovided herein. The labeling fraction (e.g., % of nucleotides includedin the flow that are attached to an optical labeling reagent) may bevaried between, e.g., 0.5% to 100%. Labeling fractions may be differentfor different nucleotide flows. Nucleotides may not be terminated tofacilitate incorporation into homopolymeric regions. The template may becontacted with a nucleotide flow, followed by one or more wash flows(e.g., as described herein). The template may also be contacted with acleavage flow (e.g., as described herein) including a cleavage reagentconfigured to cleave a portion of the optical labeling reagents attachedto labeled nucleotides incorporated into the growing nucleic acidstrand. A wash flow may be used to remove cleavage reagent and preparethe template for contact with a subsequent nucleotide flow. Emission maybe detected from labeled nucleotides incorporated into the growingnucleic acid strand after each nucleotide flow.

An example sequencing procedure 1800 is provided in FIG. 18 . In process1802, a template and primer configured for nucleotide incorporation areprovided. A first sequencing cycle 1804 is subsequently performed. Firstsequencing cycle 1804 includes four flow processes 1804 a, 1804 b, 1804c, and 1804 d, each of which multiple flows. Nucleotides 1, 2, 3, and 4may each include nucleobases of different canonical types (e.g., A, G,C, and U). A given nucleotide flow may include both labeled nucleotides(e.g., nucleotides labeled with an optical labeling reagent providedherein) and unlabeled nucleotides. The labeling fraction of eachnucleotide flow may be different. That is, A, B, C, and D in FIG. 18 maybe the same or different and may range from 0% to 100% (e.g., asdescribed herein). Labels and linkers used to label nucleotides 1, 2, 3,and 4 may be of the same or different types. For example, nucleotide 1may have a linker including a cleavable linker and a hyp10 linker and afirst green dye, and nucleotide 2 may have a linker including acleavable linker but not a hyp10 linker and a second green dye. Thefirst green dye may be the same as or different than the first greendye. The cleavable linkers associated with the different nucleotides maybe the same or different. Flow process 1804 a may include a nucleotideflow (e.g., a flow including a plurality of nucleotides of typeNucleotide 1, A % of which may be labeled). During this flow, labeledand unlabeled nucleotides may be incorporated into the growing strand(e.g., using a polymerase enzyme). A first wash flow (“wash flow 1”) maybe used to remove unincorporated nucleotides and associated reagents. Acleavage flow including a cleavage reagent may be provided to all orportions of the optical labeling reagents attached to incorporatednucleotides. For example, labeled nucleotides may include a cleavablelinker portion that may by cleaved upon contact with the cleavagereagent to provide a scarred nucleotide. A second wash flow (“wash flow2”) may be used to remove the cleavage reagent and cleaved materials.Nucleotide flow process 1804 a may also include a “chase” process inwhich a nucleotide flow including only unlabeled nucleotides of typeNucleotide 1 may be flowed. Such a chase process may be followed by awash flow. The chase process and its accompanying wash flow may takeplace after the initial nucleotide flow and wash flow 1, or after thecleavage flow and wash flow 2. The next nucleotide flow process 1804 bmay then begin and proceed in similar fashion. Following completion ofprocesses 1804 b, 1804 c, and 1804 d, the first flow cycle 1804 may becomplete. A second flow cycle 1806 may begin. Cycle 1806 may include thesame flow processes in the same or different order. Additional cyclesmay be performed until all or a portion of the template has beensequenced. Detection of incorporated nucleotides via emission detectionmay be performed after nucleotide flows and initial wash flows andbefore cleavage flows for each nucleotide flow process (e.g., flowprocess 1804 a may include a detection process between wash flow 1 andcleavage flow, etc.). A template interrogated by such a sequencingprocess may be immobilized to a support (e.g., as described herein). Aplurality of such templates (e.g., at least about 100, 200, 500, 1000,10000, 100,000, 500,000, 1,000,000, or more templates) may beinterrogated contemporaneously in this fashion (e.g., in clonalfashion). In such a system, incorporation of nucleotides may be detectedas an average over the plurality of templates, which may permit the useof labeling fractions of less than 100%.

In some cases, for any of the preceding methods, the nucleotide isguanine (G) and the linker decreases quenching between the nucleotideand the dye (e.g., fluorescent) dye.

In some cases, for any of the preceding methods, an optically (e.g.,fluorescently) labeled nucleotide comprising a linker provided herein ismore efficiently incorporated into a sequencing template than anotheroptically (e.g., fluorescently) labeled nucleotide that comprises thesame nucleotide and optical (e.g., fluorescent) dye but does not includethe linker. In some cases, for any of the preceding methods, anoptically (e.g., fluorescently) labeled nucleotide comprising a linkerprovided herein is incorporated into a sequencing template with higherfidelity than another optically (e.g., fluorescently) labeled nucleotidethat comprises the same nucleotide and optical (e.g., fluorescent) dyebut does not include the linker.

For any of the sequencing methods provided herein, the polymerase usedmay be a Family A polymerase such as Taq, Klenow, or Bst polymerase.Alternatively, for any of the sequencing methods provided herein, thepolymerase may be a Family B polymerase such as Vent(exo-) orTherminator™ polymerase.

In an aspect, the present disclosure provides methods for sequencing anucleic acid molecule using the optically (e.g., fluorescently) labelednucleotides described herein. A method may comprise providing aplurality of nucleic acid molecules, which plurality of nucleic acidmolecules may comprise or be part of a colony or a plurality ofcolonies. The plurality of nucleic acid molecules may have sequencehomology to a template sequence. The method may comprise contacting theplurality of nucleic acid molecules with a solution comprising aplurality of nucleotides (e.g., a solution comprising a plurality ofoptically labeled nucleotides) under conditions sufficient toincorporate a subset of the plurality of nucleotides into a plurality ofgrowing nucleic acid strands that is complementary to the plurality ofnucleic acid molecules. In some instances, at least about 20% of thesubset of the plurality of nucleotides are optically (e.g.,fluorescently) labeled nucleotides (e.g., as described herein). Themethod may comprise detecting one or more signals or signal changes fromthe labeled nucleotides incorporated into the plurality of growingnucleic acid strands, wherein the one or more signals or signal changesare indicative of the labeled nucleotides having incorporated into theplurality of growing nucleic acid strands.

The optically (e.g., fluorescently) labeled nucleotides of the pluralityof nucleotides may be non-terminated. In such cases, the growing strandsmay incorporate one or more consecutive nucleotides during (e.g., acomplimentary base to the plurality of nucleotides in solution is notpresent at a plurality of positions adjacent to the primer hybridized tothe nucleic acid molecule). The one or more signals or signal changesdetected from the optically (e.g., fluorescently) labeled nucleotidesmay be indicative of consecutive nucleotides having incorporated intothe plurality of growing nucleic acid strands. Methods for determining anumber of fluorophores from the detected signals or signal changes aredescribed elsewhere herein.

Alternatively, the optically (e.g., fluorescently) labeled nucleotidesmay be terminated. In such cases, each growing strand may incorporate nomore than one nucleotide per flow cycle until synthesis is terminated.The one or more signals or signal changes detected from the optically(e.g., fluorescently) labeled nucleotides may be indicative ofnucleotides having incorporated into the plurality of growing nucleicacid strands. Prior to, during, or subsequent to detection, aterminating group of the labeled nucleotides may be cleaved (e.g., tofacilitate sequencing of homopolymers, and/or to reduce potentialcontext and/or quenching issues).

Alternatively or in addition to, the optically (e.g., fluorescently)labeled nucleotides may include a mixture of terminated andnon-terminated nucleotides. In such cases, the growing strands mayincorporate one or more consecutive nucleotides generating an extendedprimer. The solution comprising the plurality of terminated andnon-terminated nucleotides may then be washed away from the sequencingtemplate. Un-labeled nucleotides of the plurality of nucleotides maycomprise nucleotide moieties of the same type as labeled nucleotides ofthe plurality of nucleotides (e.g., the same canonical nucleotide).

In an aspect, the present disclosure provides compositions comprisingone or more fluorescently labeled nucleotides and methods of using thesame. A composition may comprise a solution comprising a fluorescentlylabeled nucleotide (e.g., as described herein). The fluorescentlylabeled nucleotide may comprise a fluorescent dye that is connected to anucleotide or nucleotide analog (e.g., as described herein) via a linker(e.g., as described herein). The linker may comprise (i) one or morewater soluble groups and (ii) two or more ring systems. At least two ofthe two or more ring systems may be connected to each other by no morethan two sp³ carbon atoms, such as by no sp³ carbon atoms. For example,at least two of the two or more ring systems may be connected to eachother by no more than two atoms. For example, at least two of the two ormore ring systems may be connected to each other by an sp² carbon atom.The linker may comprise a non-proteinogenic amino acid comprising a ringsystem of the two or more ring systems. The fluorescently labelednucleotide may be configured to emit a fluorescent signal. Thefluorescently labeled nucleotide may comprise a plurality of aminoacids, such as a plurality of non-proteinogenic (e.g., non-natural)amino acids. For example, the linker may comprise a plurality ofhydroxyprolines. At least one water-soluble group of the one or morewater-soluble groups may be appended to a ring structure of the two ormore ring systems. The one or more water soluble groups may be selectedfrom the group consisting of a pyridinium, an imidazolium, a quaternaryammonium group, a sulfonate, a phosphate, an alcohol, an amine, animine, a nitrile, an amide, a thiol, a carboxylic acid, a polyether, analdehyde, a boronic acid, and a boronic ester. The linker may comprise acleavable group (e.g., an azidomethyl group, a disulfide bond, ahydrocarbyldithiomethyl group, and a 2-nitrobenzyloxy group) that isconfigured to be cleaved to separate the fluorescent dye from thenucleotide.

The solution (e.g., nucleotide flow) may comprise a plurality offluorescently labeled nucleotides, each or which may comprise afluorescent dye of a same type, a linker of a same type, and anucleotide of a same type. Each linker of each fluorescently labelednucleotide of the plurality of fluorescently labeled nucleotides mayhave the same molecular weight (e.g., they might not comprise polymerswith a range of molecular weights). The solution may also comprise aplurality of unlabeled nucleotides, in which each nucleotide of theplurality of unlabeled nucleotides is of a same type as each nucleotideof the plurality of fluorescently labeled nucleotides. The ratio of theplurality of fluorescently labeled nucleotides to the plurality ofunlabeled nucleotides in the solution may be at least about 1:4 (e.g.,the labeling fraction may be at least 20%). For example, the ratio maybe at least 1:1 (e.g., the labeling fraction may be at least 50%).Alternatively, the solution may not comprise any unlabeled nucleotidesand the labeling fraction may be 100%.

The solution (e.g., nucleotide flow) may be provided to a templatenucleic acid molecule coupled to a nucleic acid strand. The templatenucleic acid molecule may be immobilized to a support (e.g., asdescribed herein). For example, the template nucleic acid molecule maybe immobilized to a support via an adapter. For example, the templatenucleic acid molecule may be immobilized to a support via a primer towhich it is hybridized. The nucleic acid strand may be at leastpartially complementary to a portion of the template nucleic acidmolecule. The template nucleic acid molecule and nucleic acid strandcoupled thereto may be subjected to conditions sufficient to incorporatea fluorescently labeled nucleotide of the solution into the nucleic acidstrand coupled to the template nucleic acid molecule. Incorporation ofthe fluorescently labeled nucleotide may be accomplished using apolymerase enzyme (e.g., as described herein). More than onefluorescently labeled nucleotide of the solution may be incorporated,such as into a homopolymeric region of the template nucleic acidmolecule. Alternatively or in addition to, an unlabeled nucleotide maybe incorporated (e.g., adjacent to the fluorescently labelednucleotide), such as into a homopolymeric region of the template nucleicacid molecule. A signal (e.g., a fluorescent signal) may be detectedfrom the fluorescently labeled nucleotide incorporated into the nucleicacid strand. Prior to detection of the signal, a wash solution may beused to used to remove fluorescently labeled nucleotides that are notincorporated into the nucleic acid strand. After detection of thesignal, the fluorescently labeled nucleotide incorporated into thenucleic acid strand may be contacted with a cleavage reagent configuredto cleave the fluorescent dye from the nucleotide. The cleavage reagentmay be configured to cleave the linker to provide the nucleotideattached to a portion of the linker, which portion may comprise a thiolmoiety, an aromatic moiety, or a combination thereof. The nucleic acidstrand, such as a nucleic acid strand of a plurality of nucleic acidstrands coupled to a plurality of template nucleic acid molecules, maybe contacted with a chase flow comprising only unlabeled nucleotides ofa same nucleotide type (e.g., before or after detection of a signal).The nucleic acid strand coupled to the template nucleic acid moleculemay also be contacted with one or more additional wash flows. Thenucleic acid strand coupled to the template nucleic acid molecule may becontacted with an additional solution comprising an additionalfluorescently labeled nucleotide, such as an additional fluorescentlylabeled nucleotide including a nucleotide of a different type. The dyeof the additional fluorescently labeled nucleotide may be of a same typeas the dye of the fluorescently labeled nucleotide. Similarly, thelinker of the additional fluorescently labeled nucleotide may be of asame type as the linker of the fluorescently labeled nucleotide.

In another aspect, the present disclosure provides a method comprisingproviding a fluorescent labeling reagent (e.g., as described herein).The fluorescent labeling reagent may comprise a fluorescent dye and alinker that is connected to the fluorescent dye. The linker may comprise(i) one or more water soluble groups and (ii) two or more ring systems.At least two of the two or more ring systems may be connected to eachother by no more than two sp³ carbon atoms, such as by no more than twoatoms. For example, at least two of the two or more ring structures maybe connected to each other by an sp² carbon atom. The linker maycomprise a non-proteinogenic amino acid comprising a ring system of thetwo or more ring systems. The fluorescent labeling reagent may beconfigured to emit a fluorescent signal. The fluorescent labelingreagent may comprise a plurality of amino acids, such as a plurality ofnon-proteinogenic (e.g., non-natural) amino acids. For example, thelinker may comprise a plurality of hydroxyprolines. At least onewater-soluble group of the one or more water-soluble groups may beappended to a ring structure of the two or more ring systems. The one ormore water soluble groups may be selected from the group consisting of apyridinium, an imidazolium, a quaternary ammonium group, a sulfonate, aphosphate, an alcohol, an amine, an imine, a nitrile, an amide, a thiol,a carboxylic acid, a polyether, an aldehyde, a boronic acid, and aboronic ester.

A substrate may be contacted with the fluorescent labeling reagent togenerate a fluorescently labeled substrate, in which the linkerconnected to the fluorescent dye is associated with the substrate. Thesubstrate may be a nucleotide or nucleotide analog (e.g., as describedherein). Alternatively, the substrate may be a protein, lipid, cell, orantibody. The fluorescently labeled substrate may be configured to emita fluorescent signal (e.g., upon excitation at an appropriate energyrange), which signal may be detected (e.g., using imaging-baseddetection). The linker may comprise a cleavable group (e.g., anazidomethyl group, a disulfide bond, a hydrocarbyldithiomethyl group,and a 2-nitrobenzyloxy group) that is configured to be cleaved toseparate the fluorescent dye from the substrate. The fluorescentlylabeled substrate may be contacted with a cleavage reagent configured tocleave the fluorescent labeling reagent or a portion thereof from thefluorescently labeled substrate to generate a scarred substrate. Thescarred substrate may comprise a thiol moiety, an aromatic moiety, or acombination thereof. Prior to generating the scarred substrate, thefluorescently labeled substrate and a nucleic acid molecule may besubjected to conditions sufficient to incorporate the fluorescentlylabeled substrate into the nucleic acid molecule. Incorporation may beaccomplished using a polymerase enzyme (e.g., as described herein). Morethan one fluorescently labeled substrate may be incorporated, such asinto a homopolymeric region of the nucleic acid molecule. For example,an additional fluorescently labeled substrate may be incorporated into aposition adjacent to the position into which the fluorescently labeledsubstrate is incorporated. Alternatively or in addition to, an unlabeledsubstrate (e.g., a nucleotide of a same type as the nucleotide of afluorescently labeled nucleotide) may also be incorporated into thenucleic acid molecule, such as into adjacent positions of the nucleicacid molecule. Incorporation of an additional fluorescently labeledsubstrate may be done before or after generation of the scarredsubstrate. Similarly, incorporation of an unlabeled substrate may bedone before or after generation of the scarred substrate.

The nucleic acid molecule, such as a nucleic acid molecule of aplurality of nucleic acid molecules, may be contacted with a chase flowcomprising only unlabeled substrates of a same type (e.g., before orafter detection of a signal from the nucleic acid molecule). The nucleicacid molecule may also be contacted with one or more additional washflows. The nucleic acid molecule may be contacted with an additionalsolution comprising an additional fluorescently labeled substrate, suchas an additional fluorescently labeled substrate including a nucleotideof a different type. The dye of the additional fluorescently labeledsubstrate may be of a same type as the dye of the fluorescently labeledsubstrate. Similarly, the linker of the additional fluorescently labeledsubstrate may be of a same type as the linker of the fluorescentlylabeled substrate.

The nucleic acid molecule may be immobilized to a support (e.g., asdescribed herein). For example, the nucleic acid molecule may beimmobilized to a support via an adapter. For example, the nucleic acidmolecule may be immobilized to a support via a primer to which it ishybridized. The nucleic acid molecule may comprise a first nucleic acidstrand that is at least partially complementary to a portion of a secondnucleic acid strand. The second nucleic acid strand may comprise atemplate nucleic acid sequence, or a complement thereof.

The labeled nucleotides of the present disclosure may be used duringsequencing operations that involve a high fraction of labelednucleotides. For example, the present disclosure provides a methodcomprising contacting a nucleic acid molecule (e.g., a template nucleicacid molecule) with a solution comprising a plurality of nucleotidesunder conditions sufficient to incorporate a first labeled nucleotideand a second labeled nucleotide of the plurality of nucleotides into agrowing strand that is at least partially complementary to the nucleicacid molecule. The first labeled nucleotide and the second labelednucleotide may be of a same canonical base type. The first nucleotidemay comprise a fluorescent dye (e.g., as described herein), whichfluorescent dye may be associated with the first nucleotide via a linker(e.g., as described herein). The second nucleotide may comprise the samefluorescent dye (e.g., associated with the second nucleotide via alinker having the same chemical structure of the linker associating thefirst nucleotide and the fluorescent dye). A fluorescent dye coupled toa nucleotide (e.g., the first and/or second nucleotide) may be cleavable(e.g., upon application of a cleavage reagent). At least about 20% ofthe plurality of nucleotides may be labeled nucleotides. For example, atleast 20% of the plurality of nucleotides may be associated with afluorescent labeling reagent (e.g., as described herein). For example,at least about 50%, 70%, 80%, 90%, 95%, or 99% of the plurality ofnucleotides may be labeled nucleotides. For example, all of thenucleotides of the plurality of nucleotides may be labeled nucleotides(e.g., the labeling fraction may be 100%). One or more signals or signalchanges may be detected from the first labeled nucleotide and the secondlabeled nucleotide (e.g., as described herein). The one or more signalsor signal changes may comprise fluorescent signals or signal changes.The one or more signals or signal changes may be indicative ofincorporation of the first labeled nucleotide and the second labelednucleotide. The one or more signals or signal changes may be resolved todetermine a sequence of the nucleic acid molecule, or a portion thereof.Resolving the one or more signals or signal changes may comprisedetermining a number of consecutive nucleotides from the solution thatincorporated into the growing strand. The number of consecutivenucleotides may be selected from the group consisting of 2, 3, 4, 5, 6,7, or 8 nucleotides. Resolving the one or more signals or signal changesmay comprise processing a tolerance of the solution. A third nucleotidemay also be incorporated into the growing strand (e.g., before or afterdetection of the one or more signals or signal changes). The thirdnucleotide may be a nucleotide of the plurality of nucleotides of thesolution. Alternatively, the third nucleotide may be provided in aseparate solution, such as in a “chase” flow (e.g., as describedherein). The third nucleotide may be unlabeled. Alternatively, the thirdnucleotide may be labeled. The first labeled nucleotide and the thirdnucleotide may be of a same canonical base type. Alternatively, thefirst labeled nucleotide and the third nucleotide may be of differentcanonical base types.

The method may further comprise cleaving the fluorescent dye coupled tothe first labeled nucleotide. The fluorescent dye may be cleaved byapplication of a cleavage reagent configured to cleave a linkerassociating the first labeled nucleotide and the fluorescent dye. Thenucleic acid molecule may be contacted with a second solution comprisinga second plurality of nucleotides under conditions sufficient toincorporate a third labeled nucleotide of the second plurality ofnucleotides into the growing strand. At least about 20% of the secondplurality of nucleotides may be labeled nucleotides (e.g., as describedherein). One or more second signals or signal changes may be detectedfrom the third labeled nucleotide (e.g., as described herein). The oneor more second signals or signal changes may be resolved to determine asecond sequence of the nucleic acid molecule, or a portion thereof. Thefirst labeled nucleotide and the third labeled nucleotide may bedifferent canonical base types (e.g., A, C, U/T, or G). The thirdlabeled nucleotide may comprise the fluorescent dye. The fluorescent dyemay be coupled to the third labeled nucleotide via a linker (e.g., asdescribed herein), which linker may have the same chemical structure asthe linker connecting the fluorescent dye to the first labelednucleotide or a different chemical structure.

Alternatively, the method may comprise contacting the nucleic acidmolecule with a second solution comprising a second plurality ofnucleotides under conditions sufficient to incorporate a third labelednucleotide of the second plurality of nucleotides into the growingstrand. At least about 20% of the second plurality of nucleotides may belabeled nucleotides (e.g., as described herein). One or more secondsignals or signal changes may be detected from the third labelednucleotide (e.g., as described herein). The one or more second signalsor signal changes may be resolved to determine a second sequence of thenucleic acid molecule, or a portion thereof. The first labelednucleotide and the third labeled nucleotide may be different canonicalbase types (e.g., A, C, U/T, or G). The third labeled nucleotide maycomprise the fluorescent dye. The fluorescent dye may be coupled to thethird labeled nucleotide via a linker (e.g., as described herein), whichlinker may have the same chemical structure as the linker connecting thefluorescent dye to the first labeled nucleotide or a different chemicalstructure. Contacting the nucleic acid molecule with the second solutionmay be performed in absence of cleaving a fluorescent dye from the firstlabeled nucleotide or the second labeled nucleotide. This process may berepeated one or more times, such as 1, 2, 3, 4, 5, or more times, eachwith a different solution of nucleotides, in absence of cleaving afluorescent dye from the first labeled nucleotide or the second labelednucleotide. One or more of these different solutions of nucleotides maycomprise at least 20% labeled nucleotides.

The present disclosure also provides a method comprising contacting anucleic acid molecule with a solution comprising a plurality ofnon-terminated nucleotides under conditions sufficient to incorporate alabeled nucleotide and a second nucleotide of the plurality ofnon-terminated nucleotides into a growing strand that is at least partlycomplementary to the nucleic acid molecule, or a portion thereof. Thelabeled nucleotide and the second nucleotide may be of a same canonicalbase type. Alternatively, the labeled nucleotide and the secondnucleotide may be of different canonical base types. The labelednucleotide may comprise a fluorescent dye (e.g., as described herein),which fluorescent dye may be associated with the labeled nucleotide viaa linker (e.g., as described herein). The second nucleotide may be alabeled nucleotide. For example, the second nucleotide may comprise thesame fluorescent dye (e.g., associated with the second nucleotide via alinker having the same chemical structure of the linker associating thefirst nucleotide and the fluorescent dye). Alternatively, the secondnucleotide may not be coupled to a fluorescent dye (e.g., the secondnucleotide may be unlabeled). A fluorescent dye coupled to a nucleotide(e.g., the first and/or second nucleotide) may be cleavable (e.g., uponapplication of a cleavage reagent). The plurality of non-terminatednucleotides may comprise nucleotides of a same canonical base type. Atleast about 20% of said plurality of nucleotides may be labelednucleotides. For example, at least 20% of the plurality of nucleotidesmay be associated with a fluorescent labeling reagent (e.g., asdescribed herein). For example, at least about 50%, 70%, 80%, 90%, 95%,or 99% of the plurality of non-terminated nucleotides may be labelednucleotides. For example, substantially all of the plurality ofnon-terminated nucleotides may be labeled nucleotides. For example, allof the nucleotides of the plurality of non-terminated nucleotides may belabeled nucleotides (e.g., the labeling fraction may be 100%). One ormore signals or signal changes may be detected from the labelednucleotide (e.g., as described herein). The one or more signals orsignal changes may comprise fluorescent signals or signal changes. Theone or more signals or signal changes may be indicative of incorporationof the labeled nucleotide. The one or more signals or signal changes maybe resolved to determine a sequence of the nucleic acid molecule, or aportion thereof. Resolving the one or more signals or signal changes maycomprise determining a number of consecutive nucleotides from thesolution that incorporated into the growing strand. The number ofconsecutive nucleotides may be selected from the group consisting of 2,3, 4, 5, 6, 7, or 8 nucleotides. Resolving the one or more signals orsignal changes may comprise processing a tolerance of the solution. Athird nucleotide may also be incorporated into the growing strand (e.g.,before or after detection of the one or more signals or signal changes).The third nucleotide may be a nucleotide of the plurality ofnon-terminated nucleotides of the solution. Alternatively, the thirdnucleotide may be provided in a separate solution, such as in a “chase”flow (e.g., as described herein). The third nucleotide may be unlabeled.Alternatively, the third nucleotide may be labeled. The labelednucleotide and the third nucleotide may be of a same canonical basetype. Alternatively, the labeled nucleotide and the third nucleotide maybe of different canonical base types.

The method may further comprise cleaving the fluorescent dye coupled tothe labeled nucleotide. The fluorescent dye may be cleaved byapplication of a cleavage reagent configured to cleave a linkerassociating the labeled nucleotide and the fluorescent dye. The nucleicacid molecule may be contacted with a second solution comprising asecond plurality of non-terminated nucleotides under conditionssufficient to incorporate a third labeled nucleotide of the secondplurality of non-terminated nucleotides into the growing strand. Atleast about 20% of the second plurality of non-terminated nucleotidesmay be labeled nucleotides (e.g., as described herein). One or moresecond signals or signal changes may be detected from the third labelednucleotide (e.g., as described herein). The one or more second signalsor signal changes may be resolved to determine a second sequence of thenucleic acid molecule, or a portion thereof. The first labelednucleotide and the third labeled nucleotide may be different canonicalbase types (e.g., A, C, U/T, or G). The third labeled nucleotide maycomprise the fluorescent dye. The fluorescent dye may be coupled to thethird labeled nucleotide via a linker (e.g., as described herein), whichlinker may have the same chemical structure as the linker connecting thefluorescent dye to the first labeled nucleotide or a different chemicalstructure.

Alternatively, the method may comprise contacting the nucleic acidmolecule with a second solution comprising a second plurality ofnon-terminated nucleotides under conditions sufficient to incorporate athird labeled nucleotide of the second plurality of non-terminatednucleotides into the growing strand. At least about 20% of the secondplurality of nucleotides may be labeled nucleotides (e.g., as describedherein). One or more second signals or signal changes may be detectedfrom the third labeled nucleotide (e.g., as described herein). The oneor more second signals or signal changes may be resolved to determine asecond sequence of the nucleic acid molecule, or a portion thereof. Thefirst labeled nucleotide and the third labeled nucleotide may bedifferent canonical base types (e.g., A, C, U/T, or G). The thirdlabeled nucleotide may comprise the fluorescent dye. The fluorescent dyemay be coupled to the third labeled nucleotide via a linker (e.g., asdescribed herein), which linker may have the same chemical structure asthe linker connecting the fluorescent dye to the first labelednucleotide or a different chemical structure. Contacting the nucleicacid molecule with the second solution may be performed in absence ofcleaving a fluorescent dye from the first labeled nucleotide or thesecond labeled nucleotide. This process may be repeated one or moretimes, such as 1, 2, 3, 4, 5, or more times, each with a differentsolution of nucleotides, in absence of cleaving a fluorescent dye fromthe first labeled nucleotide or the second labeled nucleotide. One ormore of these different solutions of nucleotides may comprise at least20% labeled nucleotides.

Methods for Synthesis of Optical Labeling Reagents

In some cases, the linkers provided herein may be prepared using peptidesynthesis chemistry.

For example, a linker comprising a pyridinium moiety may be preparedusing peptide synthesis chemistry. Such a method may use fourbifunctional reagents to make the linker, namely: (a) R¹A, (b) BB, (c)AA, and (d) AR². Reagent A reacts with B to form a pyridinium group; R¹and R² are hetero-bifunctional attachment groups. The synthesis beginswith the group R¹A (or R²A). Excess BB is added to R¹A to form R¹A-BB.The product is precipitated and washed in a less polar solvent (such asethyl acetate or tetrahydrofuran) to remove excess BB. Excess AA isadded with heat in N-methylpyrrolidone (NMP) to produce R¹A-BB-AA. Theproduct is precipitated and washed in a less polar solvent. Thesynthesis proceeds until a linker of a particular length is formed. Thegroup AR² is appended in the final step.

-   -   1) R¹A+10BB→R¹A-BB (wash away excess BB)    -   2) R¹A-BB+10 AA→R¹A-BB-AA (wash away excess AA)    -   3) R¹A-BB-AA+10 BB→R¹A-BB-AA-BB (wash away excess BB)    -   4) R¹A-BB-AA-BB+AR²→R¹A-BB-AA-BB-AR² (use terminating reagent)

FIG. 2A shows an example of a method for synthesizing a linker of thepresent disclosure having an effective length of about 2 nanometers.

FIG. 2B shows examples of reagents that can be used in the method ofFIG. 2A for synthesizing a linker of the present disclosure, as well assome trifunctional reagents.

FIG. 2C shows an example of a method for synthesizing a linker of thepresent disclosure that is polymeric with defined molecular weight andlinking groups.

Additional synthetic methods for preparing optical labeling reagents(e.g., as described herein) are described elsewhere and in the Examplesbelow.

Methods for Constructing Labeled Nucleotides

In an aspect, the present disclosure provides methods for constructinglabeled nucleotides (e.g., optically labeled nucleotides).

Labeled nucleotides can be constructed using modular chemical buildingblocks. A nucleotide or nucleotide analog can be derivatized with, e.g.,a propargylamino moiety to provide a handle for attachment to a linkeror detectable label (e.g., dye). One or more detectable labels, such asone or more dyes, can be attached to a nucleotide or nucleotide analogvia a covalent bond. Alternatively or in addition to, one or moredetectable labels can be attached to a nucleotide or nucleotide analogvia a non-covalent bond. A detectable label may be attached to anucleotide or nucleotide analog via a linker (e.g., as describedherein). A linker may include one or more moieties. For example, alinker may include a first moiety including a disulfide bond within itto facilitate cleaving the linker and releasing the detectable label(e.g., during a sequencing process). Additional linker moieties can beadded using sequential peptide bonds. Linker moieties can have variouslengths and charges. A linker moiety may include one or more differentcomponents, such as one or more different ring systems, and/or arepeating unit (e.g., as described herein). Examples of linkers include,but are not limited to, aminoethyl-SS-propionic acid (epSS),aminoethyl-SS-benzoic acid, aminohexyl-SS-propionic acid, hyp10, andhyp20.

Examples of methods for constructing labeled nucleotides are shown inFIGS. 4, 5A, and 5B. As shown in FIG. 4 , a labeled nucleotide may beconstructed from a nucleotide, a dye, and one or more linker moieties.The one or more linker moieties together comprise a linker as describedherein. A nucleotide functionalized with a propargylamino moiety can beattached to a first linker moiety via a peptide bond. This first linkermoiety may comprise a cleavable moiety, such as a disulfide moiety. Thefirst linker moiety can also be attached to one or more additionallinker moieties in linear or branching fashions. For example, a secondlinker moiety may include two or more ring systems, wherein at least twoof the two or more ring systems are separated by no more than two sp3carbon atoms, such as by no more than two atoms. For example, at leasttwo of the two or more ring systems may be connected to each other by ansp² carbon atom. The linker may comprise a non-proteinogenic amino acidcomprising a ring system of the two or more ring systems. For example,the second linker moiety may comprise a two or more hydroxyprolinemoieties. An amine handle on a linker moiety may be used to attach thelinker and a dye, such as a dye that fluoresces in the red or greenportions of the visible electromagnetic spectrum. The labeled nucleotidegenerated in FIG. 4 comprises a modified deoxyadeninosine triphosphatemoiety, a linker comprising a first linker moiety including a disulfidemoiety and a second linker moiety including at least two ring systems,and a dye.

Construction of a labeled nucleotide can begin from either thenucleotide terminus or the dye terminus. Construction from the dyeterminus permits the use of unlabeled, unactivated amino acid moieties,while construction from the nucleotide terminus may requireamine-protected, carboxy-activated amino acid moieties.

FIGS. 5A and 5B show an example synthesis of a labeled nucleotideincluding a propargylamino functionalized dGTP moiety, a first linkermoiety including a disulfide group, a second linker moiety that ishyp10, and the dye moiety Atto633. Details of this synthesis areprovided in Example 3 below.

A nucleotide or nucleotide analog of a labeled nucleotide may includeone or more modifications, such as one or more modifications on thenucleobase. Alternatively, a nucleotide or nucleotide analog of alabeled nucleotide may include one or more modifications not on thenucleobase. Modifications can include, but are not limited to, covalentattachment of one or more linker or label moieties, alkylation,amination, amidation, esterification, hydroxylation, halogenation,sulfurylation, and/or phosphorylation.

A nucleotide or nucleotide analog of a labeled nucleotide may includeone or more modifications that are configured prevent subsequentnucleotide additions to a position adjacent to the labeled nucleotideupon its incorporation into a growing nucleic acid strand. For example,the labeled nucleotide may include a terminating or blocking group(e.g., dimethoxytrityl, phosphoramidite, or nitrobenzyl molecules). Insome instances, the terminating or blocking group may be cleavable.

Scarred Substrates and Methods of Generating the Same

In an aspect, the present disclosure provides a compound of Formula (I):

or a salt or solvate thereof, wherein:

-   -   R^(A) is an optionally substituted 5-12 membered ring system,        wherein substituents on R^(A) are independently selected from        R⁴;    -   R^(B) is selected from (i) an optionally substituted monocyclic        heterocycle comprising 2 or more heteroatoms and (ii) an        optionally substituted bicyclic heterocycle, wherein        substituents on R^(B) are independently selected from R⁵;    -   R^(C) is selected from optionally substituted C₁₋₆ alkyl,        optionally substituted C₂₋₆ alkenyl, and optionally substituted        C₂₋₆ alkynyl, wherein substituents on R¹ are independently        selected from R⁶, or is absent;    -   R¹ is selected from hydrogen, halogen, —OH, —OR⁸, ═O, ═S,        optionally substituted C₁₋₆ alkyl, optionally substituted C₂₋₆        alkenyl, optionally substituted C₂₋₆ alkynyl, optionally        substituted C₃₋₆ cycloalkyl, and optionally substituted        3-6-membered heterocycloalkyl, wherein substituents on R¹ are        independently selected from R⁶;    -   R² is selected from hydrogen, optionally substituted C₁₋₆ alkyl,        optionally substituted C₂₋₆ alkenyl, optionally substituted C₂₋₆        alkynyl, optionally substituted C₃₋₆ cycloalkyl, and optionally        substituted 3-6-membered heterocycloalkyl, wherein substituents        on R² are independently selected from R⁶;    -   each R³ is independently selected from hydrogen, halogen, —CN,        —OH, —OR⁸, —C(═O)R⁸, —CO₂R⁷, —C(═O)N(R⁷)₂, —N(R⁷)₂, —NRC(═O)R⁷,        —NR⁷C(═O)N(R⁷)₂, —SR⁷, —S(═O)R⁸, —SO₂R⁸, —SO₂N(R⁷)₂, —NO₂,        optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆        alkenyl, optionally substituted C₁-C₆ alkynyl, optionally        substituted monocyclic carbocycle, and optionally substituted        monocyclic heterocycle, wherein optional substituents on C₁-C₆        alkyl, C₁-C₆ alkenyl, C₁-C₆ alkynyl, monocyclic carbocycle, and        monocyclic heterocycle are independently selected from R⁶;    -   or two R³ are taken together with the atom to which they are        attached to form an optionally substituted 3- to 6-membered        heterocycle or carbocycle, wherein optional substituents on the        3- to 6-membered heterocycle or carbocycle are independently        selected from R⁶;    -   R⁴ is selected from halogen, ═O, ═S, —CN, —OH, —OR¹⁰, —N(R⁹)₂,        —C(═O)R⁹, —C(═O)OR⁹, —OC(═O)R⁹, —C(═O)N(R⁹)₂, —NR⁹C(═O)R⁹,        —NR⁹C(═O)N(R⁹)₂, —OC(═O)N(R⁹)₂, —NR⁹C(═O)OR⁹, —OC(═O)OR⁹,        —NR⁹SO₂R⁹, —SR⁹, —S(═O)R¹⁰, —SO₂R¹⁰, or —SO₂N(R⁹)₂, —NO₂,        optionally substituted C₁-C₆ alkyl, optionally substituted C₂-C₆        alkenyl, optionally substituted C₂-C₆ alkynyl, an optionally        substituted C₃-C₁₀ carbocycle, and an optionally substituted        3-10-membered heterocycle, wherein substituents on R⁴ are        independently selected from R⁶;    -   R⁵ is selected from halogen, ═O, ═S, —CN, —OH, —OR¹⁰, —N(R⁹)₂,        —C(═O)R⁹, —C(═O)OR⁹, —OC(═O)R⁹, —C(═O)N(R⁹)₂, —NR⁹C(═O)R⁹,        —NR⁹C(═O)N(R⁹)₂, —OC(═O)N(R⁹)₂, —NR⁹C(═O)OR⁹, —OC(═O)OR⁹,        —NR⁹SO₂R⁹, —SR⁹, —S(═O)R¹⁰, —SO₂R¹⁰, or —SO₂N(R⁹)₂, —NO₂,        optionally substituted C₁-C₆ alkyl, optionally substituted C₂-C₆        alkenyl, optionally substituted C₂-C₆ alkynyl, an optionally        substituted C₃-C₁₀ carbocycle, and an optionally substituted        3-10-membered heterocycle, wherein substituents on R⁵ are        independently selected from R⁶;    -   each R⁶ is independently selected from halogen, ═O, ═S, —CN,        —OH, —OR¹⁰, —N(R⁹)₂, —C(═O)R⁹, —C(═O)OR⁹, —OC(═O)R⁹,        —C(═O)N(R⁹)₂, —NR⁹C(═O)R⁹, —NR⁹C(═O)N(R⁹)₂, —OC(═O)N(R⁹)₂,        —NR⁹C(═O)OR⁹, —OC(═O)OR⁹, —SR⁹, —S(═O)R¹⁰, —SO₂R¹⁰, —SO₂N(R⁹)₂,        —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆        haloalkyl, C₁-C₆ hydroxyalkyl, C₁-C₆ aminoalkyl, C₃-C₆        carbocycle, optionally substituted monophosphate, optionally        substituted diphosphate, optionally substituted triphosphate,        and 3- to 6-membered heterocycle;    -   each R⁷ is independently selected from hydrogen, optionally        substituted C₁-C₆ alkyl, optionally substituted C₃-C₆        carbocycle, and optionally substituted 3-6-membered heterocycle,        wherein optional substituents on the C₁-C₆ alkyl, C₃-C₆        carbocycle, and 3-6-membered heterocycle are independently        selected from R⁶;    -   or two R⁷ are taken together with the atom(s) to which they are        attached to form an optionally substituted 3- to 6-membered        heterocycle, wherein optional substituents on the 3- to        6-membered heterocycle are independently selected from R⁶;    -   each R⁸ is independently selected from optionally substituted        C₁-C₆ alkyl, optionally substituted C₃-C₆ carbocycle, and        optionally substituted 3-6-membered heterocycle, wherein        optional substituents on the C₁-C₆ alkyl, C₃-C₆ carbocycle, and        3-6-membered heterocycle are independently selected from R⁶;    -   each R⁹ is independently selected from hydrogen, C₁-C₆ alkyl,        C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₃-C₆ carbocycle,        and 3- to 6-membered heterocycle;    -   or two R⁹ on the same nitrogen atom are taken together with the        nitrogen to which they are attached to form a 3- to 6-membered        heterocycle;    -   each R¹⁰ is independently selected from C₁-C₆ alkyl, C₂-C₆        alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₃-C₆ carbocycle, and        3- to 6-membered heterocycle; and    -   n is selected from 1, 2, 3, 4, and 5.

R^(B) may be an optionally substituted bicyclic heterocycle. Forexample, R^(B) may be an optionally substituted bicyclic heterocycle inwhich each heteroatom of the bicyclic heterocycle is N. An optionallysubstituted bicyclic heterocycle may be an optionally substituted purinesuch as adenine, guanine, or an analog thereof. For example, R^(B) mayhave a structure selected from:

R^(B) may be an optionally substituted monocyclic heterocycle comprising2 or more heteroatoms. For example, R^(B) may be an optionallysubstituted monocyclic heterocycle in which at least 2 heteroatoms areN. An optionally substituted monocyclic heterocycle may be an optionallysubstituted pyrimidine such as thymine, uracil, cytosine, or an analogthereof. For example, R^(B) may have a structure selected from:

R^(B) may be a nucleobase or nucleobase analog. For example, R^(B) maybe selected from adenine, guanine, thymine, uracil, cytosine, or ananalog thereof.

R^(B) may be substituted with at least one R⁵. For example, R^(B) may besubstituted with at least 1, 2, 3, 4, or more R⁵ moieties. The at leastone R⁵ may be independently selected from an optionally substitutedC₃-C₁₀ carbocycle and an optionally substituted 3-10-memberedheterocycle. For example, an R⁵ may selected from an optionallysubstituted 5-6 membered heterocycle such as an optionally substitutedribose or deoxyribose. A ribose or deoxyribose may be substituted with ablocking group such as a terminating group. Examples of terminatorsinclude, but are not limited to, allyl, dimethoxytrityl,phosphoramidite, or nitrobenzyl moieties. A terminator may be areversible terminator. Where the compound comprises a nucleotide, aterminator may be block incorporation of a subsequent nucleotide into anucleic acid molecule following incorporation of the nucleotide.Alternatively, the sugar moiety of the nucleotide of the compound (e.g.,ribose or deoxyribose) may not comprise a terminator, such that multiplesuch compounds could be incorporated into a nucleic acid molecule (e.g.,using a polymerase) without a terminator removal step between suchincorporations. R⁵ may be optionally substituted with an optionallysubstituted mono- or polyphosphate moiety such as a diphosphate ortriphosphate moiety.

R^(A) may be selected from an optionally substituted 5-12 memberedcarbocyclic ring system. Alternatively, R^(A) may be selected from anoptionally substituted 5-12 membered heterocyclic ring system. R^(A) maybe an aromatic ring system (e.g., a ring system comprising one or morearomatic ring structures). R^(A) may comprise one or more ringstructures. For example, R^(A) may be a monocycle. For example, R^(A)may be selected from an optionally substituted 5-8 membered monocyclicring system. For example, R^(A) may be an optionally substituted phenylmoiety. Alternatively, R^(A) may be a bicycle. For example, R^(A) may beselected from an optionally substituted 5-12 membered bicyclic ringsystem.

R^(A) may be substituted with at least one R⁴. For example, R^(A) may besubstituted with at least 1, 2, 3, 4, or more R⁴ moieties. Each R⁴ maybe independently selected from halogen, —OH, —OR¹⁰, —N(R⁹)₂, —C(═O)R⁹,—C(═O)OR⁹, —OC(═O)R⁹, —C(═O)N(R⁹)₂, —NR⁹C(═O)R⁹, —NR⁹C(═O)N(R⁹)₂,—OC(═O)N(R⁹)₂, —NR⁹C(═O)OR⁹, —OC(═O)OR⁹, and optionally substitutedC₁-C₆ alkyl. For example, each R⁴ may be independently selected fromhalogen, —OH, —OR¹⁰, and optionally substituted C₁-C₆ alkyl. Forexample, R^(A) may be substituted with a halogen. Alternatively or inaddition to, R^(A) may be substituted with —OH. Alternatively or inaddition to, R^(A) may be substituted with —OR¹⁰. Alternatively or inaddition to, R^(A) may be substituted with optionally substituted C₁-C₆alkyl.

R² may be hydrogen. Alternatively, R² may be selected from optionallysubstituted C₁-C₆ alkyl.

At least one R³ may be hydrogen. For example, each R³ may be hydrogen.Alternatively or in addition to, at least one R³ may be selected fromoptionally substituted C₁-C₆ alkyl.

In some cases, n is 1. In other cases, n is at least 2, such as 2, 3, 4,or 5. In an example, n may be 1 and R¹ may be hydrogen. In anotherexample, an R¹ may be ═O. For instance, n may be at least 2 and each R¹may be ═O. In another example, n may be at least 3, at least two R¹ maybe ═O, and a third R¹ may be —OH.

R^(C) may be present or absent. For example, R^(C) may be absent.Alternatively, R^(C) may be selected from optionally substituted C₁-C₆alkyl.

The compound may be a compound of Formula (II):

or a salt or solvate thereof, wherein:

-   -   dotted lines represent bonds that may be present or absent;    -   X is selected from C and N;    -   R¹¹ is selected from hydrogen, halogen, —OH, —OR⁸, —N(R⁷)₂,        —SR⁷, =0, and optionally substituted C₁₋₆ alkyl;    -   R¹² is an optionally substituted 5-6 membered heterocycle;    -   R¹³ is selected from hydrogen and optionally substituted C₁₋₆        alkyl, or is absent;    -   R¹⁴ is selected from hydrogen, halogen, —OH, —OR⁸, —N(R⁷)₂,        —SR⁷, ═O, and optionally substituted C₁₋₆ alkyl;    -   R¹⁵ is selected from hydrogen and optionally substituted C₁₋₆        alkyl, or is absent; and    -   R¹⁶ is selected from hydrogen, halogen, —OH, —OR⁸, —N(R⁷)₂,        —SR⁷, ═O, and optionally substituted C₁₋₆ alkyl,    -   wherein optional substituents on R¹¹, R¹³, R¹⁴, R¹⁵, and R¹⁶ are        selected from R¹⁷; and    -   each R¹⁷ is independently selected from halogen, —OH, —OR¹⁰,        —N(R⁹)₂, —C(═O)R⁹, —C(═O)OR⁹, —OC(═O)R⁹, —C(═O)N(R⁹)₂, and        —NR⁹C(═O)R⁹.

X may be C.

R¹² may be selected from optionally substituted ribose and deoxyribose.As described above, a ribose or deoxyribose may be substituted with ablocking group such as a terminating group. R¹² may be optionallysubstituted with an optionally substituted mono- or polyphosphate moietysuch as a diphosphate or triphosphate moiety.

R^(A) may be an optionally substituted 5-8 membered monocyclic ringsystem. For example, R^(A) may be an optionally substituted phenylmoiety.

R^(A) may be substituted with at least one R⁴. For example, R^(A) may besubstituted with at least 1, 2, 3, 4, or more R⁴ moieties. Each R⁴ maybe independently selected from halogen, —OH, —OR¹⁰, —N(R⁹)₂, —C(═O)R⁹,—C(═O)OR⁹, —OC(═O)R⁹, —C(═O)N(R⁹)₂, —NR⁹C(═O)R⁹, —NR⁹C(═O)N(R⁹)₂,—OC(═O)N(R⁹)₂, —NR⁹C(═O)OR⁹, —OC(═O)OR⁹, and optionally substitutedC₁-C₆ alkyl. For example, each R⁴ may be independently selected fromhalogen, —OH, —OR¹⁰, and optionally substituted C₁-C₆ alkyl. Forexample, R^(A) may be substituted with a halogen. Alternatively or inaddition to, R^(A) may be substituted with —OH. Alternatively or inaddition to, R^(A) may be substituted with —OR¹⁰. Alternatively or inaddition to, R^(A) may be substituted with optionally substituted C₁-C₆alkyl.

One or more of R¹¹, R¹⁴, and R¹⁶ may be hydrogen. Alternatively or inaddition to, one or more of R¹¹, R¹⁴, and R¹⁶ may be selected from—N(R⁷)₂.

One or more of R¹³ and R¹⁵ may be hydrogen. Alternatively or in additionto, one or more of R¹³ and R¹⁵ may be absent.

R² may be hydrogen. Alternatively, R² may be selected from optionallysubstituted C₁-C₆ alkyl.

At least one R³ may be hydrogen. For example, each R³ may be hydrogen.Alternatively or in addition to, at least one R³ may be selected fromoptionally substituted C₁-C₆ alkyl.

In some cases, n is 1. In other cases, n is at least 2, such as 2, 3, 4,or 5. In an example, n may be 1 and R¹ may be hydrogen. In anotherexample, an R¹ may be ═O. For instance, n may be at least 2 and each R¹may be ═O. In another example, n may be at least 3, at least two R¹ maybe ═O, and a third R¹ may be —OH.

The compound may be a compound of Formula (III):

or a salt or solvate thereof, wherein:

-   -   dotted lines represent bonds that may be present or absent;    -   R¹⁸ is selected from hydrogen, halogen, —OH, —OR⁸, —N(R⁷)₂,        —SR⁷, =0, and optionally substituted C₁₋₆ alkyl;    -   R¹⁹ is an optionally substituted 5-6 membered heterocycle;    -   R²⁰ is selected from hydrogen, halogen, —OH, —OR⁸, —N(R⁷)₂,        —SR⁷, =0, and optionally substituted C₁₋₆ alkyl;    -   R²¹ is selected from hydrogen and optionally substituted C₁₋₆        alkyl, or is absent; and    -   R²² is selected from hydrogen, halogen, —OH, —OR⁸, —N(R⁷)₂,        —SR⁷, =0, and optionally substituted C₁₋₆ alkyl,    -   wherein optional substituents on R¹⁸, R²⁰, R²¹, and R²² are        selected from R²³; and    -   each R²³ is independently selected from halogen, —OH, —OR¹⁰,        —N(R⁹)₂, —C(═O)R⁹, —C(═O)OR⁹, —OC(═O)R⁹, —C(═O)N(R⁹)₂, and        —NR⁹C(═O)R⁹.

R¹⁹ may be selected from optionally substituted ribose and deoxyribose.As described above, a ribose or deoxyribose may be substituted with ablocking group such as a terminating group. R¹² may be optionallysubstituted with an optionally substituted mono- or polyphosphate moietysuch as a diphosphate or triphosphate moiety.

R^(A) may be an optionally substituted 5-8 membered monocyclic ringsystem. For example, R^(A) may be an optionally substituted phenylmoiety.

R^(A) may be substituted with at least one R⁴. For example, R^(A) may besubstituted with at least 1, 2, 3, 4, or more R⁴ moieties. Each R⁴ maybe independently selected from halogen, —OH, —OR¹⁰, —N(R⁹)₂, —C(═O)R⁹,—C(═O)OR⁹, —OC(═O)R⁹, —C(═O)N(R⁹)₂, —NR⁹C(═O)R⁹, —NR⁹C(═O)N(R⁹)₂,—OC(═O)N(R⁹)₂, —NR⁹C(═O)OR⁹, —OC(═O)OR⁹, and optionally substitutedC₁-C₆ alkyl. For example, each R⁴ may be independently selected fromhalogen, —OH, —OR¹⁰, and optionally substituted C₁-C₆ alkyl. Forexample, R^(A) may be substituted with a halogen. Alternatively or inaddition to, R^(A) may be substituted with —OH. Alternatively or inaddition to, R^(A) may be substituted with —OR¹⁰. Alternatively or inaddition to, R^(A) may be substituted with optionally substituted C₁-C₆alkyl.

One or more of R¹⁸, R²⁰, and R²² may be hydrogen. Alternatively or inaddition to, one or more of R¹⁸, R²⁰, and R²² may be selected from—N(R⁷)₂.

R² may be hydrogen. Alternatively, R² may be selected from optionallysubstituted C₁-C₆ alkyl. R²¹ may be hydrogen. Alternatively, R²¹ may beselected from optionally substituted C₁-C₆ alkyl. Alternatively, R²¹ maybe absent.

At least one R³ may be hydrogen. For example, each R³ may be hydrogen.Alternatively or in addition to, at least one R³ may be selected fromoptionally substituted C₁-C₆ alkyl.

In some cases, n is 1. In other cases, n is at least 2, such as 2, 3, 4,or 5. In an example, n may be 1 and R¹ may be hydrogen. In anotherexample, an R¹ may be ═O. For instance, n may be at least 2 and each R¹may be ═O. In another example, n may be at least 3, at least two R¹ maybe ═O, and a third R¹ may be —OH.

Examples of compounds according to one or more of Formulas (I), (II),and (III) include, but are not limited to, the compounds included inTable 1.

TABLE 1 Compounds according to one or more of Formulas (I), (II), and(III). # Compound 1

2

3

4

5

6

7

8

9

10

11

12

A compound according to one or more of Formulas (I), (II), and (III) maybe included in a composition. The composition may be a solution, such asan aqueous solution. Such a solution may comprise one or more compoundsaccording to one or more of Formulas (I), (II), and (III). The one ormore compounds may be the same or different. For example, thecomposition may be a solution comprising a plurality of compoundsaccording to one or more of Formulas (I), (II), and (III), all of whichmay have the same structure.

A compound according to one or more of Formulas (I), (II), and (III) maybe included in a nucleic acid molecule. For example, a compoundaccording to one or more of Formulas (I), (II), and (III) may beincorporated into a nucleic acid strand (e.g., a growing nucleic acidstrand) coupled to a template nucleic acid molecule, where the nucleicacid strand and/or template nucleic acid molecule is immobilized to asurface.

The present disclosure also provides a method of generating a compoundaccording to one or more of Formulas (I), (II), and (III). The methodmay comprise providing a labeled substrate comprising a substrate (e.g.,a cell, protein, antibody, lipid, or nucleotide or nucleotide analog), alabeling moiety (e.g., a fluorescent dye), and a linker (e.g., asdescribed herein). The linker may couple the labeling moiety to thesubstrate. The linker may comprise a cleavable group (e.g., as describedherein) that is configured to be cleaved to separate the labeling moietyfrom the substrate. The labeled substrate (e.g., fluorescently labeledsubstrate) may be contacted with a cleavage reagent configured to cleavethe cleavable group of the linker, thereby separating the labelingmoiety and the substrate to provide the compound according to one ormore of Formulas (I), (II), and (III).

The labeling moiety may comprise a fluorescent label (e.g., fluorescentdye). The linker may comprise a plurality of amino acids, such as aplurality of non-proteinogenic amino acids. The linker may comprise aplurality of hydroxyprolines.

The cleavable group may comprise a disulfide bond. The cleavage reagentmay be selected from the group consisting oftris(2-carboxyethyl)phosphine (TCEP), dithiothreitol (DTT),tetrahydropyranyl (THP), ultraviolet (UV) light, and a combinationthereof.

The substrate may be a nucleotide or nucleotide analog, such as anucleotide or nucleotide analog that is incorporated into apolynucleotide.

A labeled substrate may have a structure according to Formula (V):

or a salt thereof, wherein:

-   -   R^(A) is an optionally substituted 5-12 membered ring system,        wherein substituents on R^(A) are independently selected from        R⁴;    -   R^(C) is selected from optionally substituted C₁₋₆ alkyl,        optionally substituted C₂₋₆ alkenyl, and optionally substituted        C₂₋₆ alkynyl, wherein substituents on R¹ are independently        selected from R⁶, or is absent;    -   R¹ is selected from hydrogen, halogen, —OH, —OR⁸, ═O, ═S,        optionally substituted C₁₋₆ alkyl, optionally substituted C₂₋₆        alkenyl, optionally substituted C₂₋₆ alkynyl, optionally        substituted C₃₋₆ cycloalkyl, and optionally substituted        3-6-membered heterocycloalkyl, wherein substituents on R¹ are        independently selected from R⁶;    -   R² is selected from hydrogen, optionally substituted C₁₋₆ alkyl,        optionally substituted C₂₋₆ alkenyl, optionally substituted C₂₋₆        alkynyl, optionally substituted C₃₋₆ cycloalkyl, and optionally        substituted 3-6-membered heterocycloalkyl, wherein substituents        on R² are independently selected from R⁶;    -   each R³ is independently selected from hydrogen, halogen, —CN,        —OH, —OR⁸, —C(═O)R⁸, —CO₂R⁷, —C(═O)N(R⁷)₂, —N(R⁷)₂, —NRC(═O)R⁷,        —NR⁷C(═O)N(R⁷)₂, —SR⁷, —S(═O)R⁸, —SO₂R⁸, —SO₂N(R⁷)₂, —NO₂,        optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆        alkenyl, optionally substituted C₁-C₆ alkynyl, optionally        substituted monocyclic carbocycle, and optionally substituted        monocyclic heterocycle, wherein optional substituents on C₁-C₆        alkyl, C₁-C₆ alkenyl, C₁-C₆ alkynyl, monocyclic carbocycle, and        monocyclic heterocycle are independently selected from R⁶;    -   or two R³ are taken together with the atom to which they are        attached to form an optionally substituted 3- to 6-membered        heterocycle or carbocycle, wherein optional substituents on the        3- to 6-membered heterocycle or carbocycle are independently        selected from R⁶;    -   R⁴ is selected from halogen, ═O, ═S, —CN, —OH, —OR¹⁰, —N(R⁹)₂,        —C(═O)R⁹, —C(═O)OR⁹, —OC(═O)R⁹, —C(═O)N(R⁹)₂, —NR⁹C(═O)R⁹,        —NR⁹C(═O)N(R⁹)₂, —OC(═O)N(R⁹)₂, —NR⁹C(═O)OR⁹, —OC(═O)OR⁹,        —NR⁹SO₂R⁹, —SR⁹, —S(═O)R¹⁰, —SO₂R¹⁰, or —SO₂N(R⁹)₂, —NO₂,        optionally substituted C₁-C₆ alkyl, optionally substituted C₂-C₆        alkenyl, optionally substituted C₂-C₆ alkynyl, an optionally        substituted C₃-C₁₀ carbocycle, and an optionally substituted        3-10-membered heterocycle, wherein substituents on R⁴ are        independently selected from R⁶;    -   each R⁶ is independently selected from halogen, ═O, ═S, —CN,        —OH, —OR¹⁰, —N(R⁹)₂, —C(═O)R⁹, —C(═O)OR⁹, —OC(═O)R⁹,        —C(═O)N(R⁹)₂, —NR⁹C(═O)R⁹, —NR⁹C(═O)N(R⁹)₂, —OC(═O)N(R⁹)₂,        —NR⁹C(═O)OR⁹, —OC(═O)OR⁹, —SR⁹, —S(═O)R¹⁰, —SO₂R¹⁰, —SO₂N(R⁹)₂,        —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆        haloalkyl, C₁-C₆ hydroxyalkyl, C₁-C₆ aminoalkyl, C₃-C₆        carbocycle, optionally substituted monophosphate, optionally        substituted diphosphate, optionally substituted triphosphate,        and 3- to 6-membered heterocycle;    -   each R⁷ is independently selected from hydrogen, optionally        substituted C₁-C₆ alkyl, optionally substituted C₃-C₆        carbocycle, and optionally substituted 3-6-membered heterocycle,        wherein optional substituents on the C₁-C₆ alkyl, C₃-C₆        carbocycle, and 3-6-membered heterocycle are independently        selected from R⁶;    -   or two R⁷ are taken together with the atom(s) to which they are        attached to form an optionally substituted 3- to 6-membered        heterocycle, wherein optional substituents on the 3- to        6-membered heterocycle are independently selected from R⁶;    -   each R⁸ is independently selected from optionally substituted        C₁-C₆ alkyl, optionally substituted C₃-C₆ carbocycle, and        optionally substituted 3-6-membered heterocycle, wherein        optional substituents on the C₁-C₆ alkyl, C₃-C₆ carbocycle, and        3-6-membered heterocycle are independently selected from R⁶;    -   each R⁹ is independently selected from hydrogen, C₁-C₆ alkyl,        C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₃-C₆ carbocycle,        and 3- to 6-membered heterocycle; or two R⁹ on the same nitrogen        atom are taken together with the nitrogen to which they are        attached to form a 3- to 6-membered heterocycle;    -   each R¹⁰ is independently selected from C₁-C₆ alkyl, C₂-C₆        alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₃-C₆ carbocycle, and        3- to 6-membered heterocycle;    -   n is selected from 1, 2, 3, 4, and 5;    -   Z is a substrate selected from a nucleotide or nucleotide        analog, cell, protein, lipid, and antibody;    -   L is a linker moiety; and    -   D is a label moiety.

Z may be a substrate such as a cell, protein, lipid, or antibody. Z maybe a nucleotide or nucleotide analog (e.g., as described herein). Thenucleotide or nucleotide analog may be incorporated into apolynucleotide (e.g., as described herein). For example, the nucleotideor nucleotide analog may comprise adenine, guanine, cytosine, thymine,uracil, or an analog thereof. The nucleotide or nucleotide analog may beterminated or non-terminated (e.g., as described herein). Z may comprisea plurality of moieties shown in Formula (IV), such as at least 1, 2, 3,or more such moieties.

D may be a label moiety, such as a fluorescent dye (e.g., as describedherein).

L may be a linker moiety (e.g., as described herein). As describedelsewhere herein, a linker may comprise multiple components, including acleavable component and another component, such as another componentincluding two or more ring systems. The structure shown in Formula (V)includes a cleavable component. The cleavable component includes adisulfide bond. The other component of the linker may comprise aplurality of amino acids, such as a plurality of non-proteinogenic aminoacids (e.g., as described herein). For example, the other component ofthe linker may comprise a plurality of hydroxyprolines.

R^(A) may be selected from an optionally substituted 5-12 memberedcarbocyclic ring system. Alternatively, R^(A) may be selected from anoptionally substituted 5-12 membered heterocyclic ring system. R^(A) maybe an aromatic ring system (e.g., a ring system comprising one or morearomatic ring structures). R^(A) may comprise one or more ringstructures. For example, R^(A) may be a monocycle. For example, R^(A)may be selected from an optionally substituted 5-8 membered monocyclicring system. For example, R^(A) may be an optionally substituted phenylmoiety. Alternatively, R^(A) may be a bicycle. For example, R^(A) may beselected from an optionally substituted 5-12 membered bicyclic ringsystem.

R^(A) may be substituted with at least one R⁴. For example, R^(A) may besubstituted with at least 1, 2, 3, 4, or more R⁴ moieties. Each R⁴ maybe independently selected from halogen, —OH, —OR¹⁰, —N(R⁹)₂, —C(═O)R⁹,—C(═O)OR⁹, —OC(═O)R⁹, —C(═O)N(R⁹)₂, —NR⁹C(═O)R⁹, —NR⁹C(═O)N(R⁹)₂,—OC(═O)N(R⁹)₂, —NR⁹C(═O)OR⁹, —OC(═O)OR⁹, and optionally substitutedC₁-C₆ alkyl. For example, each R⁴ may be independently selected fromhalogen, —OH, —OR¹⁰, and optionally substituted C₁-C₆ alkyl. Forexample, R^(A) may be substituted with a halogen. Alternatively or inaddition to, R^(A) may be substituted with —OH. Alternatively or inaddition to, R^(A) may be substituted with —OR¹⁰. Alternatively or inaddition to, R^(A) may be substituted with optionally substituted C₁-C₆alkyl.

R² may be hydrogen. Alternatively, R² may be selected from optionallysubstituted C₁-C₆ alkyl.

At least one R³ may be hydrogen. For example, each R³ may be hydrogen.Alternatively or in addition to, at least one R³ may be selected fromoptionally substituted C₁-C₆ alkyl.

In some cases, n is 1. In other cases, n is at least 2, such as 2, 3, 4,or 5. In an example, n may be 1 and R¹ may be hydrogen. In anotherexample, an R¹ may be ═O. For instance, n may be at least 2 and each R¹may be ═O. In another example, n may be at least 3, at least two R¹ maybe ═O, and a third R¹ may be —OH.

R^(C) may be present or absent. For example, R^(C) may be absent.Alternatively, R^(C) may be selected from optionally substituted C₁-C₆alkyl.

An example of a labeled substrate according to Formula (V) is shownbelow:

The labeled substrate shown above includes a hyp10 moiety, as describedherein.

The present disclosure also provides a modified polynucleotidecomprising a compound according to one or more of Formulas (I), (II),and (III). The modified polynucleotide may comprise two or morecompounds according to one or more of Formulas (I), (II), and (III). Thetwo or more compounds may have the same or different structures. The twoor more compounds may be separated by at least one nucleotide, such asby at least 1, 2, 3, 4, or more nucleotides. The two or more compoundsmay be included in a same strand of the modified polynucleotide, such asa strand coupled to a template nucleic acid strand.

The present disclosure also provides a method of generating a modifiedpolynucleotide, such as a modified polynucleotide comprising a compoundaccording to one or more of Formulas (I), (II), and (III). The methodmay comprise providing a precursor of the compound and a templatenucleic acid molecule coupled to a nucleic acid strand. The templatenucleic acid molecule coupled to the nucleic acid strand may beimmobilized to a support. The precursor of the compound and the templatenucleic acid molecule may be subjected to conditions sufficient toincorporate the precursor of the compound into the nucleic acid strandcoupled to the template nucleic acid molecule. The precursor of thecompound incorporated into the nucleic acid strand may be subjected toconditions sufficient to generate the compound from the precursor of thecompound.

The precursor of the compound may comprise a linker (e.g., as describedherein). The linker of the precursor of the compound may comprise acleavable group (e.g., as described herein). For example, the linker maycomprise a disulfide bond. The cleavable group may be configured to becleaved to separate a labeling moiety from a substrate. The linker maycouple a portion of the precursor of the compound (e.g., a substratesuch as a nucleotide or nucleotide analog) to a labeling moiety (e.g., afluorescent dye, as described herein).

Incorporating the precursor of the compound may be accomplished using apolymerase enzyme, such as a strand-displacement polymerase enzyme(e.g., as described herein).

The template nucleic acid molecule may comprise deoxyribonucleic acid.Alternatively or in addition to, the template nucleic acid molecule maycomprise ribonucleic acid.

Subjecting the precursor of the compound to conditions sufficient togenerate the compound from the precursor may comprise contacting theprecursor of the compound with a cleavage reagent configured to cleave acleavable group of a linker, thereby generating the compound. This mayachieved, e.g., in a solution. The cleavage reagent may be provided in acleavage flow (e.g., as described herein).

The present disclosure also provides a composition comprising a chemicalmoiety of Formula (IV):

or a salt or solvate thereof, wherein:

-   -   R^(A) is an optionally substituted 5-12 membered ring system,        wherein substituents on R^(A) are independently selected from        R⁴;    -   R^(C) is selected from optionally substituted C₁₋₆ alkyl,        optionally substituted C₂₋₆ alkenyl, and optionally substituted        C₂₋₆ alkynyl, wherein substituents on R¹ are independently        selected from R⁶, or is absent;    -   R¹ is selected from hydrogen, halogen, —OH, —OR⁸, ═O, ═S,        optionally substituted C₁₋₆ alkyl, optionally substituted C₂₋₆        alkenyl, optionally substituted C₂₋₆ alkynyl, optionally        substituted C₃₋₆ cycloalkyl, and optionally substituted        3-6-membered heterocycloalkyl, wherein substituents on R¹ are        independently selected from R⁶;    -   R² is selected from hydrogen, optionally substituted C₁₋₆ alkyl,        optionally substituted C₂₋₆ alkenyl, optionally substituted C₂₋₆        alkynyl, optionally substituted C₃₋₆ cycloalkyl, and optionally        substituted 3-6-membered heterocycloalkyl, wherein substituents        on R² are independently selected from R⁶;    -   each R³ is independently selected from hydrogen, halogen, —CN,        —OH, —OR⁸, —C(═O)R⁸, —CO₂R⁷, —C(═O)N(R⁷)₂, —N(R⁷)₂, —NRC(═O)R⁷,        —NR⁷C(═O)N(R⁷)₂, —SR⁷, —S(═O)R⁸, —SO₂R⁸, —SO₂N(R⁷)₂, —NO₂,        optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆        alkenyl, optionally substituted C₁-C₆ alkynyl, optionally        substituted monocyclic carbocycle, and optionally substituted        monocyclic heterocycle, wherein optional substituents on C₁-C₆        alkyl, C₁-C₆ alkenyl, C₁-C₆ alkynyl, monocyclic carbocycle, and        monocyclic heterocycle are independently selected from R⁶;    -   or two R³ are taken together with the atom to which they are        attached to form an optionally substituted 3- to 6-membered        heterocycle or carbocycle, wherein optional substituents on the        3- to 6-membered heterocycle or carbocycle are independently        selected from R⁶;    -   R⁴ is selected from halogen, ═O, ═S, —CN, —OH, —OR¹⁰, —N(R⁹)₂,        —C(═O)R⁹, —C(═O)OR⁹, —OC(═O)R⁹, —C(═O)N(R⁹)₂, —NR⁹C(═O)R⁹,        —NR⁹C(═O)N(R⁹)₂, —OC(═O)N(R⁹)₂, —NR⁹C(═O)OR⁹, —OC(═O)OR⁹,        —NR⁹SO₂R⁹, —SR⁹, —S(═O)R¹⁰, —SO₂R¹⁰, or —SO₂N(R⁹)₂, —NO₂,        optionally substituted C₁-C₆ alkyl, optionally substituted C₂-C₆        alkenyl, optionally substituted C₂-C₆ alkynyl, an optionally        substituted C₃-C₁₀ carbocycle, and an optionally substituted        3-10-membered heterocycle, wherein substituents on R⁴ are        independently selected from R⁶;    -   each R⁶ is independently selected from halogen, ═O, ═S, —CN,        —OH, —OR¹⁰, —N(R⁹)₂, —C(═O)R⁹, —C(═O)OR⁹, —OC(═O)R⁹,        —C(═O)N(R⁹)₂, —NR⁹C(═O)R⁹, —NR⁹C(═O)N(R⁹)₂, —OC(═O)N(R⁹)₂,        —NR⁹C(═O)OR⁹, —OC(═O)OR⁹, —SR⁹, —S(═O)R¹⁰, —SO₂R¹⁰, —SO₂N(R⁹)₂,        —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆        haloalkyl, C₁-C₆ hydroxyalkyl, C₁-C₆ aminoalkyl, C₃-C₆        carbocycle, optionally substituted monophosphate, optionally        substituted diphosphate, optionally substituted triphosphate,        and 3- to 6-membered heterocycle;    -   each R⁷ is independently selected from hydrogen, optionally        substituted C₁-C₆ alkyl, optionally substituted C₃-C₆        carbocycle, and optionally substituted 3-6-membered heterocycle,        wherein optional substituents on the C₁-C₆ alkyl, C₃-C₆        carbocycle, and 3-6-membered heterocycle are independently        selected from R⁶;    -   or two R⁷ are taken together with the atom(s) to which they are        attached to form an optionally substituted 3- to 6-membered        heterocycle, wherein optional substituents on the 3- to        6-membered heterocycle are independently selected from R⁶;    -   each R⁸ is independently selected from optionally substituted        C₁-C₆ alkyl, optionally substituted C₃-C₆ carbocycle, and        optionally substituted 3-6-membered heterocycle, wherein        optional substituents on the C₁-C₆ alkyl, C₃-C₆ carbocycle, and        3-6-membered heterocycle are independently selected from R⁶;    -   each R⁹ is independently selected from hydrogen, C₁-C₆ alkyl,        C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₃-C₆ carbocycle,        and 3- to 6-membered heterocycle;    -   or two R⁹ on the same nitrogen atom are taken together with the        nitrogen to which they are attached to form a 3- to 6-membered        heterocycle;    -   each R¹⁰ is independently selected from C₁-C₆ alkyl, C₂-C₆        alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₃-C₆ carbocycle, and        3- to 6-membered heterocycle;    -   n is selected from 1, 2, 3, 4, and 5; and    -   Z is a substrate selected from a nucleotide or nucleotide        analog, cell, protein, lipid, and antibody.

Z may be a substrate such as a cell, protein, lipid, or antibody. Z maybe a nucleotide or nucleotide analog (e.g., as described herein). Thenucleotide or nucleotide analog may be incorporated into apolynucleotide (e.g., as described herein). For example, the nucleotideor nucleotide analog may comprise adenine, guanine, cytosine, thymine,uracil, or an analog thereof. The nucleotide or nucleotide analog may beterminated or non-terminated (e.g., as described herein). Z may comprisea plurality of moieties shown in Formula (IV), such as at least 1, 2, 3,or more such moieties.

R^(A) may be selected from an optionally substituted 5-12 memberedcarbocyclic ring system. Alternatively, R^(A) may be selected from anoptionally substituted 5-12 membered heterocyclic ring system. R^(A) maybe an aromatic ring system (e.g., a ring system comprising one or morearomatic ring structures). R^(A) may comprise one or more ringstructures. For example, R^(A) may be a monocycle. For example, R^(A)may be selected from an optionally substituted 5-8 membered monocyclicring system. For example, R^(A) may be an optionally substituted phenylmoiety. Alternatively, R^(A) may be a bicycle. For example, R^(A) may beselected from an optionally substituted 5-12 membered bicyclic ringsystem.

R^(A) may be substituted with at least one R⁴. For example, R^(A) may besubstituted with at least 1, 2, 3, 4, or more R⁴ moieties. Each R⁴ maybe independently selected from halogen, —OH, —OR¹⁰, —N(R⁹)₂, —C(═O)R⁹,—C(═O)OR⁹, —OC(═O)R⁹, —C(═O)N(R⁹)₂, —NR⁹C(═O)R⁹, —NR⁹C(═O)N(R⁹)₂,—OC(═O)N(R⁹)₂, —NR⁹C(═O)OR⁹, —OC(═O)OR⁹, and optionally substitutedC₁-C₆ alkyl. For example, each R⁴ may be independently selected fromhalogen, —OH, —OR¹⁰, and optionally substituted C₁-C₆ alkyl. Forexample, R^(A) may be substituted with a halogen. Alternatively or inaddition to, R^(A) may be substituted with —OH. Alternatively or inaddition to, R^(A) may be substituted with —OR¹⁰. Alternatively or inaddition to, R^(A) may be substituted with optionally substituted C₁-C₆alkyl.

R² may be hydrogen. Alternatively, R² may be selected from optionallysubstituted C₁-C₆ alkyl.

At least one R³ may be hydrogen. For example, each R³ may be hydrogen.Alternatively or in addition to, at least one R³ may be selected fromoptionally substituted C₁-C₆ alkyl.

In some cases, n is 1. In other cases, n is at least 2, such as 2, 3, 4,or 5. In an example, n may be 1 and R¹ may be hydrogen. In anotherexample, an may be ═O. For instance, n may be at least 2 and each R¹ maybe ═O. In another example, n may be at least 3, at least two R¹ may be═O, and a third R¹ may be —OH.

R^(C) may be present or absent. For example, R^(C) may be absent.Alternatively, R^(C) may be selected from optionally substituted C₁-C₆alkyl.

Examples of chemical moieties according to Formula (IV) include, but arenot limited to, the compounds included in Table 2.

TABLE 2 Chemical moieties according to Formula (IV). Compound 13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

For the chemical moieties included in Table 2, Z may be, for example, anucleotide or nucleotide analog, protein, lipid, antibody, or cell. Forexample, Z may be a nucleotide or nucleotide analog (e.g., as describedherein).

The present disclosure also provides a method of generating acomposition comprising a chemical moiety of Formula (IV). The method maycomprise providing a labeled substrate comprising a substrate (e.g., acell, protein, antibody, lipid, or nucleotide or nucleotide analog), alabeling moiety (e.g., a fluorescent dye), and a linker (e.g., asdescribed herein). The linker may couple the labeling moiety to thesubstrate. The linker may comprise a cleavable group (e.g., as describedherein) that is configured to be cleaved to separate the labeling moietyfrom the substrate. The labeled substrate (e.g., fluorescently labeledsubstrate) may be contacted with a cleavage reagent configured to cleavethe cleavable group of the linker, thereby separating the labelingmoiety and the substrate to provide the composition comprising achemical moiety according to Formula (IV).

The labeling moiety may comprise a fluorescent label (e.g., fluorescentdye). The linker may comprise a plurality of amino acids, such as aplurality of non-proteinogenic amino acids. The linker may comprise aplurality of hydroxyprolines.

The cleavable group may comprise a disulfide bond. The cleavage reagentmay be selected from the group consisting oftris(2-carboxyethyl)phosphine (TCEP), dithiothreitol (DTT),tetrahydropyranyl (THP), ultraviolet (UV) light, and a combinationthereof.

The substrate may be a nucleotide or nucleotide analog, such as anucleotide or nucleotide analog that is incorporated into apolynucleotide. Alternatively, the substrate may be a protein, lipid,cell, or antibody.

In an aspect, the present disclosure provides a substrate coupled to ascar moiety. A substrate coupled to a scar moiety may be, for example, aprotein, cell, lipid, or antibody. A substrate may be a nucleotide ornucleotide analog (e.g., as described herein). A scar moiety may be amoiety comprising a portion or derivative of a cleavable group. Forexample, a scar moiety may comprise a portion or derivative of adisulfide bond such as a sulfur radical. A sulfur radical may bond to ahydrogen atom to provide a thiol group. A sulfur radical or thiol groupmay undergo an oxidation process to provide, for example, a sulfoxide,sulfone, sulfonic acid, dithiol, or another moiety. Alternatively or inaddition to, a scar moiety may comprise a portion or derivative of analkylazido (e.g., azidomethyl) moiety such as a nitrogen radical (e.g.,a nitrogen radical of a diazene moiety). Alternatively or in additionto, a scar moiety may comprise a portion or derivative of ahydrocarbyldithiomethyl moiety. Alternatively or in addition to, a scarmoiety may comprise a portion or derivative of a 2-nitrobenzyloxymoiety. A scar moiety coupled to a substrate may comprise a chemicalmoiety according to any one of Formulas (I), (II), or (III).

The present disclosure also provides a modified polynucleotidecomprising a nucleotide or nucleotide analog having a scar moietyattached thereto. As described above, the scar moiety may be a moietycomprising a portion or derivative of a cleavable group, such as aportion or derivative of a disulfide bond. For example, the modifiedpolynucleotide may comprise a thiol, a sulfoxide, sulfone, sulfonicacid, dithiol, or another moiety derived from a disulfide bond, e.g.,upon cleavage of a disulfide bond using a cleavage reagent. The modifiedpolynucleotide may comprise a chemical moiety according to any one ofFormulas (I), (II), or (III).

Computer Systems

The present disclosure provides computer systems that are programmed toimplement methods of the disclosure. FIG. 3 shows a computer system 301that is programmed or otherwise configured to perform nucleic acidsequencing. The computer system 301 can determine sequence reads basedat least in part on intensities of detected optical signals. Thecomputer system 301 can regulate various aspects of the presentdisclosure, such as, for example, performing nucleic acid sequencing,sequence analysis, and regulating conditions of transient binding andnon-transient binding (e.g., incorporation) of nucleotides. The computersystem 301 can be an electronic device of a user or a computer systemthat is remotely located with respect to the electronic device. Theelectronic device can be a mobile electronic device.

The computer system 301 includes a central processing unit (CPU, also“processor” and “computer processor” herein) 305, which can be a singlecore or multi core processor, or a plurality of processors for parallelprocessing. The computer system 301 also includes memory or memorylocation 310 (e.g., random-access memory, read-only memory, flashmemory), electronic storage unit 315 (e.g., hard disk), communicationinterface 320 (e.g., network adapter) for communicating with one or moreother systems, and peripheral devices 325, such as cache, other memory,data storage and/or electronic display adapters. The memory 310, storageunit 315, interface 320 and peripheral devices 325 are in communicationwith the CPU 305 through a communication bus (solid lines), such as amotherboard. The storage unit 315 can be a data storage unit (or datarepository) for storing data. The computer system 301 can be operativelycoupled to a computer network (“network”) 330 with the aid of thecommunication interface 320. The network 330 can be the Internet, aninternet and/or extranet, or an intranet and/or extranet that is incommunication with the Internet. The network 330 in some cases is atelecommunication and/or data network. The network 330 can include oneor more computer servers, which can enable distributed computing, suchas cloud computing. The network 330, in some cases with the aid of thecomputer system 301, can implement a peer-to-peer network, which mayenable devices coupled to the computer system 301 to behave as a clientor a server.

The CPU 305 can execute a sequence of machine-readable instructions,which can be embodied in a program or software. The instructions may bestored in a memory location, such as the memory 310. The instructionscan be directed to the CPU 305, which can subsequently program orotherwise configure the CPU 305 to implement methods of the presentdisclosure. Examples of operations performed by the CPU 305 can includefetch, decode, execute, and writeback.

The CPU 305 can be part of a circuit, such as an integrated circuit. Oneor more other components of the system 301 can be included in thecircuit. In some cases, the circuit is an application specificintegrated circuit (ASIC).

The storage unit 315 can store files, such as drivers, libraries andsaved programs. The storage unit 315 can store user data, e.g., userpreferences and user programs. The computer system 301 in some cases caninclude one or more additional data storage units that are external tothe computer system 301, such as located on a remote server that is incommunication with the computer system 301 through an intranet or theInternet.

The computer system 301 can communicate with one or more remote computersystems through the network 330. For instance, the computer system 301can communicate with a remote computer system of a user. Examples ofremote computer systems include personal computers (e.g., portable PC),slate or tablet PC's (e.g., Apple® iPad, Samsung® Galaxy Tab),telephones, Smart phones (e.g., Apple® iPhone, Android-enabled device,Blackberry®), or personal digital assistants. The user can access thecomputer system 301 via the network 330.

Methods as described herein can be implemented by way of machine (e.g.,computer processor) executable code stored on an electronic storagelocation of the computer system 301, such as, for example, on the memory310 or electronic storage unit 315. The machine executable or machinereadable code can be provided in the form of software. During use, thecode can be executed by the processor 305. In some cases, the code canbe retrieved from the storage unit 315 and stored on the memory 310 forready access by the processor 305. In some situations, the electronicstorage unit 315 can be precluded, and machine-executable instructionsare stored on memory 310.

The code can be pre-compiled and configured for use with a machinehaving a processer adapted to execute the code, or can be compiledduring runtime. The code can be supplied in a programming language thatcan be selected to enable the code to execute in a pre-compiled oras-compiled fashion.

Aspects of the systems and methods provided herein, such as the computersystem 301, can be embodied in programming. Various aspects of thetechnology may be thought of as “products” or “articles of manufacture”typically in the form of machine (or processor) executable code and/orassociated data that is carried on or embodied in a type of machinereadable medium. Machine-executable code can be stored on an electronicstorage unit, such as memory (e.g., read-only memory, random-accessmemory, flash memory) or a hard disk. “Storage” type media can includeany or all of the tangible memory of the computers, processors or thelike, or associated modules thereof, such as various semiconductormemories, tape drives, disk drives and the like, which may providenon-transitory storage at any time for the software programming. All orportions of the software may at times be communicated through theInternet or various other telecommunication networks. Suchcommunications, for example, may enable loading of the software from onecomputer or processor into another, for example, from a managementserver or host computer into the computer platform of an applicationserver. Thus, another type of media that may bear the software elementsincludes optical, electrical and electromagnetic waves, such as usedacross physical interfaces between local devices, through wired andoptical landline networks and over various air-links. The physicalelements that carry such waves, such as wired or wireless links, opticallinks or the like, also may be considered as media bearing the software.As used herein, unless restricted to non-transitory, tangible “storage”media, terms such as computer or machine “readable medium” refer to anymedium that participates in providing instructions to a processor forexecution.

Hence, a machine readable medium, such as computer-executable code, maytake many forms, including but not limited to, a tangible storagemedium, a carrier wave medium or physical transmission medium.Non-volatile storage media include, for example, optical or magneticdisks, such as any of the storage devices in any computer(s) or thelike, such as may be used to implement the databases, etc. shown in thedrawings. Volatile storage media include dynamic memory, such as mainmemory of such a computer platform. Tangible transmission media includecoaxial cables; copper wire and fiber optics, including the wires thatcomprise a bus within a computer system. Carrier-wave transmission mediamay take the form of electric or electromagnetic signals, or acoustic orlight waves such as those generated during radio frequency (RF) andinfrared (IR) data communications. Common forms of computer-readablemedia therefore include for example: a floppy disk, a flexible disk,hard disk, magnetic tape, any other magnetic medium, a CD-ROM, DVD orDVD-ROM, any other optical medium, punch cards paper tape, any otherphysical storage medium with patterns of holes, a RAM, a ROM, a PROM andEPROM, a FLASH-EPROM, any other memory chip or cartridge, a carrier wavetransporting data or instructions, cables or links transporting such acarrier wave, or any other medium from which a computer may readprogramming code and/or data. Many of these forms of computer readablemedia may be involved in carrying one or more sequences of one or moreinstructions to a processor for execution.

The computer system 301 can include or be in communication with anelectronic display 335 that comprises a user interface (UI) 340 forproviding, for example, results of nucleic acid sequence and opticalsignal detection (e.g., sequence reads, intensity maps, etc.). Examplesof UI's include, without limitation, a graphical user interface (GUI)and web-based user interface.

Methods and systems of the present disclosure can be implemented by wayof one or more algorithms. An algorithm can be implemented by way ofsoftware upon execution by the central processing unit 305. Thealgorithm can, for example, implement methods and systems of the presentdisclosure, such as determine sequence reads based at least in part onintensities of detected optical signals.

EXAMPLES Example 1: General Synthetic Principles

Certain examples of the following examples illustrate various methods ofmaking linkers and labeled substrates described herein. It is understoodthat one skilled in the art may be able to make these compounds bysimilar methods or by combining other methods known to one skilled inthe art. It is also understood that one skilled in the art would be ableto make other compounds in a similar manner as described below by usingthe appropriate starting materials and modifying synthetic routes asneeded. In general, starting materials and reagents can be obtained fromcommercial vendors or synthesized according to sources known to thoseskilled in the art or prepared as described herein.

Unless otherwise noted, reagents and solvents used in synthetic methodsdescribed herein are obtained from commercial suppliers. Anhydroussolvents and oven-dried glassware may be used for synthetictransformations sensitive to moisture and/or oxygen. Yields may not beoptimized. Reaction times may be approximate and may not be optimized.Materials and instrumentation used in synthetic procedures may besubstituted with appropriate alternatives. Column chromatography andthin layer chromatography (TLC) may be performed on reverse-phase silicagel unless otherwise noted. Nuclear magnetic resonance (NMR) and massspectra may be obtained to characterize reaction products and/or monitorreaction progress.

Example 2: A Structure of a Labeling Reagent

Described herein is an example of a semi-rigid, water-soluble linker ofa defined molecular weight that can efficiently accomplish a dye-dye ordye-quencher separation. A semi-rigid structure can be achieved througha series of linked, aromatic or non-aromatic ring systems connected byzero or one linkages with sp³ bonding, and zero or more sp or sp² bonds.Water-solubility can be achieved with the inclusion (e.g., in eachsubunit) of at least one of the moieties selected from the group:hydroxyl, pyridinium, imidazolium, sulfonate, amino, thiol, carboxyl,and quaternary ammonium. A linker can be a hetero- or homobi-(ortri-)functional reagent that allows attachment of a dye (e.g.,fluorescent dye) at one end and a biological ligand (e.g., a nucleotide)at the other end. An example of a general formula for such a linker isshown below:

in which p is a number of repeating units selected from 1-100; each R³is a water-soluble moiety independently selected from, for example,pyridinium and sulfonate; R¹ and R² are attachment groups such as aminoand carboxy moieties; each n is independently 1 or 2; each m isindependently selected from 1 and 2; and each q is independentlyselected from 4-8. In the structure above, m represents the number ofsp³ carbons linking ring moieties to one another. A ring moiety may bean aliphatic or an aromatic ring.

Multiple such subunits may be connected to one another. For example, alinker may be represented by the below formula:

in which p and r are each a number of repeating units independentlyselected from 1-100; each R³ and R⁴ is a water-soluble moietyindependently selected from, for example, pyridinium and sulfonate; R¹and R² are attachment groups such as amino and carboxy moieties; each nand i is independently 1 or 2; each m and k is independently selectedfrom 1 and 2; and each q and j is independently selected from 4-8. Inthe structure above, m and k represent the number of sp³ carbons linkingring moieties to one another. A ring moiety may be an aliphatic or anaromatic ring. In some cases, ring moieties in the left portion of thestructure are aliphatic and ring moieties in the right portion of thestructure are aromatic, or vice versa.

Note that the above structures do not capture all embodiments of thedisclosure. For example, the linker does not have to be a polymer of“P-repeating” units. Similarly, the water-soluble functional group canbe a constituent component of the ring rather than attached to the ring.

Example 3: Synthesis of dGTP-AP-SS-Hyp10-Atto633

Described herein is a method for constructing the labeled nucleotidedGTP-AP-SS-hyp10-Atto633. FIG. 5A illustrates an example method for thesynthesis of a fluorescently labeled dGTP reagent. FIG. 5B illustratesthe same synthesis with the full structures of the dye and linker. Themethod involves formation of a covalent linkage between Gly-Hyp10 andthe fluorophore Atto633 (process (a)), esterification to coupleAtto633-Gly-Hyp10 with pentafluorophenol (process (b)), substitutionwith the linker molecule epSS (process(c)), esterification to formAtto633-Gly-Hyp10-epSS-PFP (process (d)), and substitution with dGTP toprovide the fluorescently labeled nucleotide (process (e)). Details ofthe synthesis are provided below.

Preparation of Atto633-Gly-Hyp10. (FIG. 5 process (a)) A stock solutionof Gly-Hyp10 (also referred to herein as “hyp10”) in bicarbonate isprepared by dissolving 25 milligrams (mg) of the 11 amino acid peptidein 500 microliters (μL) of 0.2 molar (M) sodium bicarbonate in a 1.5milliliter (mL) Eppendorf tube. 7 mg of Atto633-NHS is weighed intoanother Eppendorf tube and dissolved in 200 μL of dimethylformamide(DMF). A volume of 300 μL of the peptide solution is added to thesolution containing Atto633-NHS. The resulting solution is mixed andheated to 50° C. for 20 minutes (min). The extent of the reaction isfollowed with reverse-phase thin layer chromatography (TLC). A 1 μLaliquot of the reaction solution is removed and dissolved in 40 μL waterand spotted on reverse phase TLC. A co-spot with Atto633 acid isincluded, and Atto633 is also run alone. The plate is eluted with a 2:1solution of acetonitrile 0.1M triethylammonium acetate (TEAA). Atto633acid and Atto633-NHS both have an R_(f) of zero, while Gly-Hyp10 has anR_(f) of 0.4. The product is purified by injecting the solution onto aC18 reverse phase column using the gradient 20%→50% acetonitrile vs.0.1M TEAA over 16 minutes at 2.5 mL/min. The desired product is themajor product, Atto633-Gly-Hyp10, eluting at 15.2 minutes. The fractionscontaining the desired material are collected in Eppendorf tubes anddried, yielding a blue solid. A major peak was observed on ESI massspec: m/z calculated for C₈₇H₁₁₅N₁₄O₂₄ ⁺, [M]⁺=1739.8; found: 1740.6.

Preparation of Atto633-Gly-Hyp10-PFP. (FIG. 5 process (b))Atto633-Gly-Hyp10 is suspended in 100 μL DMF in a 1.5 mL Eppendorf tube.Pyridine (20 μL) and pentafluorophenyl trifluoroacetate (PFP-TFA, 20 μL)are added to the tube. The reaction mixture is warmed to 50° C. in aheat block for 20 min. The reaction is monitored by removing 1 μLaliquots and adding to 1 mL of dilute HCl (0.4%). When the reaction iscomplete the aqueous solution is colorless. After 10 min the dilute HClsolution is light blue. Additional PFP-TFA (30 μL) is added. Afteranother 100 min at 50° C. a retest of precipitation gives a colorlesssolution. The remaining reaction mixture is precipitated into 1 mLdilute HCl in 20 μL portions. 20 μL is added to 1 mL dilute HCl, thetube spun down, and aqueous solution discarded. The process is repeateduntil all of the product is precipitated. The residue is thoroughlydried. After drying, the solid is washed twice with 1 mL methyltert-butyl ether (MTBE). The product is a dark blue powder. The productgives a major peak on electrospray ionization (ESI)-mass spectrometry(MS): m/z calculated for C₉₃H₁₁₅F₅N₁₄O₂₄ ²⁺, [M+H]²⁺=1906.8/2=953.4;found: 953.4.

Preparation of Atto633-Gly-Hyp10-epSS. (FIG. 5 process (c))Atto633-Gly-Hyp10-PFP (1.6 micromoles (μmol)) is dissolved in 100 μL DMFin an Eppendorf tube. A solution of aminoethyl-SS-propionic acid(Broadpharm; 6 mg in 200 μL 0.1 M bicarbonate) is mixed with theAtto633-gly-hyp10-PFP and heated to 50° C. in a heat block for 20 min.Atto633-Gly-Hyp10-epSS is purified from the resulting reaction mixtureby reverse phase HPLC using a gradient of 20%-50% acetonitrile over 16min. Atto633-Gly-Hyp10 elutes at 15 min and Atto633-Gly-Hyp10-epSSelutes at 15.6 min. The fractions containing the product,Atto633-Gly-Hyp10-epSS, are combined and dried. The product has a majorpeak on ESI-MS: m/z calculated for C₉₂H₁₂₄N₁₅O₂₅S₂ ⁺, [M]⁺=1902.8;Found: 1902.6.

Preparation of Atto633-Gly-Hyp10-epSS-PFP. (FIG. 5 process (d))Atto633-Gly-Hyp10-epSS is dissolved in 100 μL DMF in an Eppendorf tube.Pyridine (20 μL) and PFP-TFA (20 μL) are added and the mixture is heatedto 50° C. in a heat block for 20 min. A test aliquot (1 μL) in diluteHCl gives a colorless solution and a blue precipitate. The reaction isprecipitated in 20 μL aliquots in 1 mL dilute HCl, the tube spun down,and the aqueous solution discarded. The process is repeated until all ofthe PFP ester is precipitated. The residue is thoroughly dried undervacuum and washed with MTBE.

Preparation of dGTP-AP-SS-Atto633. (FIG. 5 process (e)) A solution ofaminopropargyl dGTP (Trilink; 1 μmol in 100 μL of 0.2 M bicarbonate) isadded to 50 μL of a DMF solution comprising Atto633-gly-hyp10-epSS-PFP.The mixture is heated to 50° C. for 10 min. The product,dGTP-AP-epSS-Atto633, is purified by reverse-phase HPLC using a gradientof 20%→50% acetonitrile 16 min. The product elutes at 15.3 min.Preparative HPLC provides 0.65 μmol. The product gives a major peak onESI-MS: m/z calculated for C₁₀₆H₁₃₉N₂₀O₃₇P₃S₂ ²⁻, [M−H]²⁻, 1220.4;found: 1220.6.

While synthesis of dGTP-Atto633-Gly-Hyp0-epSS-PFP is described, askilled practitioner will recognize that other fluorescently labelednucleotides can be produced in a similar manner using appropriatestarting materials.

Example 4: Synthesis of dCTP-epSS-Atto633

dCTP-SS12-Atto633 can be prepared in manner similar to the methodoutlined in Example 3. Briefly, Atto633-epSS is prepared (FIG. 6 process(a)) by mixing a 200 μL DMF solution comprising 11 mg Atto633-NHS with a200 μL aqueous solution comprising 0.2M sodium bicarbonate and 24 mgepSS, heating the resulting mixture to 50° C. for 15 min, purifyingAtto633-epSS from the mixture by reverse phase HPLC using a gradient of40%→60% acetonitrile vs. 0.1 M TEAA over 16 min at 4.5 mL/min, andconfirming the product identity with ESI-MS. The product elutes at 7.3min and the free dye elutes at 6.4 min. The yield is about 80%. Theproduct gives a major peak on ESI-MS: calculated for C₄₀H₅₁N₄O₄S₂ ⁺,[M]+=715.3; Found [M]+=715.3.

Atto633-epSS is then converted to Atto-epSS-PFP (FIG. 6 process (b)) bymixing a solution of Atto633-epSS dissolved in 100 μL DMF, 20 μLpyridine, and 20 μL PFP-TFA; heating the solution at 50° C. for 5 minbefore adding an additional 20-40 μL PFP-TFA; heating back to 50° C. for5 min; and precipitating the product in 1 mL of dilute HCl. The productis washed with an additional 1 mL of dilute HCl and the supernatantremoved by pipette and evaporation, yielding a blue solid.

dCTP-epSS-Atto633 is formed by reacting Atto-epSS-PFP withaminopropargyl dCTP (AP-dCTP) (FIG. 6 process (c)). AP-dCTP stocksolution (Trilink; 1 μmol) is added to a 100 μL DMF solution comprising0.2 M sodium bicarbonate and combined with a solution of Atto-epSS-PFPdissolved in 100 μL DMF. The mixture is left to sit overnight.dCTP-epSS-Atto633 is purified from the mixture on a C18 reverse phasecolumn using the gradient 20%→100% acetonitrile vs. 0.1 M TEAA over 16minutes at 2.5 mL/min. The product elutes at 10.7 min. The fractionsincluding the product are collected and dried. The product gives a majorpeak on ESI-MS: Calculated m/z for C₅₂H₆₆N₈O₁₆P₃S₂ ⁻, [M]⁻=1215.3;found: 1215.5.

Example 5: Preparation of Dye-Labeled Nucleotides

A set of dye-labeled nucleotides designed for excitation at about 530 nmis prepared. Excitation at 530 nm may be achieved using a green laser,which may be readily available, high-powered, and stable. There are manycommercially available fluorescent dyes with excitation at or near 530nm that are inexpensive and have a variety of properties (hydrophobic,hydrophilic, positively charged, negatively charged). Synthetic routesto such dyes may be shorter and cheaper than those for longer wavelengthdyes. Moreover, certain green dyes may have significantly lessself-quenching than red dyes, potentially allowing for the use of higherlabeling fractions (e.g., as described herein).

A viable reagent set for use in, e.g., a sequencing application consistsof each of four canonical nucleotides or analogs thereof with cleavablegreen dyes that perform well in sequencing. An optimal set may beprepared by varying each component of a labeled nucleotide structure toobtain an array of candidate labeled nucleotides with varyingproperties. The resultant nucleotides are evaluated (e.g., as describedbelow), and certain labeled nucleotides are optimized for concentrationand labeling fraction (the ratio of labeled to unlabeled nucleotide in aflow).

FIG. 7 shows a variety of components used in the construction ofcandidate labeled nucleotides. Each of four propargylaminofunctionalized nucleotides (A, C, G, and U) can be modified with one oftwo cleavable linkers, E and B; a hydroxyproline linker (hyp10) or not;and one of three fluorescent dyes, *, #, and $. Using these components,there are 48 possible nucleotide variations. The labeled nucleotides maybe prepared according to the synthetic route and principles describedherein. An example synthesis of the G*-B-H labeled nucleotide isdescribed in Example 6.

Example 6: Synthesis of G*-B-H Labeled Nucleotide

A synthetic method for preparing G*-B-H (see Example 5) is shown in FIG.8 . Similar methods may be used to prepare other labeled nucleotidesdescribed in Example 5 and elsewhere herein. As the components usedinclude amino acids, there are multiple routes to the final product.Synthetic considerations include the tendency for hydrolysis of thetriphosphate (to the diphosphate and monophosphates) under heat oracidic conditions, the tendency for disulfide to decompose in thepresence of triethylamine and ammonia, preventing the use of acid-labileprotecting groups, and preventing the use of trifluoroacetamide or FMOCprotecting groups.

Preparation of PN 40142. A solution of Atto 532 succinimidyl ester(Atto-tec, PN 40183; 5 mg=4.6 μmol) in 100 μL of DMF is mixed withgly-hyp-hyp-hyp-hyp-hyp-hyp-hyp-hyp-hyp-hyp (custom synthesis fromGenscript, PN 40035; 8.5 mg=7 μmol) in 170 μL 0.1 M bicarbonate in a 1.5mL Eppendorf tube. The reaction is purified on a Phenomenex reversephase C18 semi-prep column (Gemini 5 μM C18, 250×10 mm) using a gradientof 10%→40% acetonitrile vs. 0.1 M triethylammonium acetate over 16minutes. The fractions containing product 40142 are combined andconcentrated to dryness. The yield is determined by diluting a fractionand measuring the optical density (OD) at 633 nm and using an extinctioncoefficient for the dye of 130,000 cm⁻¹M⁻¹. The yield is 50%. Thestructure is confirmed by mass spectrometry in negative ion mode: m/zcalculated for C₈₁H₁₀₃N₁₄O₃₁S₂ ⁻, 1831.6; found: 1831.8.

Preparation of PN 40143. PN 40142 (4 μmol) is suspended in 100 μL DMF ina 1.5 mL eppendorf tube. Pyridine (20 μL) and pentafluorophenyltrifluoroacetate (20 μL) are added to the DMF solution and heated to 50°C. for five minutes. A portion (1 μL) of the reaction mixture isprecipitated into 0.4% HCl; the aqueous solution remains colorless,indicating complete conversion to the active, pentafluorophenyl ester.The remainder of the reaction is precipitated into the dilute acidicsolution and the aqueous solution pipetted off. The residue is washedwith hexane and dried to a highly colored solid (PN 40143)

Preparation of PN 40146. PN 40143 is dissolved in 100 μL DMF and mixedwith disulfide PN 40113 (5 mg, 20 μmol) in DMF. Diisopropylethylamine (5μL) is added to the mixture. The mixture is purified on reverse phaseHPLC using a gradient of 20%→50% acetonitrile vs. 0.1 M TEAA over 16minutes. Two dye-colored fractions are obtained at 8.8 min and 9.5 min.The fraction at 9.5 min is identified by mass spectrometry to be thedesired product: m/z calculated for C₉₀H₁₁₁N₁₅O₃₂S₄ ²⁻, [M−H]²⁻,1020.84; found: 1021.1.

Preparation of PN 40147. PN 40146 is suspended in 100 μL DMF in a 1.5 mLeppendorf tube. Pyridine (20 μL) and pentafluorophenyl trifluoroacetate(20 μL) are added to the DMF solution and heated to 50° C. for fiveminutes. A portion (1 μL) of the reaction mixture is precipitated into0.4% HCl; the aqueous solution remains colorless, indicating completeconversion to the active, pentafluorophenyl ester. The remainder of thereaction is precipitated into the dilute acidic solution and the aqueoussolution pipetted off. The residue is washed with hexane and dried to ahighly colored solid (PN 40147)

Preparation of PN 40150. PN 40147 is dissolved in 50 μL DMF in a 1.5 mLeppendorf tube. A solution of 0.5 μmol7-deaza-7-propargylamino-2′-deoxyguanosine-5′-triphosphate in 50 μL 1 Mbicarbonate is prepared and added to the tube. After remaining overnightat 4° C. the product is purified on HPLC; the fraction at 12 min using a20%-50% acetonitrile vs. 0.1 M TEAA gradient over 16 minutes containsthe desired product: m/z calculated for C₁₀₄H₁₂₉N₂₀O₄₄P₃S₄ ²⁻, [M−H]²⁻,1291.33; found: 1292.4.

Example 7: Evaluation of Dye-Labeled Nucleotides

A bead-based assay is used to evaluate dye-labeled nucleotides ofExample 5. A streptavidin bead is prepared with a 5′-biotinylatedtemplate strand annealed to a primer strand. The primer strand isdesigned so that the next cognate base incorporated by a DNA polymeraseis a thymidine. A DNA polymerase is bound to the bead complex. Variousmixtures containing different ratios of the dye-labeled nucleotide(dUTP*) and the natural base (TTP) is then presented to the beads. Afterwashing away excess reagent, the fluorescence of the beads is read on aflow cytometer using the PE channel (excitation=488 nm, emission=580nm). A schematic of this assay is shown in FIG. 9 .

The results of the bead assay for different labeled dUTPs is shown inFIG. 10 . The total concentration of the sum of the nucleotides ismaintained at 2 μM; a labeling fraction of 10% means 0.2 μM of dUTP* and1.8 μM of TTP. The behavior for the two nucleotides is noticeablydifferent: U #-E has a “tolerance” of about one, meaning that there isno difference in incorporation of the dye-labeled vs the naturalnucleotide over all the ratios tested; i.e., a 50% labeling fractionresults in 50% of the beads getting labeled. U*-E, on the other hand,has a negative tolerance, meaning that at every ratio it falls below theline drawn between zero and the signal at 100% labeled. A negativetolerance suggests that the dye-label makes the nucleotide a worsesubstrate than the natural substrate. This result is consistent with theobservation that negatively charged dyes such as Atto532 (the dyedenoted by U*-E) inhibit incorporation by many polymerases while dyessuch as 5-carboxyrhodamine-6G (the dye denoted by U #-E) arezwitterionic and are known to be good substrates.

Additional labeled nuclotides are evaluated using a similar assay. FIG.11 shows the result of the bead assay for labeled dATPs. FIG. 12 showsthe result of the bead assay for labeled dGTPs. For labeled dATPs, verylow fluorescence is observed at 100% labeling for A*-B compared toA*-B-H and A*-E-H. This indicates that the hydroxyproline linker (H)relieves quenching of the dye by the nucleotide. A similar result isobserved for labeled dGTPs. This result is expected for labeled dGTP, asG quenching via photoinduced electron transfer is well known. Aquenching effect from the disulfide linker, B, may also contribute tothe lower fluorescence observed for labeled dATPs and dGTPs.

Example 8: Sequencing Using Dye-Labeled Nucleotides

A nucleic acid sequencing assay may be used to evaluate dye-labelednucleotides (e.g., as described herein). An example procedure is shownin FIG. 18 .

Sequencing may be performed using an instrument outfitted with a lightemitting device (LED) and/or a laser. Each nucleotide evaluated mayinclude a dye that is configured for excitement and emission oversimilar wavelengths (e.g., all red or all green emission). One or moredifferent nucleotide types may be coupled to different dyes. Sequencingperformance may be evaluated based on base calling quality, phase lag,phase lead, and homopolymer completion.

Beads with amplified templates are primed, immobilized on a support, andincubated with a tight-binding DNA polymerase. Beads are then subjectedto multiple cycles of sequencing. Each sequencing cycle may compriseincubation with U*/T (a fixed ratio of dye-labeled and natural TTP), a“chase” process (TTP alone), imaging, and a cleavage process (10 mMtris(hydroxypropyl)phosphine (THP)) to release the dye. Each process mayhave a wash process in between. This process may be repeated for A, C,and G-including nucleotides or nucleotide analogs. This sequencingprocedure may effectively identify homopolymeric regions of at least 2,3, 4, 5, 6, 7, 8, or more nucleotides.

Sequencing is also evaluated for an all hyp-linker set in whichdye-labeled nucleotides including each canonical nucleotide include thehyp10 or hyp20 linker. This evaluation is performed to identify a setwhere higher fractions may be used with minimal quenching. Higherquenching may lead to higher scarring (e.g., as described herein), whichmay reduce incorporation efficiency by a polymerase enzyme. However,family B enzymes such as PolD may perform well with scars. Sequencingmay be evaluated with 2.5% and 20% labeling fractions with a dye such asAtto633.

Sequencing may be used to evaluate the tolerance for various labelednucleotides. FIG. 19 shows normalized bead data for nucleotides labeledwith a red-emitting dye. Bright solution fraction (b_(f)) is plottedagainst bright incorporation fraction (b_(i)). The curves are fitted tothe following equation:

$b_{i} = \frac{to{l\left( {b_{f}/d_{f}} \right)}}{1 + {to{l\left( {b_{f}/d_{f}} \right)}}}$in which d_(f) is the dark solution fraction. In FIG. 19 , thecalculated tolerances are 10.6 for G*, 2.8 for A*, 2.0 for U*, and 1.2for C*. The positive tolerance numbers indicate that at 50% labelingfraction, more than 50% is labeled. Reagents with a tolerance of 1 mayhave the least “context” in sequencing. Reagents with a very negativetolerance (e.g., tolerance<<1) may have issues with uniformincorporation across a plurality of templates coupled to a supportbecause they must be used at such low concentrations that they may fallbelow saturation and be consumed at an uneven rate.

Example 9: Dye-Labeled Nucleotides Including Guanine or Analogs Thereof

Nucleotides including guanine or analogs thereof may perform more poorlyin sequencing applications (e.g., as described herein) in base-callingaccuracy. This may be related to photoinduced electron transfer from thenucleobase to a dye linked to the nucleobase, which may quench signalemitted by the dye and thus less dynamic range of signal. Accordingly,various dye-labeled nucleotides including guanine or analogs thereof areprepared and evaluated as provided herein. Examples of such dye-labelednucleotides include:

Several of the structures shown above include the hyp10 linker whichincludes the sequence Gly-Hyp-Hyp-Hyp-Hyp-Hyp-Hyp-Hyp-Hyp-Hyp-Hyp fromthe N-terminal end. G4, which lacked the hyp10 linker, is highlyquenched. The remaining dye-labeled nucleotides are evaluated in asequencing assay, as described herein. Of the structures shown, G6provides the highest accuracy. A synthetic route for preparation of G6is shown in FIGS. 13A-13C.

Example 10: Preparation of Dye-Labeled Nucleotides

A dye-labeled nucleotide may include one or more amino acids. Asdescribed above, diamines and diacids may be used to construct aminoacids. A dye-labeled nucleotide may include two or more of a given aminoacid as a repeating unit. An example of a dye-labeled nucleotideincluding two repeating units of an amino acid is shown below:

FIGS. 14A and 14B show a synthetic route for preparation of thedye-labeled nucleotide shown above. The composition of each intermediateis confirmed by mass spectrometry. The dye-labeled nucleotide isevaluated in a bead assay, as described in Example 7. The linkerprovides a G* that is less bright than G*s with polyhydroxyprolinelinkers, but is more efficient in reducing quenching than a G* without alinker.

Example 11: Evaluation of Quenching

The dye-labeled nucleotides provided herein may improve quenchingbetween nucleobases and the dyes to which they are attached and/orbetween dyes in a nucleic acid molecule (e.g., a growing nucleic acidstrand), such as in a homopolymeric region of a nucleic acid molecule.Quenching may be evaluated in an enzyme-independent manner.

FIG. 15 shows a schematic for evaluating quenching. Synthetic oligos areconstructed with one or two “linker arm nucleotides”. Linker armnucleotides are thymidine analogs with a linker arm containing a primaryamine. The oligonucleotide containing the linker arm nucleotide can belabeled with linkers and dyes and HPLC purified. The advantage of usingthe bead-labeled assay is that exact quantitation of the reagents is notnecessary; a large excess can be used in each step and the beads washed,ensuring that only stoichiometric amounts of oligonucleotides are boundto the template. Each dye-linker is put on both oligonucleotides. Thebeads are measured on the flow cytometer in the APC (red) channel. Thepercent quenching is determined by the formula: %quenching=100×(1−Fl_(bis)/(2*Fl_(mono))).

FIGS. 16 and 17 show quenching results for red dye linkers (FIG. 16 )and green dye linkers (FIG. 17 ). The results show that the nature ofthe dye affects quenching. Negative charge (see Atto532 vs AttoRho6G)can improve quenching but if the dye is extremely large and flat (seeCy5, Alexa 647) quenching may not be improved. The hyp10 or hyp20linkers improve quenching. As shown in FIG. 16 , hyp10 improvesquenching with Atto633, and cyanine dyes quench even with four sulfonicacid groups. As shown in FIG. 17 , sulfonic acid groups on Atto532improve quenching, and the combination of Atto532 and hyp10 alsoimproves quenching.

Example 12: Interrogation of Homopolymers

A nucleic acid template is provided that has various lengths of ahomopolymer region comprising cytosines (1C, 2C, 3C, 4C, 5C). Thetemplate is contacted with guanosine-containing nucleotides labeled withAtto532 fluorophore (e.g., as described herein; denoted herein as G*).The labeled nucleotides may be provided in a solution as a nucleotideflow (e.g., as described herein). The nucleotide flow may include 100%labeled nucleotides (e.g., the nucleotide flow may include only labelednucleotides and no unlabeled nucleotides) or may include both labeledand unlabeled nucleotides (e.g., as described herein). The labeled and,where present, unlabeled nucleotides may not be terminated so thatmultiple nucleotides can be incorporated into as many positions insuccession as there appear cytosines in the template. An enzyme (e.g., apolymerase enzyme, such as Bst 3.0) may be used to incorporate labeledand/or unlabeled nucleotides into an extended primer using the nucleicacid having a polycytosine sequence as a template. A plurality of copiesof the template may be immobilized to a bead or other support (e.g., asdescribed herein). This procedure is schematically illustrated in FIGS.20A and 20B.

In some cases, the labeled nucleotide incorporates into as manypositions in succession as there appear cytosine in the template. Inother cases, less than all potential G* are incorporated. Whereunlabeled nucleotides are included in the nucleotide flow, bothunlabeled and labeled nucleotides may be incorporated. For example, fora template including a homopolymeric region including three cytosines,the incorporated nucleotides may have the sequence GGG, GG*G, GGG*,G*GG, G*G*G, G*GG*, GG*G*, or G*G*G*, where G* indicates a labelednucleotide and G indicates an unlabeled nucleotide. The sequence of theincorporated nucleotides may vary based on, for example, the labelingfraction of the nucleotide flow (e.g., the ratio of labeled to unlabelednucleotides in the flow) and the optical (e.g., fluorescent) labelingreagent used to label the nucleotides.

Labeled polynucleotide products are separated on a Biorad denaturingacrylamide gel and imaged using blue and green LEDs to detectincorporated labeled nucleotides. As shown in FIG. 20C, 1, 2, 3, 4, and5 consecutive cytosines can be detected using this method.

Example 13: Sequencing by Synthesis Using a High Fraction of LabeledNucleotides

A template nucleic acid having a length of at least 30 nucleotides issequenced using the procedures and labeled nucleotides described herein.The template to be sequenced may be immobilized to a support (e.g., asdescribed herein). The template is subjected to a sequencing bysynthesis reaction, in which the template is sequentially contacted withsolutions (e.g., nucleotide flows) comprising PolD polymerase (NewEngland Biolabs) and a plurality of nucleotides of a single canonicaltype (e.g., T, A, C, or G). In each nucleotide flow, approximately 20%of the nucleotide population is labeled with Atto633 as described hereinabove to provide a labeling fraction of about 20%. The remainingnucleotides are unlabeled. Nucleotides included in nucleotide flows arenot terminated to allow efficient sequencing of homopolymeric regions ofthe template. After contacting the template with a first nucleotide flowincluding nucleotides of a first canonical type, the template iscontacted with a wash flow to remove unincorporated nucleotides. Afluorescent image is collected. The linker of the fluorescent labelingreagent associated with incorporated labeled nucleotides is contactedwith a cleavage flow comprising a cleavage reagent configured to cleavea cleavable group of the linker to separate the fluorescent dye (e.g.,Atto633) of the fluorescent labeling reagent from the incorporatednucleotide. An additional wash flow may be used to remove the cleavageflow. In some cases, a chase flow including unlabeled nucleotides of thefirst canonical type may follow the initial nucleotide flow and precedeor follow the imaging process. The process is repeated for the second,third, and fourth nucleotide types in succession, and then the entirecycle is repeated.

FIG. 21A shows the results of application of this method to a sampletemplate. A black circle indicates that a nucleotide was incorporatedand a gray circle indicates that no nucleotide was incorporated in aparticular flow cycle. As shown in the figure, the incorporation of oneor more nucleotides in a flow cycle can be determined with a high degreeof accuracy. Furthermore, as is shown in FIG. 21B, the relationshipbetween signal intensity and labeled nucleotide homopolymer length maybe substantially linear across a plurality of templates (e.g., asdescribed herein). For example, the signal intensity may be proportionalto the length of a homopolymeric region of the template. Thisproportionality indicates that quenching effects have been substantiallyovercome. In FIG. 21B, the slope for G is 0.96, for C is 0.80, for A is079, and for T is 0.70. The dotted line indicates the actual signal,while the solid line indicates the signal after correction for phasing.

Example 14: Sequencing by Synthesis Using 100% Labeled Nucleotides

A template nucleic acid having a length of at least 30 nucleotides issequenced as described in Example 13, but with solutions in which 100%of the nucleotides are labeled. In FIG. 22 , black circles indicate thata base was incorporated in a given flow cycle, while gray circlesindicate that a base was not incorporated in a given flow cycle. As canbe seen from FIG. 22 , the sequencing method can be used to detect baseincorporation through 50 flow cycles.

Example 15: Labeled Proteins

A protein is labeled with a plurality of optical (e.g., fluorescent)labeling reagents (e.g., as described herein). For example, the proteinmay be labeled with three or more optical labeling reagents. The opticallabeling reagents associated with the protein may all comprise afluorescent dye of the same type. The optical labeling reagentsassociated with the protein may all comprise a linker of the same type.The protein may be an antibody, such as a monoclonal antibody.

The protein is used to label a cell. The cell may be a component ofsample, which sample may comprise a plurality of cells. The cells of thesample may be analyzed and sorted using flow cytometry. Flow cytometricanalysis may identify the cell as being labeled with the proteinassociated with the plurality of optical labeling reagents. In somecases, a plurality of cells of a sample may be labeled with opticallabeling reagents (e.g., as described herein). For example, cellscomprising a particular cell surface feature (e.g., an antigen)configured to associate with a protein (e.g., a protein labeled with aplurality of optical labeling reagents, such as an antibody labeled witha plurality of optical labeling reagents) may be labeled with labeledproteins and analyzed and/or sorted using flow cytometry. Analyzedand/or sorted cells may be subjected to further downstream analysis andprocessing, including, for example, nucleic acid sequencing, staining,imaging, function assays, immunoassays, isolation/expansion, additionallabeling, immunoprecipitation, etc.

While preferred embodiments of the present invention have been shown anddescribed herein, it will be obvious to those skilled in the art thatsuch embodiments are provided by way of example only. It is not intendedthat the invention be limited by the specific examples provided withinthe specification. While the invention has been described with referenceto the aforementioned specification, the descriptions and illustrationsof the embodiments herein are not meant to be construed in a limitingsense. Numerous variations, changes, and substitutions will now occur tothose skilled in the art without departing from the invention.Furthermore, it shall be understood that all aspects of the inventionare not limited to the specific depictions, configurations or relativeproportions set forth herein which depend upon a variety of conditionsand variables. It should be understood that various alternatives to theembodiments of the invention described herein may be employed inpracticing the invention. It is therefore contemplated that theinvention shall also cover any such alternatives, modifications,variations or equivalents. It is intended that the following claimsdefine the scope of the invention and that methods and structures withinthe scope of these claims and their equivalents be covered thereby.

What is claimed is:
 1. A composition comprising a compound of Formula(I):

Formula (I) or a salt or solvate thereof, wherein: R^(A) is anoptionally substituted 5-12 membered ring system, wherein substituentson R^(A) are independently selected from R⁴; R^(B) comprises anucleotide, a nucleotide analog, or a nucleoside, wherein each of thenucleotide, the nucleotide analog, and the nucleoside comprises anucleobase, wherein the alkyne of Formula (I) is covalently linked tothe nucleobase, wherein R^(B) is optionally substituted with R⁵; R^(C)is selected from optionally substituted C₁₋₆ alkyl, optionallysubstituted C₂₋₆ alkenyl, and optionally substituted C₂₋₆ alkynyl, orR^(C) is absent, wherein substituents on R^(C) are independentlyselected from R⁶; Y is —SH, —S(═O)H, —S(═O)₂H, or —S(═O)(OH); R² isselected from hydrogen, optionally substituted C₁₋₆ alkyl, optionallysubstituted C₂₋₆ alkenyl, optionally substituted C₂₋₆ alkynyl,optionally substituted C₃₋₆ cycloalkyl, and optionally substituted3-6-membered heterocycloalkyl, wherein substituents on R² areindependently selected from R⁶; each R³ is independently selected fromhydrogen, halogen, —CN, —OH, —OR⁸, —C(═O)R⁸, —CO₂R⁷, —C(═O)N(R⁷)₂,—N(R⁷)₂, —NR⁷C(═O)R⁷, —NR⁷C(═O)N(R⁷)₂, —SR⁷, —S(═O)R⁸, —SO₂R⁸,—SO₂N(R⁷)₂, —NO₂, optionally substituted C₁-C₆ alkyl, optionallysubstituted C₁-C₆ alkenyl, optionally substituted C₁-C₆ alkynyl,optionally substituted monocyclic carbocycle, and optionally substitutedmonocyclic heterocycle, wherein optional substituents on C₁-C₆ alkyl,C₁-C₆ alkenyl, C₁-C₆ alkynyl, monocyclic carbocycle, and monocyclicheterocycle are independently selected from R⁶; or two R³ are takentogether with the atom to which they are attached to form an optionallysubstituted 3- to 6-membered heterocycle or carbocycle, wherein optionalsubstituents on the 3- to 6-membered heterocycle or carbocycle areindependently selected from R⁶; R⁴ is selected from halogen, ═O, ═S,—CN, —OH, —OR¹⁰, —N(R⁹)₂, —C(═O)R⁹, —C(═O)OR⁹, —OC(═O)R⁹, —C(═O)N(R⁹)₂,—NR⁹C(═O)R⁹, —NR⁹C(═O)N(R⁹)₂, —OC(═O)N(R⁹)₂, —NR⁹C(═O)OR⁹, —OC(═O)OR⁹,—NR⁹SO₂R⁹, —SR⁹, —S(═O)R¹⁰, —SO₂R¹⁰, —SO₂N(R⁹)₂, —NO₂, optionallysubstituted C₁-C₆ alkyl, optionally substituted C₂-C₆ alkenyl,optionally substituted C₂-C₆ alkynyl, an optionally substituted C₃-C₁₀carbocycle, and an optionally substituted 3-10-membered heterocycle,wherein substituents on R⁴ are independently selected from R⁶; R⁵ isselected from halogen, ═O, ═S, —CN, —OH, —OR¹⁰, —N(R⁹)₂, —C(═O)R⁹,—C(═O)OR⁹, —OC(═O)R⁹, —C(═O)N(R⁹)₂, —NR⁹C(═O)R⁹, —NR⁹C(═O)N(R⁹)₂,—OC(═O)N(R⁹)₂, —NR⁹C(═O)OR⁹, —OC(═O)OR⁹, —NR⁹SO₂R⁹, —SR⁹, —S(═O)R¹⁰,—SO₂R¹⁰, —SO₂N(R⁹)₂, —NO₂, optionally substituted C₁-C₆ alkyl,optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆alkynyl, an optionally substituted C₃-C₁₀ carbocycle, and an optionallysubstituted 3-10-membered heterocycle, wherein substituents on R⁵ areindependently selected from R⁶; each R⁶ is independently selected fromhalogen, ═O, ═S, —CN, —OH, —OR¹⁰, —N(R⁹)₂, —C(═O)R⁹, —C(═O)OR⁹,—OC(═O)R⁹, —C(═O)N(R⁹)₂, —NR⁹C(═O)R⁹, —NR⁹C(═O)N(R⁹)₂, —OC(═O)N(R⁹)₂,—NR⁹C(═O)OR⁹, —OC(═O)OR⁹, —SR⁹, —S(═O)R¹⁰, —SO₂R¹⁰, —SO₂N(R⁹)₂, —NO₂,C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆hydroxyalkyl, C₁-C₆ aminoalkyl, C₃-C₆ carbocycle, optionally substitutedmonophosphate, optionally substituted diphosphate, optionallysubstituted triphosphate, and 3- to 6-membered heterocycle; each R⁷ isindependently selected from hydrogen, optionally substituted C₁-C₆alkyl, optionally substituted C₃-C₆ carbocycle, and optionallysubstituted 3-6-membered heterocycle, wherein optional substituents onthe C₁-C₆ alkyl, C₃-C₆ carbocycle, and 3-6-membered heterocycle areindependently selected from R⁶; or two R⁷ are taken together with theatom(s) to which they are attached to form an optionally substituted 3-to 6-membered heterocycle, wherein optional substituents on the 3- to6-membered heterocycle are independently selected from R⁶; each R⁸ isindependently selected from optionally substituted C₁-C₆ alkyl,optionally substituted C₃-C₆ carbocycle, and optionally substituted3-6-membered heterocycle, wherein optional substituents on the C₁-C₆alkyl, C₃-C₆ carbocycle, and 3-6-membered heterocycle are independentlyselected from R⁶; each R⁹ is independently selected from hydrogen, C₁-C₆alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₃-C₆ carbocycle,and 3- to 6-membered heterocycle; or two R⁹ on the same nitrogen atomare taken together with the nitrogen to which they are attached to forma 3- to 6-membered heterocycle; each R¹⁰ is independently selected fromC₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₃-C₆carbocycle, and 3- to 6-membered heterocycle.
 2. The composition ofclaim 1, wherein the heteroatoms of R^(B) are each N.
 3. The compositionof claim 2, wherein R^(B) is an optionally substituted pyrimidine, anoptionally substituted 7H-pyrrolo[2,3-d]pyrimidine, or an optionallysubstituted purine.
 4. The composition of claim 3, wherein R^(B) issubstituted with at least one R⁵ selected from an optionally substitutedC₃-C₁₀ carbocycle and an optionally substituted 3-10-memberedheterocycle.
 5. The composition of claim 3, wherein R^(B) comprises ablocked or terminated nucleotide or nucleotide analogue.
 6. Thecomposition of claim 1, wherein R^(A) is an optionally substituted 5-12membered carbocyclic ring system.
 7. The composition of claim 1, whereinR^(A) is an optionally substituted 5-12 membered heterocyclic ringsystem.
 8. The composition of claim 1, wherein the carbonyl in Formula(I) is connected to a carbon of R^(A).
 9. The composition of claim 1,wherein R^(A) is an optionally substituted 5-12 membered bicyclic ringsystem.
 10. The composition of claim 1, wherein R^(A) is substitutedwith at least 1 R⁴ moiety.
 11. The composition of claim 1, wherein twoR³ are taken together with the atom to which they are attached to forman optionally substituted 3- to 6-membered heterocycle or carbocycle,wherein optional substituents on the 3- to 6-membered heterocycle orcarbocycle are independently selected from R⁶.
 12. The composition ofclaim 1, wherein each R⁴ is independently selected from halogen, —OH,—OR¹⁰, —N(R⁹)₂, —C(═O)R⁹, —C(═O)OR⁹, —OC(═O)R⁹, —C(═O)N(R⁹)₂,—NR⁹C(═O)R⁹, —NR⁹C(═O)N(R⁹)₂, —OC(═O)N(R⁹)₂, —NR⁹C(═O)OR⁹, —OC(═O)OR⁹,and optionally substituted C₁-C₆ alkyl.
 13. The composition of claim 1,wherein Y is —SH.
 14. The composition of claim 1, wherein R^(C) isabsent.
 15. The composition of claim 1, wherein Y is —S(═O)H.
 16. Thecomposition of claim 1, wherein Y is —S(═O)(OH).
 17. The composition ofclaim 1, wherein Y is —S(═O)₂H.
 18. The composition of claim 1, whereinR^(A) is a non-aromatic optionally substituted 5-12 membered ringsystem.
 19. The composition of claim 1, wherein the carbonyl and Y inFormula (I) are not on adjacent atoms of R^(A) when R^(C) is absent. 20.The composition of claim 1, wherein the composition comprises an aqueoussolution.